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ABSTRACT
In response to the rapidly increasing number of new HIV infections in the WHO European Region, the action plan 
for the health sector response to HIV in WHO European Region was endorsed at the 66th session of the WHO 
Regional Committee for Europe in September 2016. From December 2017 to April 2018, the WHO Regional Office 
for Europe collected good practices in implementation of the action plan and compiled them in this compendium. 
National health authorities, national and international experts, and civil-society organizations involved in HIV 
prevention, treatment and care were solicited to share their practices. The practices exemplify efforts within five 
target areas: HIV prevention; HIV testing and treatment; reducing AIDS-related deaths; curbing discrimination; and 
increasing financial sustainability of the HIV/AIDS response. This first compendium of good HIV practices in the 
WHO European Region includes 52 practice examples from 32 Member States. The compendium is intended as 
a resource for relevant stakeholders in the HIV response.
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Foreword
FOREWORD
The United Nations 2030 Agenda for Sustainable Development calls for leaving no one behind. The WHO European 
Region is the only WHO Region in which the number of new HIV infections is increasing rapidly; therefore, a 
vigorous response to the epidemic has never been so crucial. An estimated one quarter of all people living with 
HIV in the Region are unaware of their status, while half are diagnosed at a late stage of infection. In addition, 
treatment coverage with life-saving antiretrovirals is as low as 28% in the eastern European and central Asian part 
of the Region.
As we accelerate progress towards ending AIDS as a public health threat by 2030, it is vital to sustain and 
continuously scale up good practices aligned with the action plan for the health sector response to HIV in the WHO 
European Region. Endorsed by the WHO Regional Committee for Europe at its 66th session in September 2016, 
the plan embodies three organizing frameworks: (i) universal health coverage; (ii) a continuum of HIV services; and 
(iii) the promotion of a public health approach. Each are to be reinforced by strong political leadership and working 
in partnership.
To document and disseminate successful interventions aligned with the action plan, I am pleased to present this 
first Compendium of good practices in the health sector response to HIV in the WHO European Region. The 
practices are examples of the progress of Member States towards the targets of World Health Organization and 
Joint United Nations Programme on HIV/AIDS on HIV prevention, treatment and care, preventing discrimination, 
and ensuring financial sustainability. Coupled with the fast-tracked actions for 2020, we encourage Member 
States and partners to sustain, replicate and scale up these and other similar good practices.
Dr Zsuzsanna Jakab
WHO Regional Director for Europe
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Compendium of good practices in the health sector response to HIV in the WHO European Region
At the 66th session WHO Regional Committee for 
Europe in September 2016, all 53 Member States 
endorsed resolution EUR/RC66/R9, the action plan for 
the health sector response to HIV in the WHO European 
Region. The action plan guides Member States in 
accelerating their response to the HIV epidemic. Its 
goals and targets are in line with the United Nations 
(UN) 2030 Agenda for Sustainable Development, 
the multisectoral strategy for 2016–2021 of the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) 
and the WHO Global Health Sector Strategy on HIV, 
2016–2021.
In line with implementation of the action plan, the WHO 
Regional Office for Europe launched an official call 
for good HIV practices in December 2017. National 
health authorities, intraregional programmes, national 
HIV technical focal points and programmes, civil 
society organizations (CSOs), and nongovernmental 
organizations (NGOs) responding to the HIV epidemic 
were invited to submit exemplary practices. The 
narratives were collected over five months from 
December to April 2018; compiled and evaluated 
against pre-defined criteria by a selection committee 
composed of colleagues from AIDS Action Europe, 
AIDS Foundation East–West (AFEW), CHIP – Centre 
of Excellence for Health, Immunity and Infections, 
Rigshospitalet, University of Copenhagen, Denmark, 
the European Centre for Disease Prevention and 
Control (ECDC), and UNAIDS and WHO; and then 
technically reviewed by WHO experts in the Regional 
Office.
The compendium includes 52 practice examples from 
32 Member States of the WHO European Region: 
29 from national HIV programmes and public health 
institutes/research institutes; 11 from NGOs and CSOs; 
eight from ministries of health (MoHs) and/or ministries 
of justice (MoJs); and four from intraregional initiatives. 
The proportions of Member States contributing to the 
practice examples by parts of the Region were: 80% 
in eastern Europe; 47% in central Europe ; and 52% in 
western Europe.
The submissions are categorized according to the 
strategic directions of the action plan as: (i) information 
for focused action; (ii) interventions for impact; (iii) 
delivering for equity; (iv) financing for sustainability; 
and (v) innovation for acceleration. This compendium 
is the first WHO Regional Office for Europe project to 
consolidate good HIV practices in the Region.
EXECUTIVE SUMMARY
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INTRODUCTION
Background
In line with the action plan for the health sector 
response to HIV in the WHO European Region and 
in collaboration with WHO country offices, the WHO 
Regional Office for Europe has provided HIV technical 
assistance and guidance towards reaching targets in the 
following areas: HIV prevention, testing and treatment; 
AIDS-related deaths; reduction of discrimination; and 
reaching financial sustainability of the HIV response.
Primary areas of technical assistance have included: (i) 
implementing WHO and UNAIDS guidelines and tools 
related to the joint WHO/ECDC surveillance protocols 
to strengthen national HIV strategic information 
systems; (ii) providing regular updates on evidence-
based guidelines and tools for combination prevention, 
testing, antiretroviral therapy (ART) delivery and scale-
up, and comorbidity management; (iii) strengthening 
national capacities and national strategic plans; 
(iv) developing differentiated care models to serve 
key populations in the HIV response; (v) facilitating 
partnerships and multisectoral collaboration efforts, 
including the engagement of civil society and people 
living with HIV; and (vi) building the investment case and 
transition plan to nationally funded country response 
efforts.
Specifically, for low- and middle-income countries in the 
Region, ensuring donor funding in addition to domestic 
resources is crucial to sustain efforts to end HIV and 
tuberculosis (TB). The Regional Office has provided 
support to improve the quality of funding applications 
from low- and middle-income countries, particularly 
to the Global Fund to Fight AIDS, Tuberculosis and 
Malaria (GFATM) on addressing HIV and TB effectively. 
In July 2017, WHO issued new guidelines and updates 
on the management of advanced HIV infection, HIV 
drug resistance and transitioning to new antiretrovirals 
(ARVs). The Regional Office additionally organized a 
master training course on these guidelines for senior 
clinicians in 14 HIV priority countries in the Region.
Back to back with the 22nd International AIDS 
Conference, the Regional Office, in collaboration with 
the Government of the Netherlands, is convening 
a Ministerial policy dialogue on HIV and related 
comorbidities in eastern Europe and central Asia 
(EECA) on 23 July 2018 in Amsterdam. The aim of 
the policy dialogue is to fast-track and share good 
practices related to implementation of the action plan 
within EECA and Baltic countries.
During the high-level meeting, ministers of health and HIV 
technical focal points from EECA and Baltic countries 
will promulgate innovative and financially sustainable 
approaches for the HIV response in their respective 
countries. The aims of this compendium are to share 
good practices among Member States and advise on 
the action points and next steps for scaling up the HIV 
response within the Region. The compendium of good 
HIV practices also functions to support the monitoring 
and evaluation of Member States’ commitment to 
implementing the action plan.
HIV in the WHO European Region
The WHO European Region is the only WHO Region 
in which HIV is rapidly increasing, so there is an urgent 
need to scale up HIV prevention, testing and treatment; 
reduce discrimination; and increase sustainable 
financing options for a consolidated HIV response. In 
2016, an estimated 221 000 people were newly infected 
with HIV in the Region and more than 160 000 were 
newly diagnosed with HIV (corresponding to a rate 
of 18.2 diagnoses per 100 000 population), thereby 
continuing the increasing trend of new HIV infections 
that has persisted for for the past decade in the Region. 
Of these 160 000 newly diagnosed cases, 80% were 
diagnosed in the eastern part of the Region, contributing 
to the 95% increase in the rate of new diagnoses in this 
area between 2007 and 2016 (Figs 1 and 2) (1).1
Regional patterns
The WHO European Region is comprised of 53 Member 
States. It is socially, politically and economically diverse 
and so are the needs of people living with HIV and the 
health systems that support them. Some governments 
in the Region also face the withdrawal of international 
funding from HIV programmes, which creates further 
challenges.
HIV remains concentrated in key populations with sub 
regional variation. In line with the UNAIDS 2016-2021 
1 The grouping of countries into the West (23 countries), Centre (15 countries) 
and East (15 countries) of the WHO European Region is based on epidemi-
ological considerations and follows the division of countries used in the joint 
ECDC/WHO HIV/AIDS surveillance in Europe reports. See the 2017 report for 
details (1).
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Fig. 1. Numbers and rates of new HIV diagnoses, WHO European Region, 2016
Source: ECDC, WHO Regional Office for Europe, 2017 (1).
A total of 160 453 people were diagnosed in 2016
Overall rate for the WHO European Region: 18.2  per 100 000 
West
26 602
6.2 per 100 000
Centre
5 772
2.9 per 100 000 
East
128 079
50.2 per 100 000 
Strategy (2) and the WHO Global Health Sector Strategy 
on HIV for 2016–2021 (3), key populations at higher 
risk of HIV (hereafter referred to as key populations) are 
defined as those groups of people most likely to be 
exposed to or to transmit HIV and whose engagement 
is critical for a successful response. In the European 
Region, key populations include people living with 
HIV, people who inject drugs, men who have sex with 
men (MSM), transgender people, sex workers (SW), 
prisoners and migrants (4).
Although recent data suggest decreasing trends in a 
handful of European Union (EU)/European Economic 
Area (EEA) countries, transmission due to sex between 
men remains high or is increasing in many western 
and central European countries, while heterosexual 
and transmission related to injecting drug use (IDU) 
predominates in eastern European countries (1). Just 
over half (51%) of people newly diagnosed with HIV in 
the WHO European Region in 2016 were diagnosed 
late,2 and an estimated one quarter of HIV-positive 
people remain undiagnosed across the Region. WHO 
recommends that all those diagnosed with HIV initiate 
ART immediately regardless of their CD4 cell count 
(5). However, in 2016 only two thirds of countries in 
the Region had policies which provide treatment 
irrespective of this measurement. The interregional 
variability of the HIV epidemic in eastern, central and 
western Europe is described in the following sections 
(1).
2 Defined as a CD4 count of below 350 cells/mL at the time of HIV diagnosis.
3©WHO/Zachary Gavry
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The east3
In 2016, 128 079 persons from 13 eastern European 
countries were newly diagnosed (out of 160 453 for the 
whole Region). In this part of the region, heterosexual 
contacts and injecting drug use remain the main 
reported modes of HIV transmission. High numbers of 
AIDS cases confirm that late HIV diagnosis, delayed 
initiation of ART and low treatment coverage remain 
major challenges. Data also suggest that most of the 
new diagnoses originated from within the reporting 
countries and that those infected abroad are infected 
in neighbouring countries within central and eastern 
Europe. Scaled-up efforts are urgently required to provide 
the full range of packages of HIV prevention, testing 
and treatment services, including bolstered efforts to 
reduce discrimination and stigma for all key populations 
and the general population. This depends on political 
commitment in the Region, as well as a comprehensive 
shift from international to domestic funding for the HIV 
response.
The centre
Although lowest in terms of the absolute numbers 
of people diagnosed with HIV, this part of the region 
3 The grouping of countries into the West (23 countries), Centre (15 countries) 
and East (15 countries) of the WHO European Region is based on epidemi-
ological considerations and follows the division of countries used in the joint 
ECDC/WHO HIV/AIDS surveillance in Europe reports. See the 2017 report for 
details (1). 
experienced the largest relative increase in new HIV 
diagnoses over the last decade, with increases reported 
in all countries (142% increase from 2007-2016 (1)). 
Transmission is predominantly through sexual contact 
between men; far more men are affected than women 
in this sub region than in any other (four out of every five 
person newly diagnosed are men).
The west
26 602 people were newly diagnosed in the 23 countries 
of western Europe.4 For countries in the EU/EEA and 
in western Europe, sexual transmission between men 
remained the predominant transmission mode in 2016, 
followed by heterosexual transmission (among whom 
61% were migrants), together accounting for 74% of 
all new diagnoses for infections where the transmission 
route is known. Emerging data from western Europe 
suggest that, in addition to MSM, a significant proportion 
of migrants, even those originating from high HIV-
endemic areas, acquire HIV after arrival in the EU/EEA 
portion of the West (6–8).
Action plan for the health sector response to 
HIV in the WHO European Region
The action plan for the health sector response to HIV in 
the WHO European Region is an implementation plan 
4 A total of 6.2 per 100 000 population (not adjusted for reporting delay); 6.5 
per 100 000 population (adjusted).
Fig. 2. Rate of new HIV diagnoses, WHO European Region, 2007–2016a
 
a Based on data from 51 countries (Turkmenistan and Uzbekistan were excluded because of inconsistent reporting during the period).
Source: ECDC, WHO Regional Office for Europe (2017).3
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for adapting the WHO Global Health Sector Strategy 
on HIV, 2016–2021, to the epidemiological, social and 
political contexts of the Region (Table 1) (4). It ensures 
that the Region can achieve the global goal to end 
AIDS as a public health threat by 2030, which the orld 
Health Assembly adopted by consensus in May 2016. 
The action plan continues the momentum generated 
through both the 2030 Agenda for Sustainable 
Development and Health 2020, the Region’s policy for 
health and well-being. It builds on the lessons learned 
from the first European action plan for HIV/AIDS 2012–
2015 by providing a roadmap for the next phase of the 
HIV response and suggesting fast-tracked actions to 
reverse the HIV epidemic in the Region (4). Region-
specific fast-track targets for 2020 are broken down 
into those focused on (i) prevention, (ii) testing and 
treatment; (iii) AIDS-related deaths; (iv) discrimination; 
and (v) financial sustainability.
Both the action plan and this compendium of good 
HIV practices are structured around the following five 
strategic directions:
1. Information for focused action: know your HIV 
epidemic to implement a tailored response.
2. Interventions for impact: all people should 
receive the full range of HIV services that they need.
3. Delivering for equity: all people should receive the 
services they need, which should be of sufficient 
quality to sustain an impact.
4. Financing for sustainability: all people should 
receive the services they need without experiencing 
financial hardship.
5. Innovation for acceleration: change the course 
of the response to achieve ambitious targets.
Table 1. Outline of the action plan for the health sector response to HIV in the WHO European Region
Items Description
Vision (2030) Zero new HIV infections, zero AIDS-related deaths, and zero HIV-related 
discrimination
Goal (2030) To end AIDS as a public health threat in the European Region by 2030
Targets (to be achieved 
by 2020)
Prevention:
• reduce new HIV infections by 75% (or an appropriate numerical target for low-
prevalence countries)
• reduce MTCT to <2% in non-breastfeeding populations and <5% in breastfeeding 
populations
• reduce the rate of congenital syphilis and the rate of child HIV cases due to 
MTCT to ≤50 per 100 000 live births
Testing and treatment:
• 90% of people living with HIV know their HIV status
• 90% of people diagnosed with HIV receive ART
• 90% of people living with HIV who are on ART achieve viral load suppression
AIDS-related deaths:
• reduce to below 30 000 (contributing towards reducing global AIDS-related 
deaths to below 500 000)
• reduce TB deaths among people living with HIV by 75% (or an appropriate 
numerical target for low-prevalence countries)
 
MTCT: mother-to-child transmission. Source: ECDC, WHO Regional Office for Europe, 2017.
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Intersectoral collaboration for a 
comprehensive response
The burden of HIV and its risk factors primarily fall on 
society’s most vulnerable and marginalized people; this 
is often due to a common range of social and economic 
determinants (9). Factors such as lack of a supportive 
legal environment, stigma and social exclusion, poverty, 
homelessness, violence, addiction, food insecurity, low 
education, mental health complications, unemployment, 
and lack of access to social support can dramatically 
impede HIV response efforts. The social determinants 
of health are outside the direct control of the health 
sector but play a vital role in HIV infection and the ability 
of people living with HIV to seek treatment and care. 
These factors also affect the exposure and vulnerability 
of people to other communicable diseases, such as TB 
and viral hepatitis, thus highlighting the advantage of 
addressing coinfections in an integrated manner.
The number of TB/HIV coinfections emerging in the 
WHO European Region increased from 13 000 to 
34 000 from 2007 to 2016 (a 260% increase) (10). 
In the eastern and central parts of the Region of the 
Region, approximately 40% of people living with HIV 
are coinfected with hepatitis C virus (HCV), while in 
western and central Europe, approximately 10.5% 
are coinfected (11). For these reasons, the epidemics 
cannot be addressed by the health sector alone. 
Hence, deliberate action to address the multisectoral 
nature of the social, economic and environmental 
determinants of health is crucial to (i) strengthen the 
response to HIV and end AIDS by 2030; and (ii) put 
people at the centre of HIV prevention, treatment and 
care, in line with the call for leaving no one behind 
and the Sustainable Development Agenda. To this 
end, within the framework of the Regional ‘UN SDG 
Issue-based Coalition on health and wellbeing for all 
at all ages’, the Regional Office led a multi-stakeholder 
consultation with 14 Regional UN partners to build a 
shared consensus on intersectoral collaboration to end 
HIV, TB and viral hepatitis. As a result, the ‘UN Common 
Position Paper on Ending HIV, TB and Viral Hepatitis 
Through Intersectoral Collaboration’, endorsed at the 
Regional UN System Meeting on 9 May 2018, calls 
upon all agencies within the regional UN system to 
address the epidemics determinants, with bolstered 
collaboration within and across sectors. The common 
position aims to accelerate implementation of evidence-
based technical assistance tailored to the local context 
of Member States, ensuring that those especially at risk 
are not left behind and preventing the epidemic from 
affecting the resilience of individuals and communities. 
By embedding multisectoral considerations within all 
five strategic directions, the action plan for the health 
sector response to HIV in the WHO European Region 
builds on the indivisible nature of the SDGs and on the 
multisectoral UNAIDS 2016–2021 strategy on the fast-
track to end AIDS. These recognize that to end the 
epidemics we must pursue progress across the entire 
spectrum of human rights (civil, cultural, economic, 
political, social, sexual and reproductive) for all.
Selection criteria for good HIV practices in 
the WHO European Region
The examples presented are the joint work of the 
authors listed for each practice.5 This compendium is 
not intended to highlight every strong practice in each 
Member State: a selection committee made up of key 
partners reviewed the submissions to ensure that the 
quality and conditions of the shared practices meet 
pre-defined criteria (Table 2).
Good practices in the response to HIV in the WHO 
European Region may include comprehensive 
combination prevention strategies for people at risk 
of acquiring HIV infection with a priority focus on key 
populations, including harm reduction interventions 
such as opioid substitution therapy (OST), needle and 
syringe programmes (NSPs); comprehensive condom 
and lubricant programmes; diversified HIV testing 
services, including testing by lay providers, HIV self-
testing and assisted partner notification; pre-exposure 
prophylaxis (PrEP); prevention and management 
of coinfections; a “treat all” approach6; and other 
evidence-informed interventions. Reducing stigma and 
discrimination and eliminating laws and policies that 
hamper access to, and uptake of, crucial HIV prevention 
and treatment services for key populations will help to 
facilitate further progress in the HIV response. National 
health authorities, including national HIV programmes, 
MoHs, MoJs or any other relevant responsible 
government organization, partner organizations, and 
NGOs responding to HIV in the Region were invited to 
submit examples of good practices through an open 
call and submission form available in both English and 
Russian.
5 Submissions were received from Regional partners and research conglom-
erates; national governments (e.g. ministries of health, ministries of justice); 
national HIV programmes (public health institutes, HIV/AIDS centres); imple-
menting partners; NGOs; and CSOs.
6 The “treat all” approach means that ART should be initiated in all children, 
adolescents, pregnant and breastfeeding women, and adults living with HIV, 
regardless of WHO clinical stage and with any CD4 cell count. WHO intro-
duced the “treat all” approach in its consolidated guidelines (5).
7Introduction
Table 2. Selection criteria for good practices for the prevention and control of HIV in the WHO European Region
Criterion Description
Relevancea Must address one of the targets or areas of intervention of the action plan for the 
health sector response to HIV in the WHO European Region, as outlined above
Sustainabilitya Must be implementable or able to be maintained over an extended period of time
Efficiencya Must produce results with a reasonable level of resources and time
Ethical appropriatenessa Must respect the current rules of ethics for dealing with human populations
Equity/gender
Addresses the needs of vulnerable populations and/or gender (identity) in an 
equitable manner
Effectiveness Must work, and achieve results that have been measured
Possibility of scale-up Can be scaled up to a larger population
Partnership Involves satisfactory collaboration between several stakeholders
Community involvement Involves participation from the affected communities
Political commitment Has support from the relevant national or local authorities
a Required.
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9STRATEGIC DIRECTION 1. Knowledge for focused action
Background
In 2016, 29 444 people were newly diagnosed with 
HIV in the EU/EEA part of the WHO European Region, 
corresponding to a rate of 5.9 per 100 000 population 
(1). To measure the continuum of HIV care in Europe, 
it has been recommended to measure four stages 
according to the 90–90–90 targets advocated by 
UNAIDS: (i) the estimated number of people living 
with HIV (ii) the number/proportion of these who are 
diagnosed; (iii) the number/proportion of these who 
on ART; and (iv) the number/proportion who are virally 
suppressed. In order to reach the 90–90–90 targets, 
the first step is critical (i.e. by 2020, 90% of all people 
living with HIV will know their HIV status). Nevertheless, 
testing rates among key populations are below 50% in 
many EU/EEA countries. New strategies are required 
to expand targeted HIV testing services, focusing on 
reaching the most affected population groups in local 
and national epidemic context(s). Community-based 
voluntary counselling and testing (CBVCT) services 
have been recognized as a good model to expand 
access to HIV testing, especially for key populations.
Description of the good practice
COBATEST is a network of CBVCT services created in the 
context of the HIV-COBATEST (HIV Community-Based 
testing practices in Europe) project (12). This network 
was established in 2009 by scaling up the Catalan DEVO 
network with the purpose of sharing similar procedures 
for monitoring the activity of CBVCT services across 
Europe to promote HIV testing, early diagnosis, and care 
for hard-to-reach groups. The CBVCT services in the 
COBATEST Network were heterogeneous in terms of 
size and capacity, and of the key populations they treat. 
Some were targeting MSM, people who inject drugs or 
SW, while others were treating the general population or 
a mixture of key populations.
A standardized protocol to monitor HIV testing 
activities in the network has been defined, including 
standard data collection instruments and procedures 
to homogenize the monitoring and evaluation of HIV 
testing activities at the community level (Guidelines 
for data collection for monitoring and evaluation 
of CBVCT for HIV in the COBATEST Network) (13). 
The Core Indicators to Monitor Community-Based 
Voluntary Counselling and testing (CBVCT) for HIV: 
guidelines for CBVCT services, developed by HIV-
COBATEST and aligned with ECDC, UNAIDS and 
WHO recommendations, are being used to monitor 
and evaluate CBVCT screening activity in the network 
(14). Members of the CBVCT services network share 
a common data collection tool and a database 
enabling the comparative analysis of global data. 
Alternatively, participating CBVCT services unable to 
use the common data collection form may collect data 
through their own data entry system and then submit 
a minimum dataset or return aggregated COBATEST 
core indicators.
Evidence of impact/efficacy
Geographical scope
Currently the network comprises 48 CBVCT services 
from 21 different countries (Austria, Bulgaria, 
Croatia, Cyprus, Czechia, Denmark, France, 
Germany, Hungary, Italy, Latvia, Lithuania, Poland, 
Portugal, Republic of Moldova, Serbia, Slovenia, 
Spain, Switzerland, the former Yugoslav Republic of 
Macedonia and Ukraine). Efforts are being made to 
include other eastern European countries and the 
Russian Federation.
Analysis of HIV testing data
According to the data submitted in the different 
formats, the total number of people tested for 
HIV with a screening test in 38 CBVCT services/
networks in 2016 was 72 916. A high proportion of 
STRATEGIC DIRECTION 1.  
Knowledge for focused action
The COBATEST Network
Submitted by: Fernàndez-López, Laura1,2 | Conway, Anna1 | Reyes-Urueña, Juliana1 | Klavs, Irena3 | Kustec, Tanja3 | Serdt, Mojca3 | 
Casabona, Jordi1,2 | COBATEST Network Group
1Agència de Salut Pública de Catalunya (ASPCAT) “Public Health Agency of Catalonia”, Barcelona; 2Consortium for Biomedical Research in 
Epidemiology and Public Health (CIBERESP), Madrid; 3National Institute of Public Health, Ljubljana, Slovenia
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the individuals tested were MSM (44.7%, including 
male SW), compared with heterosexual men (23.8%) 
and heterosexual women (22.3%). Of the total number 
of individuals tested, about 35% were first-time testers. 
Repeat testers had a higher percentage of reactive tests 
(2.0%) compared with first-time testers (1.1%).
For 2016, the proportion of clients with reactive 
screening HIV test results varied from 0% to 8.4% (mean 
1.8%; median 1.3%) among individual CBVCT services/
networks. The percentage of reactive screening tests 
was particularly high among transgender people, with 
an overall rate of 8.4% (the rate decreased from 9.6% 
in 2014 to 6.8% in 2016). Those considered foreigners 
have a higher percentage of reactive screening tests 
(2.3%) compared with non-foreign-born people 
(1.4%). Regarding the transmission group, the highest 
percentage of reactive screening tests is for male SW 
(at 6.4% overall; decreased from 7.8% in 2014 to 5.7% 
in 2016), followed by people who inject drugs (3.3% 
overall; increased from 0.7% in 2014 to 9.1% in 2016) 
and MSM (2.8% overall; ranging between 2.6% to 2.9% 
during 2014–2016).
The standardized data collection and data entry system 
allowed more detailed analysis of the data collected by 
CBVCT services using the COBATEST common tools 
(i.e. data collection and data entry tools). In 2014, 20 
CBVCT centres from the COBATEST Network used 
the common data collection tools; the number of sites 
increased to 25 in 2015 and to 29 in 2016. The total 
number of tests performed during the 2014–2016 
period increased by roughly a quarter, and data from 
more CBVCT sites were included in the analyses as they 
began to use the common tools. Over this period, the 
percentage of confirmatory tests improved from 63.0% 
to 90.0% and percentage of reactive screening tests 
that were linked to care increased from 43.0% to 79.9%.
Rapid tests were used in 98.1% of cases (rapid blood 
tests, 73.9%; rapid oral tests, 24.2%), with most 
performed in CBVCT offices (88.3%). HIV testing 
in outreach activities represents just 11.7% of the 
total number of tests performed but reaches a higher 
proportion of key populations (20.1% of people who 
inject drugs, 13.3% of female SW, 11.9% of MSM and 
7.5% of male SW).
It is crucial to know the number of tests performed 
and the HIV prevalence among those tested to assess 
progress towards achieving the first objective of the 
90–90–90 target (i.e. by 2020, 90% of all people living 
with HIV will know their HIV status). The indicators are 
also important to enable CBVCT services to evaluate 
the effectiveness of their model. The results indicate that 
CBVCT services are successful in diagnosing previously 
undiagnosed HIV-infected individuals in key populations, 
especially among MSM and male SW, transgender 
people and people who inject drugs.
The analyses found a high percentage of first-time 
testers (35.4%), showing increased potential for 
CBVCT services to reach people who have never been 
tested. Those first-time testers are mainly men, young, 
heterosexual and non-foreign born, although a non-
negligible percentage are MSM (24.4%) and foreign 
born (29.6%). Once a CBVCT service has reached those 
first-time testers, it is important to use the opportunity to 
encourage regular HIV testing.
Data impact
The information collected through CBVCT services 
strengthens the case for integrating community-based 
service delivery models into HIV strategic investments. 
The data are an important source of information to 
ensure quality services along the HIV care cascade. The 
monitoring and evaluation results from the COBATEST 
Network prove the feasibility of collecting standardized 
data from CBVCT services in different countries across 
Europe, as well as demonstrating the usefulness of such 
data (15–17).
Within Europe, the COBATEST Network has stimulated 
the process of developing indicators to monitor 
HIV testing at the community level, which are being 
incorporated into various ECDC documents and guides 
(18).
Sustainability
The COBATEST Network and analysis of the data 
collected on monitoring and evaluation indicators will be 
essential for selecting which CBVCT indicators should be 
included in the Dublin Declaration monitoring process, 
which measures the progress of the HIV response of 
each country, thus allowing better assessment of the 
HIV care cascade and improving the effectiveness of 
CBVCT services across Europe.
The COBATEST Network was implemented within the 
framework of the European HIV-COBATEST project, 
with co-funding from the Executive Agency for Health 
and Consumers under the EU Public Health Programme 
(Grant Agreement no. 2009-12-11) and grew and 
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continued to operate within the Operational knowledge 
to improve HIV early diagnosis and treatment among 
vulnerable groups in Europe project (Euro HIV EDAT) (19), 
with co-funding from the Consumers, Health and Food 
Executive Agency, acting under the powers delegated 
by the European Commission (Grant Agreement no. 
2013-11-01). The Network also receives a grant from 
the pharmaceutical industry to increase the Network, 
develop a specific website and logo, improve the data 
entry system, and organize a strategic meeting. The 
Network has now also been included in AIDS Action 
Europe’s Operating Grant, thus providing additional 
ongoing finances.
GERMANY. From pills to patients: an evaluation of data sources to determine 
the number of people living with HIV who are receiving ART
Submitted by: Schmidt, Daniel1 | Kollan, Christian1 | Stoll, Matthias 2 | Stellbrink, Hans-Jürgen3 | Plettenberg, Andreas4 | Fätkenheuer, Gerd5 
| Bergmann, Frank6 | Bogner, Johannes R7 | van Lunzen, Jan8 | Rockstroh, Jürgen9 | Esser, Stefan10 | Jensen, Björn-Erik 11 | Horst, Heinz-
August12 | Fritzsche, Carlos13 | Kühne, Andrea1 | an der Heiden, Matthias1 | Hamouda, Osamah1 | Bartmeyer, Barbara1 | ClinSurv Study Group
1Robert Koch Institute Berlin; 2Medical University Hannover; 3ICH Study Centre Hamburg; 4iFi Hamburg; 5University of Col ogne; 6Charité 
Uiversity Medicine Berlin; 7University Hospital Munich; 8University Clinic Hamburg Eppendorff; 9University of Bonn; 10University of Essen; 
11University of Düsseldorf; 12University of Kiel; 13University Hospital Rostock
Background
This practice describes a study aimed to determine 
the number of people living with HIV and receiving 
ART between 2006 and 2013 in Germany. 
Antiretroviral drug prescription data (APD) reported 
by billing centres for pharmacies were used, along 
with treatment data from a long-term observational 
multicentre cohort study with HIV-positive patients 
(ClinSurv HIV cohort). The APD are reported by 
billing centres for pharmacies covering around 99% 
of nationwide pharmacy sales of all individuals with 
statutory health insurance in Germany (~85%) (20). 
Exactly one thiacytidine-containing medication (TCM) 
with either emtricitabine or lamivudine is present in all 
antiretroviral fixed-dose combinations. Emtricitabine is 
only approved for the treatment of HIV and lamivudine 
is approved for the treatment of HIV at a dose of 
300 mg once daily or 150 mg twice a day.7 Thus, each 
daily dose of TCM documented in the APD represents 
one person per day receiving ART. ART has been 
documented for an average of 86% of ClinSurv HIV 
cohort patients; the medication history of this cohort is 
well documented. The observed study population (i.e. 
the ClinSurv HIV cohort) represents more than 20% of 
all HIV patients treated in Germany (21). In this study, 
the ClinSurv HIV cohort was only used to determine 
the corresponding proportion of non-TCM (7%) and 
treatment interruptions (2%). The proportion of non-
TCM ART regimen days in the ClinSurv HIV cohort 
was used to determine the corresponding number of 
individuals in the APD.
7  Lamivudine is also approved for the treatment of hepatitis B (although no 
longer recommended by WHO),, but with a daily dose of 100 mg for persons 
not infected with HIV.
Description of the good practice
This surveillance method represents the first 
comprehensive approach to estimating the number 
of people living with HIV who receive ART using the 
different existing and available data sources in Germany, 
with APD as the main source.
The steps used to calculate of the number of people 
living with HIV and with experience of ART are as 
follows.
1. Identify a data source (e.g. nationwide, regional or 
local prescription data or cohort data) containing 
the prescribed or administered drugs against HIV 
(or another infection).
2. Determine the representativeness of the source 
data to determine the proportion of those not 
covered by the source data (important for 
subsequent extrapolation).
3. Classify each drug combination according to 
whether it includes marker substances (i.e. 
substances typically used for treatment of a 
particular disease) or a drug that should not 
be not given simultaneously. Regarding ART, 
marker substances for TCM are emtricitabine or 
lamivudine, representing one person treated per 
day (or the relevant period). Determine the number 
of (standard-) units – generally pills, but can also 
be an injection pen or packages.
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4. Determine the defined daily dose (DDD) for the 
drugs and apply a drug/unit factor, if necessary. For 
the two TCM marker substances administered as 
pills, the DDD for adults is 300 mg for lamivudine 
and 200 mg for emtricitabine. On the European 
market, lamivudine is also available in a dose of 
150 mg, which is given twice daily and is therefore 
half a DDD; thus, a factor of 0.5 must be included. 
If other dosages are available in other countries, 
they must be converted according to the DDD.
5. Choose the smallest or most useful unit of time 
to observe a period. Observation over time does 
not mean tracking the same population over 
time: new people will initiate treatment and others 
will leave due to death or migration (denominator 
problem).
6.  Calculate the DDD for the TCM marker substances 
(or the respective marker substances) over time 
(each DDD of TCM represents one person per day 
receiving ART). This gives the number of people 
living with HIV receiving TCM (Fig. 3, red line).
7. The proportion of persons not covered by the 
data source should be added to the total and 
extrapolated to obtain the number of people 
living with HIV and treated with TCM in the whole 
country (Fig. 3, blue line). As most (~95%) ART 
regimens and all ARV fixed-dose combinations 
contain TCM, with the ongoing use of fixed-dose 
combinations this will provide a close estimate of 
the number of treated people living with HIV in the 
country. This is true for industrialized countries, 
as well as for developing countries, where there 
could be less drug variety.
8. If a factor for the proportion of ART regimens that 
do not contain TCM can be determined, then 
this proportion should be added to the total and 
extrapolated to provide the number of people 
living with HIV and receiving ART (including TCM 
and non-TCM ART regimens) in the country 
(Fig. 3, green line). Data from cohorts or similar 
sources can be used for this step.
9. If the proportion of persons who are interrupting 
treatment can be determined (e.g. from cohort 
data), this proportion should be added to the total 
and extrapolated to give the number of people 
living with HIV and with experience of ART in the 
country (Fig. 3, green line).
10. Owing to the observed seasonal variation in our 
data, the trend line was smoothed by negative 
binomial regression with a quadratic time trend 
(Fig. 3, purple line) (22). This is assumed to be 
unnecessary in most settings.
This surveillance method can also be applied to 
other infections treated with a variety of drugs or 
combination therapies. It is important to identify the 
marker substances or regimens on which to base 
calculations of the DDD for a treated person per day or 
packages for a treated person per month/quarter. The 
approach may lead to overestimation of the number of 
people receiving continuous ART by including patients 
receiving only short-term ART. This might be relevant 
in cases where therapy was discontinued early in a 
quarter or where patients have received post-exposure 
prophylaxis (PEP); however, PEP would only contribute 
to a potential overestimation of approximately 200–233 
patients in total.
Evidence of impact/efficacy
The methodological approach of calculating the 
number of individuals based mainly on unambiguous 
TCM drug treatment provides a simple and appropriate 
surveillance method for assessing the second 90–90–
90 target of the continuum of HIV care ( Fig. 4; column 
3, people on ART).
  
The analyses indicate that the number of people living 
with HIV in Germany and receiving ART has increased 
over time at an average rate of around 2900 persons per 
year. Most ART regimens (93%) in the cohort included 
TCMs with ongoing use of fixed-dose combinations. 
Based on these results, the future number of people 
receiving ART could be estimated based on TCM 
prescription data alone, assuming that treatment 
guidelines will not change with respect to TCM use in 
ART regimens.
This surveillance method can also be useful to estimate 
the number of people living with HIV and those 
receiving ART in other countries and settings. In other 
settings with fewer available ARVs, the proportion of 
ART containing TCM is even higher and the estimation 
would therefore be more accurate. The main data 
source was APD for patients with statutory health 
insurance, which covers ~85% of German residents. 
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In other countries or settings with a different structure 
of the health care system, other sources can be used 
such as: national surveillance data; drug prescription 
data of national registries, where available; data from 
special HIV prescription programmes; or private health 
insurance data for countries with a lower proportion of 
statutory health coverage. The methodology can be 
adapted for different investigations or medications. For 
example, it was recently assessed and is now used for 
the surveillance of hepatitis C treatment in Germany 
(23). By expanding this approach, the authors also 
successfully determined treatment levels for those 
receiving OST or treatment for HCV infection, HIV, or 
TB in German prisons (24).
Sustainability
The Robert Koch Institute, including its work on 
developing this surveillance method, is funded by the 
Federal MoH. The study is repeated annually to estimate 
the number of people living with HIV receiving ART and 
the HIV prevalence and measure the continuum of HIV 
care in Germany.
IRELAND. An evaluation of HIV case-based surveillance and change in the  
national surveillance case definition
Submitted by: O’Donnell, Kate1 | Igoe, Derval1 | Giese, Coralie 2,3
1HSE Health Protection Surveillance Centre; 2Ministry of Solidarity and Health, France; 3European Programme for Intervention Epidemiology 
Training (EPITET), Health Protection Surveillance Centre
Background
From the early 1980s to the end of 2016, a total of 
8341 people were diagnosed with HIV in Ireland (25). 
Since 2000, the rate of HIV has varied between 7.0 per 
100 000 population and 10.7 per 100 000 population, 
with approximately 10 new diagnoses per week in 
2016. HIV case-based reporting was introduced in 
Ireland in mid-2002, thereby improving surveillance. 
HIV was made a notifiable disease (mandatory 
reporting) in the country in 2011 and was included in the 
national computerized infectious disease surveillance 
system in 2012. In 2013, the HIV surveillance focal 
point in the National Virus Reference Laboratory 
(University College Dublin) found that some people 
diagnosed with HIV were not notified because they 
did not have the required confirmatory testing for two 
separate samples (according to the nationally agreed 
laboratory protocol). These were either cases with an 
anti-HIV serological positive result and subsequent 
viral load tests with undetectable viral loads or 
cases with only one antibody-positive result and no 
subsequent tests. Although the number of cases in 
these categories was small between 2009 and 2012, 
the number increased significantly in 2013 and action 
was needed. In addition, although it took time for the 
enhanced information to be collected and entered 
into the computerized infectious disease surveillance 
system, the length of the delays in notifying new HIV 
diagnoses and in providing enhanced surveillance 
data for HIV prior to the evaluation was unknown.
Description of the good practice
In an effort to assess national HIV reporting, an ECDC 
EPIET Fellow (on the field epidemiology path (26)) 
based at the Health Protection Surveillance Centre 
(HSPC) undertook a surveillance system evaluation, 
working closely with the HIV/sexually transmitted 
infection (STI) surveillance team at the HSPC and the 
surveillance focal point at the National Virus Reference 
Laboratory. The aims of the evaluation were to describe 
the surveillance system, focusing on the key attributes 
of sensitivity and timeliness. Prior to commencing 
the evaluation process, a protocol was reviewed 
and approved by key stakeholders involved in HIV 
surveillance. This included the national Public Health 
STI/HIV Special Interest Group and the HSPC national 
HIV/STI operational surveillance group, representing 
public health, surveillance scientists, laboratory and 
clinical specialties. The evaluation followed the United 
States Centers for Disease Control and Prevention 
(CDC) guidelines for evaluation of public health 
surveillance systems (27) and the ECDC handbook 
on data quality monitoring and surveillance system 
evaluation (28), along with the WHO guideline on 
evaluating a national surveillance system developed by 
the UNAIDS/WHO Working Group on Global HIV/AIDS 
and STI Surveillance (29).
Steps of the surveillance system evaluation
• Describe the national HIV surveillance system 
based on: (i) a review of documents at the HSPC 
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(including surveillance reports, computerized 
infectious disease surveillance system database 
reports, the HIV surveillance form, standard 
operating procedures, surveillance guidelines and 
other strategic documents) and (ii) semi-structured 
interviews with National Virus Reference Laboratory 
staff in charge of surveillance. The evaluator visited 
the Department of Public Health in the East Region 
and met the staff in charge of HIV surveillance.
• Estimate sensitivity by analysing new HIV diagnoses 
that were not notified in 2013 by the National Virus 
Reference Laboratory because they did not fit 
nationally agreed laboratory criteria for reporting.
• Measure the median (and range) time intervals in 
HIV surveillance steps and identify possible ways of 
reducing or eliminating them.
Insights from the evaluation
• The sensitivity of the system (measured by comparing 
National Virus Reference Laboratory data with 
notification data) was 82%; underreporting of new 
HIV diagnoses was due to the two-sample notification 
threshold required by the nationally agreed reporting 
procedures. A total of 71 (18%) diagnoses in 2013 
detected by the National Virus Reference Laboratory 
were not notified in the computerized infectious 
disease surveillance system because they did not fulfil 
the criteria for notification; in comparison, 334 cases 
were notified in the computerized infectious disease 
surveillance system in 2013. Twenty-three (32%) of 
the non-notified cases had only one sample with 
positive serology results. No additional information 
is available on the profile of these patients, but it is 
assumed that there may have been a delay in the 
second sample being sent; alternatively, some 
patients may not have accessed care or may have 
moved outside Ireland after their first diagnosis in 
the country. Forty-eight (68%) of the non-notified 
cases had one sample with positive serology results 
and an undetectable viral load. Most of these cases 
were persons who had transferred care from another 
country.
• Based on the available data, overall HIV surveillance 
in Ireland is timely for trend monitoring and fits 
within the CDC and national standards of timeliness 
(28,30), although recent standards are not available. 
The system is able to identify new diagnoses within 
approximately 19 days overall (delay from first 
positive test to confirmation to notification in the 
computerized infectious disease surveillance system). 
Eighty-one per cent of enhanced surveillance forms 
were completed within six months of diagnosis 
confirmation. It was therefore concluded that a 
reliable trend analysis could be undertaken after six 
months and that the interval between testing of the 
first and second samples (median: 10 days) could 
be eliminated if the system moved to a one-sample 
threshold for notification.
• Formal surveillance objectives were not documented 
prior to the evaluation and the system lacked 
harmonized procedures across the country.
Actions subsequent to the evaluation
• The national HIV surveillance case definition was 
changed (in 2015 for one region and in 2016 for 
all other regions) to improve sensitivity: all new 
diagnoses were notified following confirmatory 
testing of a single sample.
• To improve quality, the timing of national 
epidemiological reports was changed to account for 
the delay in receiving the majority of enhanced forms. 
As a result, annual epidemiological reports are now 
produced six months after the end of each calendar 
year.
• New surveillance objectives were agreed on with 
stakeholders.
Evidence of impact/efficacy
The purpose of the evaluation was to increase the 
sensitivity and timeliness of the national HIV surveillance 
system in Ireland via a change in the national surveillance 
case definition. This resulted in a large increase (28%) 
in notifications of HIV in 2015, followed by a smaller 
increase in 2016 (5%; Fig. 5). The change from the 
requirement for testing two separate samples to a single 
sample also eliminated the delay in waiting for the second 
sample. This change, undertaken in collaboration 
with the National Virus Reference Laboratory and 
other surveillance partners, resulted in more accurate 
and reliable information for action. The National Virus 
Reference Laboratory estimated that of the notifications 
in 2015 (n = 483), at least 50 (10%) were the direct 
result of this change to the case definition.
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Fig. 5. Notifications of HIV, Ireland, 2003–2016
The evaluation resulted in better documentation of 
the national HIV surveillance system, including the 
preparation of formal objectives.8
Sustainability
The change of case definition will continue without the 
provision of any additional resources. The evaluation 
was undertaken by the EPIET Fellow as part of her 
8  The full report of the evaluation is available (31).
training and the work of HSPC staff and the report 
were funded from existing resources by HSPC (Health 
Service Executive). The findings and recommendations 
of the evaluation also provided an impetus to proceed 
with plans for electronic reporting of HIV and STIs from 
clinics. Funding was secured for building an STI/HIV 
module within the computerized infectious disease 
surveillance system; this is due to be piloted later in 
2018.
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POLAND. Estimating the HIV viral suppression rate: a national study
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Background
In Poland, approximately 0.1% of population is infected 
with HIV, with more than 21 000 diagnosed cases 
as of January 2017. The country has seen a shift in 
transmission over the past decade: from transmission 
primarily from injecting drug use to sexual transmission 
between men, with high rates of HCV coinfection. 
Immediate initiation of ART irrespective of CD4 count 
leading to virological suppression is considered the 
most effective treatment option to preserve immune 
system function; it also decreases the risk of AIDS-
related morbidity and mortality, may reduce the 
likelihood of onward transmission and limits drug 
resistance. Initiation of ART regardless of CD4 cell count 
is recommended by all major treatment guidelines 
worldwide, including those of the Polish Scientific AIDS 
Society (32). Since 1996, unrestricted, free-of-charge 
coverage has been available for all EU-registered ART 
medications and combinations, as well as for genotypic 
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drug resistance, HIV viral load and CD4 cell assays. All 
ARVs and single-tablet ART regimens approved in the 
EU are purchased centrally based on orders from 16 
local HIV treatment centres (and one primary centre for 
ART distribution for the prisoner population).
Description of the good practice
To assess the national rate of virological suppression 
in Poland, a study was undertaken of a random 
selection of 50% of all patients at treatment centres in 
the country. The study aimed to estimate the national 
virological suppression rate, defined as HIV-RNA 
viremia of <50 copies/ml or <200 copies/ml.
Cross-sectional data on ART efficacy were collected 
for 5152 patients (56.92% of total national number of 
treated cases from 14 of the 17 HIV treatment centres. 
The data were nationally representative: two smaller 
clinical centres did not participate but the largest centres 
randomly selected approximately 50% of their patients. 
Inclusion criteria were ART adherence for at least six 
months, with at least one virological measurement in 
2016 after the period of ART adherence. Exclusion 
criteria were patients who did not report to the HIV 
clinic for at least six months, did not adhere to ART or 
did not have an HIV-RNA measurement at least once 
in 2016. The researchers estimate that approximately 
15–20% of cases were excluded (1200 persons). Loss 
to follow-up resulted from loss of medical insurance,9 
migration or the patient’s wish to stop treatment 
(<5% of cases). Fifteen HIV patients resulting from 
vertical transmission and four haemophilia patients 
were excluded from the final analysis owing to the 
small sample size. Data were disaggregated by age 
at HIV diagnosis, sex, date of HIV diagnosis, route 
of transmission, history of HCV coinfection based on 
anti-HCV serology results (anti-HCV positive/negative), 
history of AIDS (via medical records), baseline viral load 
(from entry to care), and the baseline, nadir and latest 
CD4 cell counts. The date of diagnosis was assumed to 
be the date of the positive recorded HIV test following 
western blotting, immunoblotting or positive serum 
HIV-RNA confirmation. As the time of seroconversion 
was often unavailable, acute HIV infection data were 
9  Since 2018, Poland requires all those receiving ART to have access to 
health insurance (at a cost of approximately €80 per month) (33).
not collected. The latest CD4 cell count was taken 
from the last value recorded in the medical records and 
the transmission route was self-reported. Collected 
ART data included drug classes for the current (or 
last) treatment and their drug combinations. Data 
on ART history was not collected. Engagement of 
people living with HIV with loss of medical insurance, 
their decision to stop treatment and the motivation of 
patients for regular follow-up and viral load testing/
monitoring were the primary bottlenecks to assessing 
the national virological suppression rate. In addition, 
data from the prison population were missing owing 
to lack of consent by the prison management. A lack 
of collected data on the number of people living with 
HIV emigrating from Poland also affected the ability to 
make conclusions regarding viral suppression for this 
section of the migrant population.
Evidence of impact/efficacy
Virological suppression at the viral load threshold of 
<50 copies/mL was observed in 4672 (90.68%) and 
of <200 copies/mL was observed in 4934 (95.77%) 
individuals. For the viral load threshold of 200 copies/mL, 
higher rates of viral suppression were only associated 
with a baseline CD4 cell count of at least 200 cells/
µl. In this study of people who are highly adherent to 
ART, the proportion of virologically suppressed patients 
(90.68%) proved to be in line with the 90–90–90 target, 
and specifically the last viral suppression target of 90% 
in the nationally representative sample. Virological 
suppression rates depend on baseline patient 
characteristics, which should guide individualized ART 
decisions.
Sustainability
This study was funded by the Polish Government. 
However, some patients are becoming uninsured, 
and thereby losing the right to free ART and HIV-
RNA monitoring. This needs to be considered a key 
risk when aiming for the UNAIDS 90–90–90 targets 
in the country. Member States choosing to adopt a 
similar nationally representative study may consider the 
limitations of this Polish experience in developing an 
adapted protocol that may also work closely with the 
prison population, the migrant population or those key 
populations where the burden of HIV is highest.
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UNITED KINGDOM. HIV surveillance beyond viral suppression: monitoring of 
quality of life and patient experience with a national HIV patient survey
Submitted by: Kall, Meaghan1 | Auzenbergs, Megan2| Brown, Alison1 | Kelly, Carole1 | Delpech, Valerie1
1Public Health England; 2Watipa
Background
The United Kingdom has an HIV population of around 
100 000, concentrated in men who have acquired HIV 
through sex with other men, as well as in men and 
women originating from sub-Saharan Africa (46% and 
24% of all persons living with HIV, respectively). HIV 
care and treatment are provided for all free of charge 
through the National Health Service. In 2016, 93% of 
persons living with diagnosed HIV were on ART and 
virally suppressed. The success of HIV treatment has 
reduced the HIV mortality rate; as a result, the United 
Kingdom has an ageing HIV cohort, with over one in 
three aged over 50 years.
Description of the good practice
Public Health England, the national public health 
institute responsible for HIV surveillance, has 
developed and implemented a novel self-reporting tool 
to routinely monitor the quality of life and experiences 
of people living with HIV, the Positive Voices survey. A 
representative sample of people accessing HIV care 
was invited to partake in the survey to ensure that 
findings were generalizable and comparable with the 
general population aimed to invite a representative 
sample of people accessing HIV care to ensure that 
findings are generalizable and comparable with the 
general population. The pilot phase of the survey 
was conducted in 2014 using a National Institute for 
Health Research grant. An advisory group of clinicians, 
social scientists, commissioners, survey experts and 
people living with HIV was established to guide the 
project. In the formative research phase, qualitative 
methods (i.e. focus groups, group interviews and 
structured observations) were used with HIV patients 
and health care staff to assess the acceptability and 
feasibility of various survey approaches, such as the 
use of incentives (a shopping voucher), survey formats 
(paper and electronic), survey length and recruitment 
approaches (face to face, text and email). To achieve 
a representative sample, the survey used an existing 
national HIV surveillance cohort (from the HIV and 
AIDS Reporting System) as a sampling frame to 
randomly select patients to invite to participate. Patient 
confidentiality and anonymity was of paramount 
importance; this approach ensured no other patient 
identifiers were collected. Pre-selected patients were 
assigned a unique six-letter survey identifier that had 
dual purpose: (i) as a logon to the online survey to avoid 
duplicate or fake responses; and (ii) as a means to link 
survey data to clinical and demographic data in the HIV 
and AIDS Reporting System. This linkage provides a 
unique opportunity to assess the relationship of patient 
experiences and needs with their clinical outcomes. 
The questionnaire was populated with validated 
survey questions and instruments, such a quality 
of life instrument (EQ-5D-5L) and a depression and 
anxiety scale (General Health Questionnaire (GHQ-12), 
generic patient-reported experience measures to allow 
comparison with the general population and pre-tested 
using cognitive interviews with HIV patients. Ethical 
approval was obtained.
Evaluation of the 2014 pilot (involving 777 participants 
from 30 clinics) of an electronic, clinic-based self-
completion survey showed high acceptability and 
feasibility overall but disproportionately low response 
rates among women, younger people and people of 
non-white ethnicity. Through an iterative consultation 
with the advisory group review of the qualitative and 
quantitative data, a final protocol was developed; this 
included the choice of both paper and online response 
formats; the option of face-to-face, email or postal 
recruitment; a recruitment period of up to eight months; 
and a £5 unconditional shopping voucher incentive. 
Postage paid envelopes were provided for patients to 
complete and return the paper survey outside of the 
HIV clinic.
National scale-up of the survey was made possible by 
a further grant; recruitment for Positive Voices 2017 
ran from January to September 2017 in 73 HIV clinics 
in England and Wales (serving half of all people with 
HIV in care). Overall, 4422 responses were obtained 
(51% response rate), resulting in a highly representative 
sample of people living with diagnosed HIV (Fig. 6). 
Data quality was high, with good internal and external 
validity, high item-response rates and over 97% of 
respondents submitting a fully completed survey. 
Weighting has been applied to further improve the 
reliability of the population estimates.
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The Positive Voices pilot and 2017 surveys provide 
proof of concept that high-quality patient-reported 
information can be collected at a national level to create 
a powerful bio-behavioural dataset that can be securely 
linked to surveillance and clinical data (e.g. ART uptake 
and viral suppression). Employing robust formative 
research methods and a flexible, iterative approach 
and ensuring community and expert involvement was 
crucial to the success of the survey. 
An example of the outputs is given in Fig. 7, showing 
the met and unmet needs of participants in the previous 
12 months. Despite excellent clinical outcomes for HIV 
care, a high level of need for social and welfare services 
was reported, with help in dealing with loneliness or 
isolation being the single greatest unmet need among 
people living with HIV (80% of people reported that 
this had not been met).These findings have important 
implications for future service provision and planning.
Evidence of impact/efficacy
For the first time in the United Kingdom, the Positive 
Voices 2017 survey data has provided an understanding 
of the overall well-being of people living with HIV and 
their experiences of the NHS during a time of significant 
changes in the delivery of health and social care 
services. While the initial aim was to provide knowledge 
to inform patient-centred care and the inclusion of 
patient experience measures in local and national 
quality standards, the survey has attracted much wider 
interest and the data are used by a broad range of 
stakeholders. For instance, the data have been used at 
the local and regional levels for HIV service evaluations 
and strategic needs assessments, and civil society 
for government policy briefing advocacy reports. The 
findings have been presented at national meetings and 
call for greater integration of HIV care with other health 
services, as well as greater support from peers and third 
sector organizations. Several manuscripts are planned 
for publication, including quality of life among people 
living with HIV compared with the general population, 
mental health and depression and the prevalence of 
comorbidities among people living with HIV. These will 
also form the basis of modelling and health economics 
work to assess future health needs and costs. Finally, a 
community-led co-analysis of the survey data informed 
by workshops with people with HIV who took part in 
the survey is under way.
Fig. 6. Representativeness of the Positive Voices survey sample compared with the national United Kingdom 
cohort
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Fig. 7. Positive Voices 2017: population prevalence of the need and unmet need for specific servicesa,b
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HIV RELATED SERVICES
Peer support
Disclosure support
Support managing LTC
Information - living with HIV
HIV treatment advice
Adherence support
HEALTH SERVICES
Drug detox or maintenance
Chemsex support
Stress management
Smoking cessation
Alcohol counselling/treatment
Weight management
Drug counselling
Advice regarding sex life
Psychologist or counsellor
Home health services
Family planning
SOCIAL & WELFARE SERVICES
Loneliness or isolation
Career skills and training
Childcare services
Financial advice
Employment advice
Legal advice
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Immigration support
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Housing support
Benefit claim support
Unmet needNeed
 
a n = 4416.
b Percentage need: the proportion of persons who stated that they had needed a specific service in last year; percentage unmet need; of those who had a need, 
the proportion who could not access the specific service in the last year.
LTC: long-term condition.
Sustainability
The Positive Voices programme costs around £100 000 
per year, including costs for three staff members, survey 
consumables and incentives (the per response cost is 
£67, very low for a probability survey). The success of 
the survey was possible owing to significant up-front 
investment for the formative research and pilot study; 
however, subsequent running costs are kept low by 
using the HIV and AIDS Reporting System as a sampling 
frame and automating the process. The novel design 
approach and methodology have been adapted and 
applied to a survey of attendees of sexual health clinics 
in the United Kingdom. The European Commission has 
provided funding through the INTEGRATE Joint Action 
(34) to adapt the Positive Voices method to survey 
HIV and HCV-infected patients across Europe. Public 
Health England aims to repeat the survey every three 
years.
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All people should 
receive the full range of 
HIV services they need
©WHO/James Hammond 
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STRATEGIC DIRECTION 2. Interventions for impact
Background
Before 2001, no prevention of mother-to-child 
transmission (PMTCT) of HIV (PMTCT) services were 
provided in Armenia. Pregnant women had low access 
to provider-initiated HIV testing and counselling and 
to ART, and prophylaxis for HIV-positive mothers and 
newborns was not available. Prenatal services for 
pregnant women and during childbirth required out-of-
pocket payment due to weak regulatory frameworks, 
lack of trained personnel, tests and ARV drugs, and 
low state and donor investment. Before 2005, less than 
10% of pregnant women were tested for HIV.
Description of the good practice
Under the Armenian Elimination of Mother-to-Child 
Transmission of HIV (EMTCT) project, the new 
comprehensive PTMCT system provides women with a 
free-of-charge package of medical services, including 
HIV testing and counselling; ARVs for pregnant women, 
mothers and children; free delivery of milk formula; 
and perinatal and child health protection services 
until age 7 years. Starting from 2016, HIV test kits for 
pregnant women and milk formula for infants born 
to HIV-positive mothers have been purchased from 
state budget allocations. Laboratory infrastructures, 
laboratory equipment and information technology 
requirements were established with support from the 
GFATM. Furthermore, personnel were trained and a 
countrywide PMTCT network was established. The 
training programme covers HIV testing strategies and 
algorithms; HIV laboratory diagnostics; HIV confirmatory 
testing; laboratory diagnostics for opportunistic 
infections; CD4 cell count, viral load monitoring; and 
qualitative and quantitative polymerase chain reaction-
based laboratory quality assurance. Supply chain 
management was also established at the national level, 
including forecasting, procurement and distribution of 
ARVs, HIV test kits, formula and consumables needed 
for early HIV detection among children. Annual external 
audits/quality control by the National Centre for AIDS 
Prevention were instituted in all HIV testing laboratories, 
with on-site technical assistance. This allowed Armenia 
to pass the external laboratory assessment, as part of 
WHO/UNAIDS validation of elimination of MTCT of HIV.
From 2010, training and retraining of health care 
workers on HIV/AIDS has been institutionalized via 
introduction of a HIV training course into the National 
Institute of Health platform. This course became part 
of the credit system of advanced training for health 
care workers. In addition, the National Monitoring and 
Evaluation Framework was established to coordinate 
the effective collection, analysis, aggregation and use of 
data and indicators (in alignment with WHO guidelines) 
related to prevention and treatment activities, including 
PMTCT services.
Evidence of impact/efficacy
The number of HIV tests performed among pregnant 
women has sharply increased since 2004 (Fig. 8). 
Since 2012, testing sites have been available in all 
antenatal clinics and more than 95% of pregnant 
women (over 40 000 women) have been tested. More 
than 200 women benefited from the PMTCT services 
and gave birth to HIV-free children. Since 2007, no 
HIV cases have been registered among children born 
to HIV-positive mothers who received PMTCT; since 
2014, the MTCT transmission rate has remained 
below 2% (Fig. 9).10 The practice additionally led to 
a revision of the Law of the Republic of Armenia on 
HIV/AIDS Prevention in 2009, in which mandatory HIV 
testing for pregnant women was replaced with health 
care provider-initiated HIV testing and counselling 
(including for children born to HIV-positive mothers). 
The National Institute of Health training programme 
10 The MTCT rate for HIV in non-breastfeeding populations in Armenia were 
1.78 per 100 000 population in 2014, 1.25 per 100 000 population in 2015 
and 1.36 per 100 000 population in 2016.
STRATEGIC DIRECTION 2. 
Interventions for impact
ARMENIA. From prevention to Elimination of Mother-to-Child 
transmission of HIV: the EMTCT project
Submitted by: Grigoryan, Samvel1 | Papoyan, Arshak1 | Ghukasyan, Gayane2
1National Centre for AIDS Prevention (NCAP); 2WHO Country Office Armenia
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has resulted in the provision of trained personnel in 
all antenatal clinics and laboratories countrywide, 
including obstetrician–gynaecologists, nurses and 
assistants, focused on strengthening PMTCT capacity, 
counselling and testing, patient management, and 
laboratory diagnostics. These trained personnel also 
understand legislative issues and the need to reduce 
stigma and discrimination for people living with HIV. 
In April 2016, WHO and UNAIDS experts performed 
a validation mission for the elimination of MTCT to the 
country; the certificate for validation was awarded on 7 
June 2016 (Fig. 8).
Sustainability
The EMTCT project is sustained by collaboration 
between the Department of Maternal and Child 
Health Care of the MoH, the National Centre for 
AIDS Prevention and the Institute of Reproductive 
Health, Perinatology, Obstetrics and Gynaecology. 
The programme is fully funded by the Republic of 
Armenia, except for procurement of some ARVs under 
the GFATM grant. Complete coverage with ARVs for 
PMTCT is expected after implementation of the current 
National AIDS Programme. Technical assistance is 
provided by UNAIDS, the United Nations Children’s 
Fund (UNICEF) and WHO.
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Figure 8. Armenia’s certificate of validation. ©UNAIDS
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Background
The spread of HIV infection in prisons is a particular 
concern in Azerbaijan. In 2007 and 2011, a range 
of integrated bio-behavioural studies (IBBS) were 
conducted to assess HIV prevalence among key 
populations, including surveys among inmates. 
Comparative analysis of the survey results shows an 
increase in the prevalence of HIV infection among 
inmates from 2.9% (n = 1000) in 2007 to 5.8% (n = 400) 
in 2011. In 2011, the Knowledge, Attitudes and 
Practices (KAP) survey on HIV/AIDS was conducted 
in 12 correctional institutions. The survey found that 
only half of respondents knew that HIV is transmitted 
both sexually and through contaminated needles 
and syringes. NSP and OST were not implemented 
among inmates because the necessary regulatory 
framework was lacking. Strengthening the expansion 
and improvement of HIV prevention interventions was 
the main task of the Main Medical Department (MMD) of 
the MoJ of Azerbaijan.
Description of the good practice
The types of activities included educational activities 
on HIV prevention and harm reduction; theatre 
performances; an educational documentary; the 
establishment of “health rooms” in selected penitentiary 
settings; condom distribution programming; improving 
laboratory capacities for HIV testing (including HIV testing 
in parallel with screening for TB); and continued policy-
related debate towards implementation of those NSP and 
OST programmes agreed by all stakeholders. With the 
participation of WHO experts, cycles of HIV prevention 
training and harm reduction programmes in prisons 
were provided to 180 medical and 440 nonmedical 
staff of penitentiary institutions throughout the country. 
Additional training on VCT for HIV and sessions on 
treatment and ART have also been conducted since 
2011 by leading staff of the Republican HIV/AIDS 
Centre. To increase HIV awareness among inmates, a 
documentary film was produced by leading specialists 
in the MoH and MoJ on HIV transmission, prevention 
and treatment. An annual theatrical performance was 
used to highlight issues of drug use, HIV transmission 
and alcohol use. Related health information materials 
including brochures and booklets have also been 
prepared, published and distributed.
Health rooms were set up in all 23 of the country’s 
penitentiary institutions, where inmates, including 
people living with HIV, can receive qualified assistance 
from psychologists and other multidisciplinary 
psychosocial support from specialized NGO staff. 
These health information and support sessions help in 
raising awareness on HIV transmission and care and in 
promoting healthier lifestyles among inmates. In 2012, 
a condom distribution programming was launched 
in all Azerbaijani penitentiary institutions. To further 
identify HIV-positive inmates, a special HIV laboratory 
facility was set up in 2013 in the penitentiary treatment 
institution to perform all necessary tests (including 
enzyme-linked immunosorbent assays (ELISAs), CD4 
cell counting and viral load monitoring), with the aim 
of bringing testing and treatment monitoring services 
closer to the needs of people living with HIV and of 
reducing delays in confirming test results. Provider-
initiated VCT for HIV is offered when inmates apply for 
health care assistance, during hospital treatment and 
periodically among at people who inject drugs. This 
includes annual voluntary HIV testing and an information 
campaign in parallel with TB screening. Furthermore, a 
medical consultative commission has been established 
to link those diagnosed with HIV to ART and care, in 
line with WHO recommendations.
Evidence of impact/efficacy
The rate of new HIV infections among inmates in 
Azerbaijan showed a decreasing tendency between 
2010 and 2017, despite increasing HIV testing rates 
(Fig. 10). The decrease coincides with the implemented 
health interventions and improved access to HIV testing 
and ART coverage. The IBBS and KAP surveys will be 
repeated in 2018 to monitor the achievements.
Sustainability
Costs related to laboratory testing, ART and the 
publication of health information materials are covered by 
the MMD of the MoJ in Azerbaijan. The support provided 
by NGOs, the provision of multidisciplinary psychosocial 
services through health rooms in penitentiaries, other 
health information and educational activities, including 
theatrical performances on health issues, along with 
condom distribution programmes require financial 
support from the national HIV programme and existing 
AZERBAIJAN. The influence of harm reduction programmes in prisons
Submitted by: Rafael İbrahim Oğlu, Mehtiev | Elnur Rovshan Oğlu, Mamedov | Natavan Faig gizi, Alikhanova
Main Medical Department of the Ministry of Justice
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donors. The plan for 2018–2021 is to support the work 
of NGOs and other preventive activities in penitentiary 
institutions using the national GFATM grant funds. 
Despite this, increased national allocations to cover HIV 
prevention programmes in penitentiaries will be needed 
to support this model of care.
Fig. 10. Testing coverage and HIV diagnoses among inmates (% of total inmates), 2010–2017
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AZERBAIJAN. Isoniazid preventive therapy among prisoners living with HIV
Submitted by: Rafael İbrahim Oğlu, Mehtiev | Elnur Rovshan Oğlu, Mamedov | Natavan Faig gizi, Alikhanova
Main Medical Department of the Ministry of Justice, Azerbaijan
Background
WHO estimates the risk of TB among HIV-infected 
people is to be 16–27 times greater in people living 
with HIV than in those without HIV infection (10). For 
HIV-infected inmates, this risk is much higher owing 
to additional factors associated with living in a closed 
setting. The benefits of isoniazid preventive therapy 
(IPT) among HIV-infected persons with latent TB 
infection have been known since 1998. In 2012, WHO 
re-examined the body of evidence on IPT initiation and 
recommended that HIV-infected people with latent 
TB infection should receive a six-month course of IPT 
every five years as an effective method of preventing 
active TB. Evidence for the benefits and harms of 36 
months versus six months of IPT was reassessed by 
WHO in 2015 and the following recommendation was 
made:
In resource-constrained settings with high 
TB incidence and transmission, adults and 
adolescents living with HIV, who have an 
unknown or positive tuberculin skin test 
status and among whom active TB disease 
has been safely ruled out, should receive at 
least 36 months of IPT. IPT should be given 
to such individuals regardless of whether 
or not they are receiving ART. IPT should 
also be given irrespective of the degree of 
immunosuppression, history of previous TB 
treatment, and pregnancy (35).
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The penitentiary institutions of Azerbaijan comprise 19 
correctional institutions, three pre-trial detention centres 
and two medical institutions, one of which is specialized 
for treating TB patients. In 2012, an agreement was 
reached between the MMD and the Republican AIDS 
Centre to fully transfer authority for the diagnosis, 
registration, treatment and monitoring of HIV-positive 
inmates to the MMD. All medical documentation for HIV-
infected individuals was transferred to the institutions of 
the penitentiary sector; this allowed the registration of 
HIV-positive inmates and preparation of special health 
care cards. Health care unit personnel received special 
training in the Republican AIDS Centre on the national 
algorithms for diagnosis and treatment and monitoring 
of HIV infection. In addition, a laboratory facility was 
established at the Medical Facility of the MMD by 
the end of 2013 to bring HIV diagnosis and infection 
monitoring closer to the needs of people within the 
penitentiary institution. One of the first actions was 
the introduction of IPT as the most effective method 
of preventing the development of active TB in people 
living with HIV.
Description of the good practice
The Order on the prevention of TB among HIV-infected 
persons from the inmate contingent was issued in 
2013. Training courses have been conducted for 
health care staff in the penitentiary sector, based on 
the latest WHO recommendations. Two mobile medical 
teams were created: each included a TB specialist, an 
HIV/AIDS specialist and an inspector from the MMD. 
In accordance with internal protocol, all HIV-infected 
persons who do not receive IPT are screened for TB 
using the an MTB/RIF assay twice per year. Results 
are recorded in health care cards and are available to 
the doctors of the mobile teams. In autumn and spring 
each year, these teams of doctors visit all penitentiary 
institutions and conduct a clinical examination of people 
living with HIV using a condensed screening algorithm 
based on identification of the four main symptoms 
of TB: persistent cough, fever, weight loss and night 
sweats. If any one of these symptoms is detected, 
sputum samples are taken and sent for diagnostic 
testing. In the absence of clinical and laboratory 
confirmation of active TB, the medical team prescribes 
IPT to the HIV-infected person and recommends further 
supervision by the medical staff of the relevant health 
care unit. Administration of a daily dose of isoniazid 
plus pyridoxine is documented on the prescription 
sheet. An electronic database of HIV-positive persons 
was created in the MMD, enabling the frequency of viral 
load testing and linkage to ART and IPT to be tracked.
Evidence of impact/efficacy
The number of patients with TB/HIV coinfection 
decreased by half (from 71 to 30 patients) from 2012 to 
2017, coincident with implementation of an integrated 
approach that includes a wide range of activities 
for the early detection and treatment of active TB 
and for the diagnosis and treatment of HIV-positive 
persons to prevent TB among people living with HIV. 
In addition, from the end of 2013 to 2017, 763 HIV-
infected persons were linked to IPT.11 Furthermore, 
a decrease in the number of new HIV infections was 
observed, despite an increase in coverage with HIV 
testing among inmates from 46% in 2012 to 71% in 
2017. The proportion of patients in whom latent TB 
infection progressed to active TB was lower compared 
with WHO data on the probability of developing TB 
among people living with HIV (Table 3). WHO estimates 
that the risk of TB in individuals infected with both 
Mycobacterium tuberculosis and HIV is much higher 
than for those without HIV infection (at 5–10% risk per 
year and 5–10% lifetime risk, respectively) (36).
Sustainability
This practice is based on the necessary legislative 
framework and is fully implemented without donor 
support: it is fully funded from the budget of the 
MMD of the MoJ. The practice has demonstrated its 
effectiveness and will continue following updates by 
WHO on recommendations for TB screening and TB 
preventive treatment for people living with HIV.
11 Breakdown by year: 261 in 2013, 160 in 2014, 132 in 2015, 130 in 2016 
and 89 in 2017.
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Background
Although the annual number of new HIV cases has 
been increasing in Belarus, the annual rate of increase 
in HIV diagnoses declined significantly from 23.6% in 
2013–2015 to 3.3% in 2016–2017. According to the 
National Centre of Hygiene, Epidemiology and Public 
Health, HIV incidence in 2017 was 25.9 per 100 000 
population, prompting the urgent need to increase 
early detection through testing and diagnostics. 
Although the country offers universal HIV testing and 
counselling in health care facilities and through social 
organizations working with key populations, one-third 
of the estimated number of people living with HIV in 
Belarus are unaware of their status.
Description of the good practice
Active discussion on introducing self-testing for 
HIV began immediately after the release of the 
WHO Guidelines on self-testing for HIV and partner 
notification in December 2016 (37). Participants in 
the discussion included representatives of the MoH, 
patient organizations, NGOs, doctors, international 
partners [UNAIDS, UNICEF, the United Nations 
Population Fund (UNFPA), the United Nations 
Development Programme (UNDP)]. After making the 
decision to implement this practice, the preparatory 
work was launched, including an information 
campaign in the media. Since 1 May 2017, Belarus 
has implemented self-testing for HIV via rapid saliva 
tests sold in pharmacies. A pilot programme was 
initiated in the Homiel region, which has the highest 
HIV prevalence in the country (Homiel, 521.4 per 
100 000; Belarus, 202.3 per 100 000). The self-
test was introduced in the capital city, Minsk, on 9 
September 2017. Currently, this practice has been 
introduced country-wide. As of 1 February 2018, the 
test costs 5.75 rubles (less than US$ 3).
The MoH of the Republic of Belarus, with support from 
UNAIDS and UNICEF, conducted a national information 
campaign, entitled “Concerns even those who are not 
concerned”, in an attempt to reach those who may be 
infected but may have little personal concern about HIV. 
The main objectives of the information campaign were 
to facilitate voluntary rapid HIV testing among different 
age groups of the population; attract the attention of 
central and regional media; ensure the support and 
participation of the heads of executive authorities; 
and change stereotypes in different target groups. 
The most effective PR activities included talk shows, 
press conferences, touring the country accompanied 
by mass media representatives, participation in local 
events organized by executive power bodies, and 
regular coverage of the information campaign. An 
important component in achieving the goals and 
objectives of the campaign was the involvement of 
Belarusian and foreign celebrities and artists.
Evidence of impact/efficacy
The self-test for HIV has proven to be popular. By 
1 February 2018, pharmacies had sold about 2000 
rapid tests and 20 people had sought further medical 
assistance after self-testing. Those with positive self-
test results are further tested by rapid blood test or 
ELISA followed (for those with a positive result) by a 
second ELISA and immunoblotting, in accordance 
with current HIV testing policy in the country. Those 
with a confirmed positive result for HIV were linked to 
the dispensary registration system for further medical 
attention and initiation of ART. A hotline telephone 
Table 3. Annual risk of TB among people living with HIV receiving IPT in Azerbaijani prisons, 2013–2016
Year of IPT First year after 
IPT
Second year after 
IPT
Third year after 
IPT
Fourth year after 
IPT
2013 3.7% 5.6% 2.9% 3%
2014 3.7% 5.6% 2.9% –
2015 3.6% 4.2% – –
2016 4.1% – – –
BELARUS. Introduction of HIV self-testing
Submitted by: Grankov, Viatcheslav1 | Hlinskaya, Iryna2 | Rusanovich, Anna2
1WHO Country Office Belarus; 2National Centre of Hygiene, Epidemiology and Public Health
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number is also provided for those who need further 
help, including psychological support.
Sustainability
No additional funds from the state budget are required 
for this practice. Self-tests are affordable at the price 
set by the local manufacturer. Support from the MoH of 
the Republic of Belarus, NGOs, doctors and various UN 
agencies facilitated the launch of this practice. As an 
area for improvement, the full media campaign may be 
continued by Belarus and adapted for key populations 
following expansion of the self-test to the entire country 
after 2018.
CROATIA. Integration of community HIV and HCV testing through a 
comprehensive sexual health approach: HUHIV – CheckPoint Zagreb
Submitted by: Nemeth Blažić, Tatjana1 | Delaš Aždajić, Marija2 | Beganović, Tomislav3 | Dišković, Arian3| Erceg, Maja3,4| Kosanović Ličina, 
Mirjana Lana5 | Vince, Adriana4
1Croatian Institute of Public Health; 2Sestre Milosrdnice University Hospital Centre; 3Croatian Association for HIV and Viral Hepatitis (CAHIV); 
4University Hospital for Infectious Disease “Dr Fran Mihaljević”; 5Andrija Štampar Teaching Institute of Public Health
Background
In the period from 1985 to 2017, 1540 cases of HIV 
infection were documented in Croatia, 500 of which 
progressed to AIDS, resulting in 265 deaths. Most HIV/
AIDS patients are male (88%). Almost 90% of people 
living with HIV in Croatia have been infected as a 
result of sexual contact and 5% as a result of injecting 
drug use. Since 2013, the average annual number of 
reported HIV/AIDS cases has been 100 (range 77–
116), an increase of around 150% since before 2004. 
This may be partly explained by a genuine increase 
in the number of infections, along with an increase 
in HIV testing following the introduction of voluntary, 
free and anonymous counselling and testing for HIV 
in eight Croatian cities in 2004. The predominant 
mode of transmission is sexual contact between men, 
representing 64% of all registered cases. In 2016 
alone, 84% of all newly diagnosed cases were MSM. 
Although Croatia has a low incidence rate of two 
cases per 100 000 population, the large increases in 
transmission via MSM are worrying. The number of 
registered cases of hepatitis C rose steadily during 
the 1990s, remained relatively stable at about 400 
per year from 2000 to 2007 and has been gradually 
decreasing since 2008. The overall prevalence of 
HBV and HCV infection is less than 1% in the general 
population; thus, Croatia is a low-prevalence country 
for these infections. However, estimates of HBV and 
HCV infection prevalence in high-risk populations are 
higher: 3% for prevalence of HBV infection in people 
who inject drugs and 40% for HCV infection (ranging 
from 30% to 65%, depending on the study design) 
(38).
Description of the good practice
In response to the HIV epidemic, decentralized access 
to VCT centres provides an excellent solution of HIV 
prevention, especially for youth and adolescents. 
Operating within the Croatian Association for HIV and 
Viral Hepatitis (CAHIV), CheckPoint Zagreb provides 
health education to young people, counselling, 
and psychosocial support, along with voluntary, 
anonymous, confidential and free testing for HIV 
and HCV. The centre provides health care for youth, 
counselling and education (e.g. on HBV, HCV, HIV 
and HPV vaccination and on STIs), testing and early 
detection of HIV and HCV, and linkage to care and early 
treatment. CheckPoint Zagreb is a valuable addition to 
the existing network of 10 VCT centres in Croatia that 
collaborates with the National Institute of Public Health 
and the University Hospital for Infectious Disease “Dr 
Fran Mihaljevic´ ”. Half of the CheckPoint users in Zagreb 
are aged under 29 years (39). Risk factors for youth 
may include having multiple partners and unprotected 
sexual intercourse and data show that young men and 
women in Croatia are increasingly becoming vulnerable 
to STIs. In addition to youth, CheckPoint Zagreb 
attracts older age groups with a sexual risk history such 
as previously untested MSM, including those who may 
be hard to reach or conceal their sexual orientation.
Those with a positive test result are referred to the 
University Hospital for Infectious Disease “Dr Fran 
Mihaljevic´ ” for diagnostic confirmation, linked to care and 
given information on the benefit of partner notification 
(including anonymous options) by counsellors and 
two licensed psychologists specialized in psychosocial 
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support for people with HIV and STI. These trained 
personnel also offer further psychological education, 
psychological counselling and other types of support 
for people living with these infections and their close 
contacts. Quality assurance is of the utmost importance 
within CheckPoint Zagreb. Operational protocols for 
testing and counselling services have been designed in 
collaboration with experts from the University Hospital 
for Infectious Disease “Dr Fran Mihaljevic´ ” in Zagreb. 
Standard operating procedures are implemented in 
accordance with Croatian legislation and CDC, ECDC 
and WHO guidelines. Testing in accordance with 
protocols is conducted externally by doctors and experts 
from the University Hospital for Infectious Disease “Dr 
Fran Mihaljevic´ ”, the Croatian Institute of Public Health 
and the Croatian Red Cross. The organization and 
coordination of activities, implementation of pre- and 
post-test counselling and education, recruitment and 
motivation of targeted users, quality control (internal 
quality control for all working processes of the services), 
and results management and monthly/annual reporting 
are performed by the Croatian Association for HIV and 
Viral Hepatitis (HUHIV) with additional oversight from 
the Zagreb City Office for Health. Biannual meetings 
are organized for counselling service members to share 
their experiences and discuss quality improvement. 
Counselling protocols and testing activities are regularly 
reviewed and updated in accordance with new 
developments in the field. Finally, users are routinely 
invited to answer a standardized customer satisfaction 
survey, which is then incorporated into programmatic 
development efforts.
Evidence of impact/efficacy
Since its establishment in 2013 until the end of 2017, 
just over 7000 individuals have received individual 
counselling at CheckPoint (Zagreb centre) and over 
5500 people have been tested (for HIV and/or HCV), 
an average of 150–200 persons per month (Table 4). 
Data show that 80% of CheckPoint users were 
recommended for testing based on a risk assessment 
(high-quality coverage and screening) and 20% of 
all users have had a history of STIs when presenting 
for testing. More than 50% were informed about 
their health status and also directed to specialized 
health care services (STI screening, mental health 
and psychosocial support, and addiction prevention 
support). For those seropositive for HIV and HCV, a 
team of doctors specialized in HIV and viral hepatitis 
together with CheckPoint counsellors informs users 
about further diagnostics and treatment. They also 
offer to arrange the first appointment after receiving 
patient consent. A paper copy of the test result is 
also provided for linking to the hospital system. This 
approach provides comprehensive access to health 
care for those with positive results, including a high 
percentage of individuals that were tested for the first 
time (reaching 60–70%).
The number of new cases of HIV and HCV infection 
discovered in users of Checkpoint represents about a 
fifth of all newly discovered cases in Croatia per year. 
Checkpoint Zagreb offers a safe environment where 
users feel respected and valued. Moreover, knowledge 
and experience gained through the work of the 
Zagreb centre (e.g. implementing the system, creating 
indicators for HBV/HCV infection modelled on HIV, 
access to the users, recognition and screening) have 
been included in the draft National Strategy for the 
Prevention of Viral Hepatitis in the Republic of Croatia. 
Fig. 11 shows the levels of collaboration in CheckPoint 
and Fig. 12 shows the interior of CheckPoint Zagreb.
Fig. 11. CheckPoint collaboration levels
Table 4. Checkpoint Zagreb Report, 2013–2017
EDUCATION TESTING HIV TESTING HCV TESTING
Total num-
ber of pre-
counselling 
services 
provided
Total num-
ber of post-
counselling 
services 
provided
Total 
number 
of tests 
provided
Total 
number 
of people 
tested for 
HIV 
infection
Total 
number 
of HIV-
positive 
people
Propor-
tion of 
HIV-
positive 
people
Total num-
ber of 
people 
tested for 
HCV 
infection
Total 
number of 
HCV-
positive 
people
Proportion 
of HCV-
positive 
people
2013 1319 1277 1277 1215 13 1.07% 1002 6 0.60%
2014 1461 1382 1382 1339 9 0.67% 1230 14 1.14%
2015 1338 1043 1043 998 9 0.90% 738 5 0.68%
2016 1507 975 975 921 17 1.85% 662 18 2.72%
2017 1483 981 981 923 13 1.41% 702 7 1.00%
TOTAL 7108 5658 5658 5396 61 1.13% 4334 50 1.15%
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LOCAL 
COMMUNITY
(City of Zagreb)
CIVIL 
SOCIETY
(HUHIV)
PROFESSIONAL 
BODIES
National HIV AND HCV 
reference centres, certified 
viral testing laboratories, 
experts and colloborators 
(the clinic, CIPH, CRC)
CIPH: Croatian Institute for Public Health.
Sustainability
Programmatic success is included in the objectives 
and activities of the Croatian National HIV/AIDS 
Prevention programme and in the draft National 
Strategy for the Prevention of Viral Hepatitis. Moreover, 
CheckPoint is included as key priority in network health 
services development in the City of Zagreb as part 
of the Social Plan for the City of Zagreb 2014–2020. 
CheckPoint is also recognized as part of the registry 
of valorized programmes of the Croatian Healthy Cities 
Network, which aims to systematically evaluate the 
effectiveness of current national programmes and 
develop recommendations and guidelines for further 
improvements in policy and public health activity. 
CheckPoint Zagreb is a HUHIV project conducted in 
partnership with the City of Zagreb (i.e. the City Office 
for Health, the University Hospital for Infectious Disease 
“Dr Fran Mihaljevic´  ”, the MoH and numerous partners 
and health professionals). Collaborators include the 
University Hospital for Infectious Disease “Dr Fran 
Mihaljevic´  ”, the Croatian Institute of Public Health, the 
Croatian Red Cross and the School of Public Health “Dr 
Andrija Štampar”, underscoring the strong intersectoral 
and political commitment.
CheckPoint Zagreb has the following funding sources: 
City of Zagreb through developing services in health 
care and other public health grants, 50%; MoH through 
national cooperation programmes with NGOs, 30%; 
and additional funding from national and international 
Fig. 12. Inside CheckPoint Zagreb
©Arian Disković/Maja Erceg
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public and private sector organizations, 20%. National 
and local stakeholders have also recognized the 
importance of the Zagreb centre in helping to overturn 
stigmatization, and thus provide additional annual 
funding to support the centre’s activities. The annual 
financial plan ensures continuous funding and ongoing 
funding applications to European structural and 
investment funds. Media coverage, including press 
conferences, is popular with the interested public. 
These conferences are strongly supported by the 
City of Zagreb, resulting in enhanced visibility for the 
project. Structured interviews and focus groups for 
users, ongoing reduction of stigma through enhanced 
community-based programmes and outreach, and 
implementation of programme-designed/derived 
partner notification tools may also benefit the practice.
ESTONIA. Providing quality harm reduction services for people who inject drugs
Submitted by: Kurbatova, Aljona | Abel-Ollo, Katri | Ojalo, Jürgen2
1National Institute for Health Development; 2Ministry of Social Affairs Estonia
Background
Estonia is the only country in eastern Europe that has 
seen a sustained decrease in new HIV diagnoses over 
the last decade: following the 2001 peak, the rate 
continued a steady decline throughout 2016 (1). There 
are an estimated 3906–9837 people who inject drugs 
in Estonia. Injecting drug use is primarily confined 
to the capital city, Tallinn (in Harjumaa County), and 
north-east Estonia (Ida-Virumaa County). According 
to cross-sectional studies conducted between 2013 
and 2016, approximately 48–66% of people who inject 
drugs are also living with HIV. Among those with new 
HIV infections, approximately 20% were also injecting 
drugs in 2015; the proportion has been stable in recent 
years around 17–23% in 2010–2014).
Description of the good practice
A NSP was launched in Estonia in 1997 and now 
forms part of the essential harm reduction package. 
The package includes needle and syringe exchange; 
a take-home naloxone programme to reduce the 
number of fatal overdoses; referral to HIV, STI and TB 
testing and linkage to care; referral to drug addiction 
treatment, HIV and TB treatment; and social support 
and counselling services. These services are mostly 
provided in areas with the largest burden of HIV (Tallinn 
and surrounding areas and north-eastern Estonia). The 
number of service provision sites (both stationary units 
and mobile outreach units (MOUs), increased from 13 
in 2002 to 34 in 2017 in 17 cities and settlements; this 
was the work of nine organizations, mostly NGOs. 
In 2017, about 5500 clients visited harm reduction 
services. In the same year, the NSP distributed almost 
2 million free syringes and needles, exceeding the 
recommended 200 syringes per person who injects 
drugs per year. Although HIV testing is not routinely 
offered at all harm reduction sites, point-of-care rapid 
HIV testing is provided at larger centres and clients are 
referred to VCT sites.
Evidence of impact/efficacy
Estonian cross-sectional studies show that sharing of 
used needles and syringes has recently decreased in 
some regions but in others has remained stable over 
the years (Table 5). HIV prevalence is still high among 
people who inject drugs but knowledge of HIV status 
has increased over the study period. The Estonian 
population of people who inject drugs is ageing and 
the average injecting history (i.e. number of years of 
injecting drug use) is increasing; thus, the population 
seems to have stabilized or be stabilizing (Table 5). In 
2011, Uusküla et al. (2011) concluded that the decrease 
in the number of new HIV cases among new injectors 
coincided with a large scale up of the NSP in Estonia 
(40). The estimated HIV incidence among new injectors 
decreased significantly from 18 per 100 person-years 
in 2005 and 21 per 100 person-years in 2007 to 9 per 
100 person-years in 2009 (p = 0.026).
Sustainability
Harm reduction interventions are funded entirely 
from the national budget within the framework of 
the National Health Plan, while the current National 
HIV and AIDS action plan and White Paper on drug 
policy provide wider strategic directions (45). The 
White Paper for 2014−2018 sets out the government-
approved set of evidence-based principles and policy 
recommendations for reducing drug use and the 
obligation to take these into account in planning actions 
for illicit drug prevention.
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Reducing drug-related harm is a key target of drug 
policy and of public health policy in Estonia. Estonia 
included harm reduction services in the essential 
package during the GFATM HIV programme that began 
in 2003. This enabled the country to establish a more 
systematic harm reduction approach between 2003 
and 2007 and to include harm reduction as one of the 
priority actions in the National HIV and AIDS strategy 
for 2005–2015. In 2007, the GFATM stopped financing 
harm reduction programmes, but the joint national 
and local government financing model that was put in 
place ensured that the country was ready to transition 
from international to national funding. Since 2007, 
Estonia has fully financed harm reduction programmes 
from domestic sources and assured good coverage 
with NSP across the country while continuing efforts 
to increase coverage with OST. Long-term financial 
planning and presenting evidence on the effectiveness 
and cost–effectiveness of harm reduction interventions 
were essential in ensuring political support.
Table 5. Results of risk behaviour and HIV prevalence studies among people who inject drugs, 2012, 2013, 
2014 and 2016
Measure 2012 2013 2014 2016
Area Kohtla-Järve Tallinn Narva Kohtla-Järve
Average age, years 30 32 34 35
History of IDU, years 11 12 14 16
Proportion sharing needles/syringes, 
last 4 weeks
6% 23% 10% 1%
Proportion sharing needles/syringes, 
lifetime
65% 67% 66% 60%
Sources: Institute for Health Development, 2012 (41), 2013 (42), 2014 (43) and 2015 (44).
FRANCE. Implementing PrEP for populations at a high risk of sexual acquisition 
of HIV
Submitted by: Molina, Jean-Michel1 | Comboroure, Jean-Christophe2 | Dabis, François3
1University of Paris Diderot, St-Louis Hospital AP-HP; 2Ministry of Health, France; 3National Agency for Research on AIDS and Hepatitis (ANRS)
Background
Since 2006, the annual number of newly diagnosed 
HIV infections in France has remained unchanged at 
approximately 6000 (in 2016), despite free access to 
HIV testing and ART and recommendations to start 
all HIV-infected patients on ART regardless of their 
CD4 cell count. MSM and heterosexuals born abroad 
(75% originating from sub-Saharan Africa) account for 
44% and 39% of all new diagnoses, respectively. In 
February 2012, the French Agency for Research into 
HIV/AIDS (ANRS) decided to launch the Intervention 
Préventive de l’Exposition aux Risques avec et pour 
les Gays (IPERGAY) PrEP study of high-risk MSM using 
on-demand tenofovir disoproxil fumarate combined 
with emtricitabine. The results of a trial of MSM taking 
a daily dose of tenofovir disoproxil fumarate combined 
with emtricitabine (TDF/FTC) reported a reduction in 
HIV incidence of only 44% (46). However, researchers 
thought that a less-demanding or more convenient 
ART regimen might be more sustainable (i.e. improve 
adherence) and have greater treatment efficacy. The 
results of the ANRS IPERGAY study released at the 
2015 Conference on Retroviruses and Opportunistic 
Infections showed that provision of on-demand TDF/
FTC led to a remarkable 86% relative reduction of HIV 
incidence compared with placebo (47). Furthermore, the 
high efficacy was confirmed in an open-label extension of 
this trial, which reported a 97% relative reduction of HIV 
incidence with on-demand TDF/FTC (48). In response to 
the study results and recommendations made by French 
groups of experts mandated by the French Drug Agency 
at the end of 2015, the French MoH granted TDF/FTC 
the status of “recommendation for temporary use” for 
HIV prevention in individuals at a high risk of sexual 
acquisition of HIV, with full reimbursement of costs by 
the National Health care system since January 2016. 
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Full approval was granted in February 2017 following 
the European Medicines Agency’s (EMA) approval of 
TDF/FTC for preventing HIV acquisition.
Description of the good practice
Since January 2016, PrEP with TDF/FTC has been 
recommended in France for individuals at a high risk of 
sexual acquisition of HIV, defined as MSM or transgender 
people and have had unprotected/condomless anal sex 
with at least two partners during the last six months, 
have had episodes of STIs over the last 12 months, 
have received more than one PEP treatment in the 
last 12 months or use drugs during sexual intercourse 
[such as cocaine, GHB (gamma-hydroxybutyric acid) 
or MDMA (ecstasy)]. Other persons with a high risk of 
HIV infection were assessed on a case-by-case basis. 
These included SW exposed to condomless sex and 
persons exposed to condomless sex with people from 
a group with a high prevalence of HIV: people from 
areas/countries of high HIV prevalence, people with 
multiple sexual partners and people who inject drugs.
PrEP can be prescribed either daily (one pill a day) or on 
demand, as in the ANRS IPERGAY trial (a loading dose 
of two pills taken two to 24 hours before sex and then 
two pills after sex: one 24 hours after the first intake 
and one 48 hours after the first intake). The on-demand 
regimen is only recommended for MSM who plan to 
engage in sexual intercourse. The first PrEP prescription 
should be given by a hospital specialist in HIV medicine 
or in a sexual health clinic. Patients should provide the 
results of a recent HIV test using a fourth-generation 
combined ELISA and the results of testing for other STIs 
and for creatinine clearance to assess kidney function 
(since tenofovir disoproxil fumarate can cause renal 
toxicity). Patients are seen again after one month (to 
rule out a primary HIV infection and assess tolerability 
and adherence) and then every three months. General 
practitioners can renew prescriptions and monitor 
PrEP users, as stated in the 2018 Guidelines for PrEP 
implementation and monitoring (which were updated 
by a French group of experts) (49). The cost of PrEP 
is fully reimbursed by the national health care system 
and TDF/FTC can be delivered by both hospital and 
private pharmacies. Generic versions of TDF/FTC have 
been available in France since July 2017 and are used 
for PrEP. A national awareness campaign for MSM 
(Fig. 14) was launched in all French cities in November 
2016 and a website was created to provide information 
on HIV prevention, HIV testing and PrEP (50).
Evidence of impact/efficacy
Data on PrEP use from 1 January 2016 to 31 July 
2017 via reports from the National Health Insurance 
database showed that a total of 5352 people started 
PrEP (including daily and on-demand PrEP) during this 
period, with 300–400 new PrEP initiations per month. 
Of the people taking PrEP, 97.5% are men with a 
median age of 37 years (interquartile range: 30–45 
years); and 49% live in the Ile de France region (Paris), 
10% in Auvergne-Rhone-Alpes (Lyon) and 10% in 
Provence-Alpes-Cote d’Azur (Nice). Approximately 
92.2% of initial prescriptions come from hospitals. The 
number of high-risk MSM in France is estimated to be 
around 32 000 (those with fewer than two receptive 
anal sex encounters). Data from the first year of PrEP 
use in France were reported at the International AIDS 
Conference in 2017 (51). Among 2774 individuals 
(98% MSM), only four HIV seroconversions were 
reported: of these individuals, two had already been 
infected at the time of PrEP initiation and the other two 
reported poor adherence. The overall HIV incidence 
in this cohort was only 0.28 per 100 person-years of 
follow-up, similar to that reported in the open-labelled 
phase of the ANRS IPERGAY study. Impact data 
Fig. 13. HIV awareness campaign, Municipality of Paris
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Fig. 14. National awareness campaign for MSM
for PrEP in new HIV diagnoses are eagerly awaited, 
but data for 2017 will only be available at the end 
of 2018. Implementation of PrEP has enabled more 
frequent testing for STIs, including HIV, in PrEP users 
(every three months), leading to earlier diagnosis and 
treatment of (mostly) asymptomatic infections and has 
influenced French guidelines on STI testing for high-
risk individuals (recommended every three months for 
chlamydia and gonorrhoea).
Sustainability
Cost–effectiveness analyses have shown that 
providing PrEP to high-risk individuals could be cost-
saving if generic versions of TDF/FTC are used with on-
demand dosing, which requires only half the number of 
pills compared with a daily dosing regimen. Based on 
data from the ANRS IPERGAY study, it was estimated 
that for each group of 17 high-risk MSM taking PrEP 
for one year, one HIV infection would be prevented. 
Although the cost of PrEP is fully covered, individuals 
still have out-of-pocket expenses for travelling to the 
clinic every three months and for laboratory tests 
and doctor visits (only 60% of which covered by the 
national health care system), unless they have private 
health insurance. In May 2017, ANRS also launched 
a three-year project to assess the impact of scaling 
up PrEP in MSM in the Ile de France (the region most 
affected by the HIV epidemic in France).
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GEORGIA. Progress towards ART and viral suppression targets through 
implementation of a “treat all” policy
Submitted by: Tsertsvadze, Tengiz | Chkhartishvili, Nikoloz | Abutidze, Akaki | Chokoshvili, Otar | Sharvadze, Lali | Gabunia, Pati 
Infectious Diseases, AIDS and Clinical Immunology Research Centre of Georgia
Background
The first HIV-infected patient in Georgia was diagnosed 
in 1989. By the end of 2017, a total of 5090 diagnosed 
persons were living in the country. Similar to in other 
eastern European countries, the HIV epidemic in 
Georgia was driven by injecting drug use for many years, 
accounting for around 60% of new diagnoses annually. 
However, recent trends indicate a decrease in the 
proportion of IDU-related cases, with a corresponding 
increase in STIs both through heterosexual contact and 
in MSM. Heterosexual contact accounts for 48% of 
newly diagnosed infections, followed by injecting drug 
use (36%) and MSM (13%). Notably, there was a fivefold 
increase in new diagnoses among MSM between 2010 
and 2017. IBBS conducted during the same period 
show that HIV prevalence is being maintained at below 
5% among people who inject drugs (52) and has 
increased to 21% among MSM (53).
ART was introduced in Georgia in the 1990s, but with 
very limited access. Since 2004, through support from 
the GFATM, Georgia has ensured universal access 
to ART in accordance with existing international 
guidelines, resulting in a dramatic reduction in AIDS-
related mortality.
Description of the good practice
Georgia has made remarkable progress in HIV treatment 
and care. The National AIDS Treatment programme 
became operational in 1995 and was substantially 
strengthened by the arrival of GFATM support in 2004. 
The Georgian model of service delivery builds on the 
principles of equity and human rights towards ensuring 
universal access to HIV treatment and care for all.
Georgia has been moving towards earlier ART initiation, 
in line with WHO recommendations, by introducing a 
criterion for a CD4 cell count of <350 per mm3 criteria 
in 2011, followed by a criterion for a CD4 cell count 
of <500 per mm3 in 2013 and a “treat all” policy in 
September 2015. The country had been preparing for 
the “treat all” policy for several years, initially inspired by 
results of the landmark treatment-as-prevention trial, 
HPTN 052 (54), and further supported by evidence 
from the TEMPRANO and START trials (55,56). The 
early-release guideline on when to start ART published 
by WHO in September 2015 enabled the country to 
remove ART eligibility limitations and recommend or 
provide life-saving therapy to all persons living with 
HIV in Georgia, regardless of their CD4 cell count (57). 
The new recommendations were rapidly disseminated 
and the countrywide policy was in place by the end 
of 2015. With implementation of the “treat all” policy, 
Georgia maintained its public health approach to ART. 
Standard first-line regimens for ART are provided and 
viral load is prioritized for treatment monitoring. The 
comprehensive package of care in Georgia also includes 
support services provided by both health care workers 
and lay professionals, including community-based 
organizations (CBOs). These support services include 
adherence monitoring and support, psychological 
counselling, and peer-driven interventions.
In 2011, Georgia launched National AIDS Health 
Information System (AIDS HIS), a secure web-based 
system connecting all HIV care providers in the country. 
The system ensures the real-time collection of case-
based information, including detailed demographic, 
epidemiological, clinical and laboratory data. Each 
person is identified using a unique national identity 
number in the system, and this effectively prevents 
duplications. This unique system incorporates both 
surveillance and clinical information, thus enabling 
high-quality analysis of granular data to inform both 
public health actions and clinical practice. Equitable 
access to ART has been prioritized since the scale-
up of ART in the country in 2004. All persons receive 
quality care regardless of their risk behaviour, sex or 
ethnicity. Moreover, special efforts are made to ensure 
greater engagement of key populations, such as people 
who inject drugs. There are strong links with addiction 
services that provide free harm reduction services to all 
eligible HIV-positive persons, including OST.
Strong collaboration between HIV and TB services 
ensures effective management of TB/HIV-coinfected 
patients; Georgia has one of the highest rates of 
coverage among persons with known TB/HIV status 
in the WHO European Region (1). Hepatitis care has 
been fully integrated into HIV care. All persons are 
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also screened for viral hepatitis. HIV/HBV-coinfected 
persons are started on regimens for ART containing 
tenofovir. For HIV/HCV-coinfected persons, free 
hepatitis C treatment has been universally available 
since 2011. In 2015, with the support of CDC and a 
pharmaceutical manufacturer, Georgia launched the 
world’s first hepatitis C elimination campaign; from that 
point onwards, all HIV/HCV-coinfected persons have 
received direct-acting antivirals free of charge.
Evidence of impact/efficacy
The current analysis focused on Georgia’s progress 
towards reaching the ART and viral suppression targets 
of the 90–90–90 strategy. Indicator definitions were 
taken from the Guidance for Global AIDS Monitoring 
2018 (58).
By the end of 2017, 5090 HIV-positive persons had 
been diagnosed and were living in Georgia and 4144 
of these (81%) were on ART. This falls short from 90% 
target, but overall progress is visible and commendable. 
The number of people on ART in Georgia more than 
doubled over the five years from 2013 to 2017 and 
the proportion of diagnosed persons on treatment 
increased from 57% to 81%, respectively (Fig. 15). 
There was also a respective increase in the number and 
proportion of persons with viral suppression: 71% of 
the total diagnosed population were virally suppressed 
in 2017. The 90% target of viral suppression was 
almost reached for persons on ART: overall, 87% (3598 
out of 4144) had a viral load of less than 1000 copies/
mL at the last measurement in 2017 (Table 6). Stratified 
analysis by transmission category showed that the 
90% target for ART and viral suppression had already 
been reached for heterosexually infected women in 
the country. The lowest coverage with ART was seen 
among MSM, while viral suppression was lowest 
among people who inject drugs.
Although all persons are offered treatment, not all of 
them initiate treatment and some of those that do are 
lost from care. Experts conducted further analyses 
to explore the reasons for loss to follow-up between 
diagnosis and treatment initiation. For this, they 
constructed one additional stage in the HIV continuum 
between diagnosis and ART initiation – retention in care 
– defined for these data as at least one measurement 
of CD4 cell count or viral load in 2017. This analysis 
showed that among people who inject drugs and 
heterosexually infected men, loss from care occurs both 
Fig. 15. HIV care cascade among diagnosed persons, Georgia, 2013–2017
57
45
60
49
62
52
74
63
81
71
0
10
20
30
40
50
60
70
80
90
On ART Virally suppressed
P
er
ce
nt
ag
e 
o
f 
d
ia
g
no
se
d
 p
er
so
ns
 (%
)
2013 2014 2015 2016 2017
38
Compendium of good practices in the health sector response to HIV in the WHO European Region
between diagnosis and retention and between retention 
and ART initiation. Regarding MSM, 97% are retained 
and often test positive with high CD4 cell counts; the 
latter might decline therapy because of their perceived 
overall well-being.
After two years of implementing the “treat all” policy, 
Georgia has shown that achieving the 90% targets for 
coverage with ART and viral suppression are feasible 
(see Fig. 16). The country has made substantial 
progress in scaling up ART and the 90% targets are 
within sight. The targets of 90% coverage with ART 
and viral suppression have already been reached for 
heterosexually infected women, and this can also be 
achieved for other populations as the gaps are clearly 
identified and filled. The implementation of ART since 
2004 has already resulted in a significant decline in AIDS-
related mortality. Further expansion of ART is expected 
to save more lives and improve quality of life. Spectrum 
projection models suggest that the estimated number of 
new infections in Georgia have been declining for several 
years, coincident with the implementation of earlier ART 
initiation recommendations.
Success of the ART programme in Georgia stimulated a 
movement to end the epidemic in the country by 2030. 
Table 6. Achievement of the 90–90–90 targets for ART and viral suppression
Category Proportion of persons with 
diagnosed HIV on ART (%, n)
Proportion of persons on ART 
who are virally suppressed (%, n)
All people living with HIV 81 (4144/5090) 87 (3598/4144)
People who inject drugs 78 (1435/1843) 84 (1205/1435)
MSM 75 (479/640) 88 (422/479)
Heterosexually infected men 78 (894/1150) 87 (774/894)
Heterosexually infected women 92 (1219/1328) 90 (1102/1219)
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On 1 December 2017, the National AIDS Conference 
adopted the declaration to Test all, treat all, end the AIDS 
epidemic in Georgia.
Although the country is steadily moving towards meeting 
the global targets for coverage with ART and viral 
suppression, achieving the target of diagnosing 90% 
of people living with HIV remains a serious challenge. 
Currently, only 48% of the estimated 10 500 people 
living with HIV in Georgia are aware of their status; this 
significant gap prevents the country from deriving the 
maximum individual and public health benefits of ART. 
Improving HIV diagnosis will place the country on the 
path to achieving the goal of ending the epidemic.
Sustainability
Georgia’s commitment to universal health coverage 
ensures equitable access to basic health services for all 
people living in the country. In 2013, the MoH launched 
a universal health care programme that, among others, 
prioritizes the response to communicable diseases such 
as HIV, HCV and TB. This commitment, along with a 
public health approach to HIV prevention, testing and 
treatment, provides the basis for ensuring sustainability 
of the practice. The national ART programme procures 
WHO-prequalified generic drugs, thus ensuring a low 
cost of treatment. In 2017, Georgia started procuring a 
generic formulation of a new integrase inhibitor which, 
along with its low cost, has benefits such as high potency, 
a high genetic barrier to HIV drug resistance and low 
toxicity. Given these circumstances, the 2018 revision 
of national guidelines recommends a combination of 
tenofovir/emtricitabine plus dolutegravir as the preferred 
first-line regimen for ART; the cost of less than US$ 120 
per person per year will help to reduce the financial 
burden for the country’s health system.12
Initially supported by the GFATM, the national ART 
programme is now in the process of transitioning to 
domestic funding. The Government of Georgia has 
been strictly fulfilling its obligations through increasing 
the budget of the National AIDS Programme. The 
Government already covers 100% of costs related 
to first-line drugs and 50% of costs associated with 
second-line treatment. By 2020, funding is expected 
to be fully transitioned to the domestic source (i.e. 
covering all aspects of treatment and care). Transition 
to domestic funding for HIV has been an integral part 
of the national policy towards universal health coverage. 
The Government of Georgia has substantially increased 
public spending on health, which more than doubled 
between 2012 and 2015 (according to the national 
health accounts for 2011–2015) after implementation of 
the universal health programme, and the national health 
budget continues to increase annually. AIDS-related 
spending increased from US$ 4.5 million to 8.6 million 
over the last few years, with national funding now 
accounting for 70% of the total expenditure on AIDS.
12 In May 2018, WHO issued a statement concerning a potential risk of neural 
tube defects in infants born to women taking dolutegravir at the time of con-
ception (59). As more countries have scaled up ART optimization efforts and 
include or plan to include dolutegravir-containing regimens in their national 
protocols as the preferred first-line option, WHO issued a briefing note in April 
2018 on the clinical advantages of and programmatic information about the 
new fixed-dose combination tenofovir/lamivudine/dolutegravir (60). Additional 
and diverse analyses are planned for July 2018 to expand on the original 
data, which originated from a single country.
GREECE. A seek–test–treat–retain intervention to decrease HIV transmission 
among people who inject drugs in the Athens metropolitan area: the Aristotle 
Programme
Submitted by: Sypsa, Vana | Paraskevis, Dimitrios | Psichogiou, Mina | Malliori, Meni | Hatzakis, Angelos
National and Kapodistrian University of Athens
Background
Until 2010, Greece had a low-level HIV epidemic, mainly 
among MSM. From 2002 to 2010, 10–20 cases were 
reported annually among people who inject drugs, 
representing 2–4% of newly diagnosed HIV infections per 
year. In 2011, the number of reported HIV cases among 
people who inject drugs increased sharply to 260, more 
than 16 times the number in 2010. In early 2010 in 
Athens, the coverage of harm reduction programmes 
was considerably lower than the level recommended 
by WHO and other organizations: more than 5500 
opioid dependent individuals were waiting to receive 
OST for an average of 7.6 years and NSPs distributed 
approximately 16 syringes per person who inject drugs 
per year. Thus, the 2011 HIV outbreak occurred in the 
context of low levels of harm reduction service provision 
and a severe economic recession: these contexts have 
been proposed as macro-level causes for this increase.
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Description of the good practice
ARISTOTLE was a community-based combination 
prevention programme implemented in response to 
the HIV outbreak in 2011 (61,62). Its objective was to 
rapidly identify as many people who inject drugs residing 
in Athens as possible, offer testing for HIV infection, 
inform them about how to prevent HIV infection and 
transmission, and link those found to be HIV positive to 
treatment. The programme provided multiple services: 
HIV testing; linkage to care; linkage to OST; counselling 
with the programme’s psychologist, doctor and 
social workers; syringes and injecting paraphernalia; 
condoms; light snacks in the waiting room; information 
leaflets; and linkage to the Addicts Care Facility of the 
Organization Against Drugs, where people who inject 
drugs have access to meals and shower, laundry 
and other amenities. The National and Kapodistrian 
University of Athens, the Greek Organization Against 
Drugs and the Hellenic Scientific Society for the Study 
of AIDS and STDs implemented the programme. There 
was collaboration with two NGOs: an experienced 
volunteer from the Positive Voice NGO was located at 
the programme site to assist in counselling seropositive 
people who inject drugs; and seropositive migrants 
without documents were referred to Praxis NGO.
ARISTOTLE was a peer-driven intervention: respondent-
driven sampling with monetary incentives was employed 
to reach the target population of people who inject drugs 
(€5 for participating plus €3 per recruit for up to three 
recruits). Formative research (interviews with a small 
number of people who inject drugs, discussions with 
key informants) were used to decide on the appropriate 
amount to avoid offering monetary incentives that were 
too high or too low. From August 2012 to December 
2013, five rounds of respondent-driven sampling were 
conducted, with approximately 1400 people who inject 
drugs recruited per round. These participants were 
informed about the programme and told that they 
were free to withdraw their consent at any point in the 
process. After obtaining written informed consent from 
the participants, blood samples were collected for HIV 
testing and personal interviews were performed using 
a questionnaire that included sections on injecting drug 
use and sexual behaviour. Non-Greek nationals were 
encouraged to participate through cultural mediators 
and interviewing in multiple languages (in addition to 
Greek and Farsi, languages included Arabic, English, 
French, and Kurdish). Over a 16-month period, there 
were 7100 visits from 3320 individuals who inject 
drugs, representing coverage of 88% of the target 
population based on the capture–recapture estimate of 
the number of people who inject drugs in Athens, as 
reported by the Greek Documentation and Monitoring 
Centre for Drugs (61,62). Of those, 1533 people who 
inject drugs participated only once and the remainder 
(n = 1787; 53.8%) participated in multiple rounds: 
681 (20.5%) participated in two rounds, 469 (14.1%) 
in three rounds, 374 (11.3%) in four rounds and 263 
(7.9%) in all five rounds.
Evidence of impact/efficacy
ARISTOTLE provided services for people who inject 
drugs inside and outside the formal health system. It 
promoted equity in service delivery because it reached 
most people who inject drugs, including more vulnerable 
people such as those without documents. It enabled 
HIV testing to be scaled up among people who inject 
drugs, linkage to HIV care after testing and coverage 
with ART for people living with HIV. It also included 
implementation of NSP and linkage of participants 
to OST. In addition, it enabled data collection on risk 
behaviours and HIV from the population of active 
people who inject drugs.
The programme was highly efficient: it was possible to 
quickly reach a large proportion of the target population 
and test them for HIV. During the period from August 
2012 to December 2013, the programme recorded 
a strong decline in HIV incidence (from 7.8 per 100 
person-years to 1.7 per 100 person-years, a decrease 
of 78%) (61,62). There were remarkable changes in 
risk behaviours over time, including a decline in the 
proportion of people who inject drugs reporting injecting 
drug use at least once per day in the past 12 months 
(from 45.2% in August – October 2012 to 18.8% in 
September – December 2013; P < 0.001) and in those 
sharing syringes in the past 12 months (from 36.8% to 
26.0%, respectively; p = 0.007) (61,62). The proportion 
of undiagnosed HIV-positive participants declined 
from 84.3% in August – October 2012 to 15.0% in 
September – December 2013 (Fig. 17). There was an 
increase in the proportion of people who inject drugs 
reporting being currently on OST: from 12.2% in August 
– October 2012 to 27.7% in September – December 
2013 (P < 0.001; Fig. 17). Regarding linkage to HIV 
care, almost half (48.4%) of seropositive people who 
inject drugs had visited an infectious disease unit and 
a quarter (24.5%) had initiated ART after participation 
by the end of programme (Fig. 18). Repeat ARISTOTLE 
participants reported higher rates of adequate syringe 
coverage, linkage to HIV care and OST.
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The reduction in the number of new HIV diagnoses 
among people who inject drugs, as reported to the 
Hellenic Centre for Diseases Control and Prevention, 
has been maintained to the present day. As a result of 
the high coverage of ARISTOTLE, a large proportion of 
HIV-infected people who inject drugs were diagnosed, 
became aware of their infection and were linked to 
HIV care and OST programmes. Respondent-driven 
sampling based on monetary incentives enabled 
effective recruitment and high coverage of the target 
Fig. 18. Cumulative proportion of previously unlinked HIV-positive people who inject drugs who were linked to HIV 
care and initiated ART by the end of each round during the ARISTOTLE programme, August 2012 – December 2013
Fig. 17. HIV prevention results among of people who inject drugs, ARISTOTLE programme, August 2012 – De-
cember 2013
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population. The fact that respondent-driven sampling 
was implemented in multiple successive rounds also 
enabled prevalence, incidence and risk behaviours to 
be monitored. The programme was implemented in a 
site in the centre of Athens and people who inject drugs 
could participate multiple times (up to five times over 
a 16-month period). This engendered trust between 
the participants and investigators and is likely to ease 
the implementation and reduce the cost of similar 
programmes in the future. Finally, the programme also 
promoted teamwork between academia, NGOs and 
the Organization Against Drugs, which proved helpful in 
implementing additional programmes in this population 
in recent years.
ARISTOTLE was an intensive programme implemented 
during an ongoing epidemic with the aim of controlling 
transmission. This type of intervention may be useful 
in epidemic settings for the timely and effective 
implementation of structural approaches for HIV 
prevention, as well as in non-epidemic settings, to 
provide HIV prevention, screening and linkage to care; 
to assess treatment retention and community viral 
load; and for the early recognition of an outbreak risk. 
Organizations providing low-threshold substance use 
services could implement similar programmes without 
many additional resources to enable people who inject 
drugs to access testing/counselling/linkage to care 
services once or twice per year.
Sustainability
ARISTOTLE was implemented under the National 
Strategic Reference Framework for 2007–2013 
with European Social Fund and national resources, 
additional funding by the Hellenic Scientific Society 
for the Study of AIDS and STDs and a grant from the 
United States National Institutes of Health – National 
Institute of Drug Abuse.
KYRGYZSTAN. Universal health coverage and better-quality medical services 
for women who use drugs during pregnancy, childbirth and the postpartum 
period
Submitted by: van Dam, Anke1 | Imankulova, Chinara1 | Stakeeva, Cholpon2
1AIDS Foundation East–West (AFEW); 2Kyrgyz State Medical Institute for Post-Graduates
Background
Despite significant efforts by government agencies, 
NGOs and international organizations, the HIV 
epidemic is continuing to grow in Kyrgyzstan. Over a 
five-year period from 2011 to 2016, the number of HIV 
cases in the country more than doubled from 3270 to 
7108. Moreover, according to national epidemiological 
reports, the number of pregnant women diagnosed 
with HIV increased from 97 in 2011 to 147 in 2017 
(Fig. 19).
In Kyrgyzstan, as in other EECA countries, the HIV 
epidemic is at a concentrated stage. This is mainly 
due to spread of the epidemic among key populations 
who are at increased risk of infection. The number of 
cases among people who inject drugs is continuing to 
increase, as is sexual transmission of HIV. According 
to the 2014 estimation study conducted under the 
GFATM project in the country, the number of people 
who inject drugs in Kyrgyzstan was 25 000, of whom 
around 12% were women. Approximately 47.4% of all 
people who inject drugs live in the two largest cities, 
Bishkek and Osh. Women who use drugs are a hidden 
subpopulation who are less likely to access medical 
support because of their fear of being condemned 
by society, violence from family members, stigma and 
discrimination, and losing custody of their children. 
Pregnant women who use drugs are especially 
vulnerable in this regard and comprehensive and timely 
medical support is vital for well-being of this group. 
According to the most recent IBBS in Kyrgyzstan (in 
2016) conducted by AFEW jointly with the Republican 
AIDS Centre in Kyrgyzstan, HIV prevalence among 
women who inject drugs was 9% (16% of respondents 
were women who inject drugs) (63).
Description of the good practice
In 2016, the public foundation, AFEW in the Kyrgyz 
Republic (AFEW-Kyrgyzstan), within the Bridging the 
Gaps: Health and rights for key populations project (64), 
supported the Kyrgyz MoH in creating a working group 
that included an expert in narcology, an obstetrician–
gynaecologist, an expert in evidence-based medicine 
and a representative of the community of women who 
use drugs. In January 2017, the clinical guideline, 
Care in pregnancy, childbirth and the puerperium for 
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women who use psychoactive substances, was 
approved by the order of the MoH and became 
mandatory for doctors’ use. The country’s leading 
medical specialists in gynaecology and narcology 
worked closely with community leaders to learn about 
the specific needs and concerns of people who use 
drugs during pregnancy. At this point, OST was not 
included in the support package for pregnant women 
who use drugs. Gynaecologists had little knowledge 
about OST during pregnancy and were reluctant to 
prescribe it. The clinical guideline includes criteria 
and checklists for OST. Information on OST in the 
Kyrgyz guideline includes advice about which NGOs 
doctors can refer women to for low-threshold services 
and other medical, legal and social support, and 
recommendations on consultations with pregnant 
women using drugs.
To integrate the guideline into the curriculum of Kyrgyz 
State Medical Institute for Post-Graduates (KSMI), 
modules were developed for KSMI teaching staff and 
gynaecologists from two the large cities where most 
people who use drugs live. Women from community 
organizations also delivered some of these courses. In 
August 2017, training was offered to 100 obstetrician–
gynaecologists from family medical centres and 
obstetric institutions. At these courses, specialists 
became familiar with the latest research in this field 
and studied specific issues related to pregnancy and 
the pre- and postnatal periods for women who use 
drugs, as well as ways to avoid or minimize the risk of 
drug exposure for both women and children.
Evidence of impact/efficacy
AFEW brought together the Kyrgyz MoH, KSMI and 
community leaders to make changes for female drug 
users. The guideline is the first official document to 
sensitize general practitioners and gynaecologists to 
the needs of women who use drugs; they are intended 
to avoid or minimize the risks and consequences 
associated with drug use for women and their children 
through building strong therapeutic relationships 
with each pregnant woman based on trust and non-
discrimination. This approach is designed to help 
women to overcome their fears and obtain adequate 
medical support during pregnancy while continuing 
care.
After the training sessions, 80% of participants report 
changing their attitude to women who use drugs. In 
total, 100 people received training.
An obstetrician–gynaecologist who attended the 
training course said:
Fig. 19. Number of pregnant women living with HIV in Kyrgyzstan, 2005–2017
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“Before the training course, I met several 
pregnant women who use drugs. To be honest, 
I was not sure that they could give birth to 
healthy children. Having received the clinical 
protocol, and with the knowledge I obtained 
in training, I realize that these women should 
not be discriminated against. I learned about 
the scientific recommendations for planning 
pregnancy in situations that cannot harm either 
the mother or child. This helped me a lot.”
The first results, based on feedback from pregnant 
women who use drugs, show improved counselling 
and prenatal care. While writing up this good practice, 
AFEW-Kyrgyzstan decided to create focus groups to 
further assess the impact of introducing the clinical 
standards.
AFEW does not have access to any more evidence-
based data for Kyrgyzstan because no studies of women 
using drugs have been done and disaggregation by sex 
is uncommon in the country. The organization plans 
to address this gap in the future through continued 
engagement of local authorities and CSOs.
All regions of Kyrgyzstan have received the new clinical 
guideline. Doctors who have received training share 
their experiences with colleagues and help women 
who use drugs to safely plan their pregnancies and give 
birth to healthy children. AFEW-Kyrgyzstan continues 
to monitor the work of specialists who have been 
trained and monitors whether all health specialists have 
access to the guideline. In the future, AFEW-Kyrgyzstan 
will continue to work on improving the quality of life of 
people who use drugs and will monitor usage of this 
protocol by doctors.
Sustainability
The clinical guideline has been approved by the MoH 
of the Kyrgyz Republic for compulsory use by relevant 
medical workers. Sections of this guideline have been 
integrated into existing KSMI courses for training 
relevant medical workers, starting from the next 
academic year.
LATVIA. Formula feeding for infants born to HIV-positive mothers
Submitted by: Feldmane, Jana1 | Veikenieks, Andris2 | Azina, Inga3 | Freimane, Agnese4
1Ministry of Health of the Republic of Latvia; 2AGIHAS – Support Group for People Living with HIV/AIDS; 3Riga Easter Clinical University 
Hospital; 4Center for Disease Prevention and Control
Background
Since 2010, the number of new HIV cases in Latvia 
has increased (from 14.4 per 100 000 in 2011 to 16.8 
per 100 000 in 2017) and is now one of the highest 
rates in Europe. In the country, rates for different types 
of transmission among people newly diagnosed with 
HIV infection in 2017 were: heterosexual transmission, 
35%; IDU, 21%, between MSM, 6%; and vertical 
transmission, less than 1%. Of all new cases of HIV, 
the rate with unknown transmission is 36%.
The first case of MTCT of HIV was reported in 1999. 
Between 1999 and 2015, 75 cases of MTCT of HIV 
were recorded. According to the current procedure, 
virological testing13 and erythrocyte counts are 
performed for all newborns of HIV-positive mothers. 
The percentage of infants born to HIV-positive women 
who undergo an HIV RNA test for HIV infection within 
two months of birth increased from 68% in 2012 
13  HIV RNA testing is described in Cabinet Regulation No. 611 (65).
to 84% in 2017. During 2011–2017, a total of 147 
new HIV cases in pregnant women were registered. 
Most of these women (91 out of 147) were infected 
through heterosexual HIV transmission, 13 were people 
who inject drugs and the remaining 43 women had an 
undetermined/unknown mode of HIV transmission. Over 
the same seven-year period, 34 HIV-positive children 
were born to HIV-positive mothers in Latvia. The highest 
annual number of cases of MTCT over these seven years 
was 10 (in 2013). Since 2013, the number of cases of 
MTCT has fluctuated, reaching six cases in 2016 and 
three in 2017. The target for MTCT of HIV of under 2% 
for non-breastfeeding population must be reached for 
Latvia to move towards elimination validation (66).
Recent missions found that possible reasons for 
continued vertical transmission include: low adherence 
to ART for those who present to antenatal care; and late 
or lack of antenatal care visits (especially for SW and 
people who inject drugs). Some women refuse treatment 
because they do not believe that ART is effective. Others 
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refuse medication because they believe it is unhealthy 
for themselves and the children, while yet others noted 
that accepting treatment is against their religious 
beliefs (67). Low coverage rates are probably a result 
of women who give birth abroad: there is a lack of 
proper reporting to the infectologist when HIV-positive 
mothers give birth outside Riga’s largest maternity 
hospitals/units.
The number of cases of MTCT due to breastfeeding in 
Latvia is unknown. WHO recommendations on HIV and 
infant feeding state that national or subnational health 
authorities should decide whether health services will 
mainly counsel and support mothers known to be living 
with HIV to either (i) breastfeed and receive ARV drug 
interventions or (ii) avoid all breastfeeding (5,68). Latvia 
has decided to support the latter approach in their 
attempt to eliminate MTCT of HIV. Other interventions 
supporting the PMTCT of HIV in Latvia include: HIV 
screening of pregnant women at 8–12 weeks of 
pregnancy, early ART for all infected pregnant women, 
HIV testing of newborns with an HIV-positive mother 
and early ART for newborns with an HIV-positive 
mother.
Description of the good practice
Support for HIV-positive pregnant women in formula 
feeding for infants was introduced by an NGO, AGIHAS 
(Support Group for People Living with HIV/AIDS), in 
2015. The decision to use this strategy in Latvia was 
based on considerations related to: the socioeconomic 
and cultural contexts of the populations served by 
maternal and child health services; the availability and 
quality of health services; the local epidemiological 
context; and the absence of malnutrition/undernutrition 
or increased risk of serious infections as the main 
causes of maternal, infant and child mortality. Thanks 
to the financial support of the Latvian State Forestry 
Agency and in collaboration with Ziedot.lv (Donate; 
an NGO), Riga’s Maternity Hospital and Riga Eastern 
Clinical University Hospital in collaboration with 
AGIHAS started to provide assistance for newborn 
babies whose mothers are HIV-positive or have AIDS.
In 2017, approximately 2844 packs of free formula milk 
for the children of HIV-positive mothers were provided 
through the state budget. The National Health Service 
provides centralized procurement of formula milk, 
which is disseminated to maternity hospitals and to 
Riga Eastern Clinical University Hospital. In the 2017 
reporting year, 48 of the 74 babies born to HIV-infected 
mothers received the formula milk: the other 26 babies 
were living in social institutions and received full state 
care. The formula feeding programme also offers social 
support for HIV-positive mothers, including counselling 
on child care and additional information materials. 
The 48 babies whose mothers participated in the 
programme underwent regular health monitoring.
Evidence of impact/efficacy
The annual number of cases of MTCT has fluctuated 
since peaking in 2013 but shows a decreasing 
tendency over 2016–2017. None of the 48 infants 
who received formula feeding within this programme 
were infected with HIV. The actual contribution of free 
formula provision to the decreasing tendency of new 
MTCT cases in 2016–2017 is, however, yet to be 
documented.
Sustainability
Special funds are allocated for distributing free formula 
milk for infants born to HIV-positive mothers. An NGO 
for people living with HIV began distributing free formula 
for infants born to HIV-positive mothers as a pilot project 
financed by donations. However, in 2017 the MoH took 
over this intervention within a state-financed programme. 
Although considered the standard of care in many 
countries, this practice is example of good collaboration 
among the MoH, NGOs and patient organizations to 
implement a sustainable HIV prevention intervention 
that navigates various social, sexual and, even, religious 
barriers within the target population in Latvia.
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Background
In the Netherlands, MSM accounted for 65% of new 
HIV diagnoses in 2015 and HIV incidence has not 
declined in this population. These findings indicate an 
urgent need for new methods of HIV prevention. The 
use of oral tenofovir disoproxil fumarate combined with 
emtricitabine as PrEP effectively protects MSM against 
HIV infection. Issues that impede PrEP implementation 
in high-income countries include uncertainty about the 
number and characteristics of PrEP users and the costs 
related to its use. More information is needed on the 
uptake of both daily and event-driven dosing regimens 
in real-life settings and on the determinants for choosing 
between these regimens.
Description of the good practice
In 2015, the Amsterdam Pre-exposure Prophylaxis 
(AMPrEP) demonstration project was initiated with the 
aim of assessing uptake of daily and event-driven PrEP, 
at the participant’s discretion, among HIV-negative MSM 
and transgender persons at an increased risk for HIV 
infection. This project was part of a comprehensive HIV-
reduction package, including quarterly counselling on 
sexual health, risk reduction strategies and STI testing, 
offered at a large STI clinic.
A press release announced the start of the project and 
the number of available places (n = 370). This was 
followed by large-scale media attention at the local 
and national levels. In addition, HIV-negative MSM and 
transgender people who visited the STI clinic of the 
Public Health Service of Amsterdam were informed 
about the demonstration project. Those interested 
in participating applied via an online application form 
during a fixed application period. HIV-negative MSM and 
transgender (both male-to-female and female-to-male) 
persons who have sex with men were eligible if they 
were aged at least 18 years of age with one or more 
of the following risk factors for HIV infection within six 
months prior to the screening visit: condomless anal 
sex with casual partners; at least one bacterial STI (i.e. 
syphilis, rectal or urethral chlamydia or gonorrhoea); use 
of PEP after a sexual risk incident; or an HIV-positive 
sexual partner with a detectable viral load. In addition to 
providing participants with PrEP, an effective way of HIV 
prevention was offered (quarterly testing for STIs other 
than HIV, including HCV infection), in line with international 
guidelines (69). An unexpected finding was that 18 (4.8%, 
95% confidence interval 2.9–7.5%) of participants were 
anti-HCV antibody and/or HCV RNA positive at baseline 
(70). This was substantially higher than among the 370 
non-PrEP-using HIV-negative MSM who visited the STI 
clinic in November 2015 (anti-HCV antibody prevalence, 
1.4%) and 584 HIV-negative MSM participating in the 
Amsterdam Cohort Studies between January and June 
2016 (anti-HCV antibody prevalence, 0.34%).
Evidence of impact/efficacy
About 870 persons submitted online applications to take 
part in the PrEP project, of whom 587 were invited for a 
screening visit; 283 were not invited because of limited 
capacity. Of those 587, 415 were screened for eligibility 
and 376 initiated PrEP; 172 cancelled or did not respond 
and 27 people were excluded (one because they tested 
HIV positive, three because of exclusion criteria and 
23 because they failed to meet the eligibility criteria). 
A quarter (103/376; 27%) chose event-driven PrEP: 
two pills between 24 hours and two hours before sex, 
followed by one tablet after 24 hours and again after 48 
hours. The prevalence of bacterial STI was 19% and the 
median number of condomless anal sex episodes in 
the preceding three months was 11, indicating that this 
group is indeed at considerable risk for HIV infection (71). 
Overall effectiveness data for PrEP use in this project are 
not yet available; however, one person acquired wild-type 
HIV infection despite good adherence (72).
Sustainability
In the Netherlands, PrEP is not yet implemented nationwide 
at the time of this publication. The Minister of Health will 
advise on its implementation in 2018 following advice 
from the National Health Council (73). From the second 
half of 2018, continuation of PrEP provision through the 
AMPrEP project is dependent on national policy-making 
and/or additional funding. The Public Health Service of 
Amsterdam is advocating for PrEP for all of those who 
can benefit from it. This project one of many implemented 
in Amsterdam through the HIV Transmission Elimination 
Amsterdam (H-TEAM) initiative (74).
NETHERLANDS. The Amsterdam Pre-exposure Prophylaxis (AMPrEP) project
Submitted by: Hoornenborg, Elske1 | Achterbergh, Roel C.A.1 | van der Loeff, Maarten F. Schim1,2 | Davidovich, Udi1 | Matser, Amy1 | 
Hogewoning, Arjan1,2 | van Duijnhoven, Yvonne T.H.P.1 | Sonder, Gerard J.B.1 | de Vries, Henry J.C.1,2 | Prins, Maria1,2 (on behalf of AMPrEP in 
the HIV transmission Elimination Amsterdam (H-TEAM) initiative)
1Public Health Service of Amsterdam; 2University of Amsterdam
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Background
Poland is a low-prevalence country for HIV with a stable 
HIV epidemiological situation of approximately 1000 
new infections diagnosed each year. In 2017, 1526 new 
HIV cases were registered in Poland, the vast majority 
(86%) of them male. Poland has a well-established 
and constantly expanding national system of early HIV 
detection, as well as treatment and support for people 
living with HIV. It was one of the first countries in the 
EECA region to offer a diversified package comprising 
free-of-charge access to diagnostics, ART and care for 
people living with HIV/AIDS. The Polish framework for 
HIV prevention and control is built around a sustainable 
national policy, the National HIV/AIDS Programme, a 
strong network of 31 VCT centres, and particularly 
robust partnerships between NGOs/CSOs and the 
national government. The National AIDS Centre, 
from the MoH budget, subsidizes and monitors HIV 
prevention and health promotion activities implemented 
by Polish NGOs and CSOs, based on the Schedule 
for implementation of the national programme for 
preventing HIV infections and combating AIDS. These 
activities aim to address the needs of the general 
population, people living with HIV and key populations, 
including people who inject drugs, prisoners and MSM, 
along with their relatives. HIV infection has been reported 
in the Polish penitentiary system since 1989. As of 31 
December 2017, the total population of incarcerated 
persons in Poland was 73 822. At the end of 2017, 
265 inmates had received ART. Available data from 
the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) on drug use among prisoners 
(from the 2007 prison survey) show that around half 
of prisoners in Poland have a lifetime experience of 
drug use before imprisonment. At present, among 
incarcerated persons who are HIV positive, 70% report 
being people who inject drugs; thus, treatment efforts 
are being directed towards this group.
Description of the good practice
Since 2001, the Penitentiary Service implements the 
Antiretroviral treatment of persons living with HIV in 
Poland programme, financed by the MoH. In alignment 
with WHO guidelines, this programme allows prisoners 
full access to free-of-charge ART and provides 
same services those as offered to people living with 
HIV outside the penitentiary system. Each year, the 
MoH allocates funding to ensure the procurement of 
ARVs, tests and vaccines for children (totalling more 
than €90 million in 2017). The National AIDS Centre 
developed the system of purchasing ARVs and 
monitoring drug management optimize the use of 
funds and streamline drug distribution in the country, 
including among key populations. As of 1 July 2015, 
OST has been made available to all those in need in 
all 155 penitentiary units in the country, in alignment 
with the national Strategy on dedication to treatment 
of persons living with HIV in Poland, 2017–2021. This 
good practice is the direct result of a strong relationship 
between the National AIDS Centre (a MoH agency ) and 
the Central Board of Prison Service (MoJ). Both entities 
actively participate in the European Joint Action on HIV 
and Co-infection Prevention and Harm Reduction (HA-
REACT (75)) programme, which addresses existing 
gaps in the prevention of HIV and related comorbidities 
such as TB and viral hepatitis among people who inject 
drugs. OST and ART are administered by medical staff 
in the penitentiary system.
Evidence of impact/efficacy
In 2008, OST was only an option for inmates who had 
been receiving OST prior to incarceration. In 2008, 87 
inmates were receiving OST and OST programmes 
were running in 19 penitentiary units in five cities in 
Poland. As a national strategy on OST was lacking, it 
was difficult to provide continuous OST during referral 
from one institution to another or between the penal 
system and re-entry to the community. As of 1 July 
2015, OST has been made available to all those in 
need in all 155 penitentiary units in the country. ART 
and OST programmes are available to all inmates 
who need and want to join them. On 31 December 
2017, 135 patients/prisoners were on the methadone 
programme in Poland. To strengthen implementation, 
close partnership was established between the 
National AIDS Centre and the Central Board of Prison 
Service in Poland through the EU HA-REACT Project 
with the intention of providing international seminars 
and training on harm reduction, OST, and continuity of 
care in prison based on the country’s needs and on EU 
POLAND. Implementation of OST through partnership between the Central 
Board of the Prison Service and the National AIDS Centre
Submitted by: Wysocki, Piotr | Marzec-Boguslawska, Anna
National AIDS Centre, Poland
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and WHO recommendations. After the partnership was 
established, the National AIDS Centre and Central Board 
of Prison Service designed a curriculum and organized 
international seminars and training on the effective 
implementation of harm reduction programmes in prison 
and the criminal justice system. These were designed 
for medical personnel and social workers who interact 
with members of the prison population who are living 
with HIV. The first seminar took place in March 2017 and 
was attended by technical experts from 12 European 
countries (Czech Republic, Finland, Germany, Greece, 
Hungary, Italy, Latvia, Lithuania, Luxemburg, Poland, 
Portugal and Slovenia). At the seminar, barriers to OST 
and the needs of Member States were discussed and 
targets were operationalized. During seminars and in 
working groups, participants decided on the topics and 
content of the training session and the materials used 
to educate the medical and social staff in prisons. The 
training session was held in November 2017, attended 
by participants of the seminar in March. It consisted 
of practice-based training modules such as health and 
social care responses to drug problems; and harm 
reduction services in prisons and the criminal justice 
system, including needle and syringe exchange, 
condom distribution and OST. One of the training 
modules was aimed at adapting the publication, Opioid 
substitution treatment in custodial settings – a practical 
guide (76), to the specific context of the Polish prison 
service.
Sustainability
ART and OST programmes in Poland are fully funded by 
the MoH and MoJ, respectively. Both programmes are 
implemented by medical and social staff working in the 
prison service. A large emphasis is placed on involving 
inmates in educational programmes organized in 
prisons, including for health. For example, through the 
EU HA-REACT programme and during development 
of the Polish adaptation of the publication, Opioid 
substitution treatment in custodial settings. A practical 
guide, the National AIDS Centre and Central Board 
of Prison Service organized a drawing competition to 
supplement the publication with hand-drawn images 
(and testimonials) from the prisoners. A small prize (a 
watch) was given to the inmate who won the competition. 
The ongoing partnership between the National AIDS 
Centre (of the MoH) and the Central Board of Prison 
Service (of the MoJ) bolsters intersectoral collaboration 
and political commitment to reducing the burden of 
HIV in the prison population. In accordance with the 
national regulations, health care programmes run in 
prisons are subject to annual monitoring.
PORTUGAL. Ares do Pinhal: a mobile outreach programme promoting harm 
reduction
Submitted by: Belo, Elsa | Faria, Hugo A | Main, Lula
Ares Do Pinhal, Portugal
Background
In the 1990s, over 6000 people who use drugs visited 
the Casal Ventoso (the neighbourhood in Lisbon where 
this intervention first started) to buy and use a range of 
illicit substances – mainly heroin. Over 400 people who 
use drugs lived in vacant lots in the neighbourhood 
in improvised shelters. Sharing of drug paraphernalia 
was very common; during the initial intervention 
(1998–2000), 61% of individuals were found to be HIV 
positive, 14% were positive for TB, 79% were HCV 
positive, 80% took drugs by injection and 90% had 
never sought treatment.
Description of the good practice
Ares do Pinhal is a mobile outreach programme 
promoting harm reduction focused on people who use 
drugs. The targeted populations are people who use 
drugs (in particular, people who inject drugs), homeless 
individuals and SW; the programme specifically 
aims to reach those people who use drugs who are 
unable to engage in conventional drug treatment 
services. Individuals who use the services of Ares do 
Pinhal usually engage in very high-risk behaviours, 
have physical impairments and/or diseases, have 
psychological illness and vulnerability and are socially 
marginalised. The programme is run using mobile 
vans (two methadone mobile units, one mobile office 
for medical support and one support car for patient 
transport and as back up for the three other vans). 
The vans have been specifically adapted for clinical 
use. The mobile vans operate daily, 365 days of the 
year; they stop daily at five locations throughout the 
city of Lisbon (Fig. 20).
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When first starting the programme, all patients are 
interviewed with psychological professionals and 
nurses and undergo blood testing for HBV, HCV and 
HIV infection, syphilis and TB. Blood samples are 
collected in mobile vans by the nursing team. For 
individuals that do not have a national health number 
(such as migrants), a rapid test for HIV may be offered. 
Blood samples are analysed at the National Health 
Institute. Patients are informed of the services provided 
and methadone substitution is initiated if indicated and 
wanted, in individualized doses and through directly 
observed treatment at mobile outreach units.
If HIV test results are positive, patients are referred to 
a specialist hospital consultation. For those who have 
difficulty (due to mobility issues and/or financial issues), 
a service car with a psychologist to help with mediation 
can transport the individual to their appointments 
and also for complementary diagnostic testing. The 
programme collaborates with every major hospital in 
Lisbon. Ongoing collaboration with the hospital teams 
is ensured during the patient’s hospitalization or for 
conflict management or problem solving (e.g. the patient 
may be a migrant or emotionally unbalanced). Help in 
managing of appointments for follow-up consultations 
in hospitals includes giving the patient a timely reminder 
of the dates of follow-up consultations and providing 
transport, if necessary. The harm reduction approach is 
based on: getting closer to the drug users, addressing 
all drug users, and leveraging the safer use of drugs. 
The main aspects of the mobile outreach programme 
are ease of access (close proximity to problem 
neighbourhoods and transport links); prompt response 
to a request for admission; and simplified admission 
procedures. The main concerns are symptoms of 
abstinence, withdrawal and craving; and low-threshold 
methadone (i.e. abstinence from drug use is not 
required).
Along with psychosocial support, these services are 
all provided by the monitoring teams and general 
practitioners in mobile vans, for 365 days of the year. 
Providing dignified living conditions through appropriate 
referral to health and social care services and promoting 
personal reorganization for those most excluded from 
society are the mainstays of the programme. As part 
of its harm reduction approach, the programme also 
operates a NSP and distributes condoms and tinfoil 
from the office and mobile units. The patients of this 
service are assigned a case manager who provides 
follow-up care through learning all of the major problems 
Fig. 20. Mobile unit, Ares do Pinhal
©Hugo Amaral Faria
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and/or needs of the user (e.g. health, social, judicial), 
gradually aiming to create the best possible relationship 
with the patient.
Hospitals provide the programme with HIV medication 
for specifically for individuals who are homeless, 
marginalised, or are in other relevant situations 
requiring care. Programme staff collect medication 
from the hospital and the nursing team monitors 
its administration. The nursing team also note any 
complaints regarding symptoms related to HIV 
medication and/or interactions with methadone and 
ensure information exchange among the various agents 
involved in treating/monitoring the problem. Timely 
adjustment of the dosage of methadone hydrochloride 
in the face of interaction with ART is ensured and 
so is administration and monitoring of other medical 
drugs (e.g. anti-HCV drugs, anti-TB drugs, antibiotics, 
antipsychotics, antidepressants and injected 
contraceptive drugs). In cases of transfer, detention or 
referral to other institutes, it is necessary to organize 
the entire clinical and psychosocial programme and 
transfer medication and treatment data (e.g. date of the 
next consultation and/or complementary diagnostic 
testing) to ensure continuity of HIV treatment. The Ares 
do Pinhal fact sheet shows many of the programme’s 
achievements (Fig. 21).
Since the enactment of the 2001 law on decriminalization 
of drugs (77), Ares Do Pinhal has also participated in, 
supported and promoted the creation of community 
working groups for collaboration with the police 
force. In the various parishes of Lisbon, meetings 
take place periodically with police representatives to 
discuss and assess drug use developments, drug 
trafficking and the litter related to drug use. Several 
partners are represented, including the Municipal 
Police and the Public Security Police. This partnership 
has caused high-risk health behaviours to be seen as 
health problems instead of judicial problems, enabling 
frequent monitoring by local police and community 
representatives. Police members indicate consumption 
places where intervention is necessary and also 
escort patients to mobile units for on-site methadone 
administration. Police officers identify syringes and 
other drug paraphernalia discarded in the street and 
contact Ares do Pinhal to remove them. Furthermore, 
partnership with the police force has enabled 
methadone to be dispensed to patients in temporary 
custody to avoid withdrawal symptoms or to patients 
being detained for a court hearing to ensure continuity 
for the methadone programme when patients are 
released from prison.
Evidence of impact/efficacy
Outreach approach to vulnerable people, especially 
those who use drugs has made it possible to 
track the major infectious diseases and, if in 
case of having positive cases, refer them to the 
specialist consultations in hospitals. The screenings 
are performed on more than 90% of the users 
included in the program and renewed annually. 
The population in the program actively injecting drugs 
in 1998 was around 80%, and currently it is only around 
20%. Authors observe the HIV prevalence of users 
integrated in the Mobile Outreach Program (PSBLE) 
shows a slight but steady decline over the last few 
years, accompanying the tendency of the numbers at 
the national level. 
Since the enactment of the 2001 law on decriminalization 
of drugs (77), Ares Do Pinhal has participated in, 
supported and promoted the creation of community 
working groups for collaboration with the police force. 
In the various parishes of Lisbon, meetings take place 
periodically with police representatives to discuss 
and assess drug use developments, drug trafficking 
and the litter related to drug use. Several partners are 
represented, including the Municipal Police and the 
Public Security Police.
This partnership has caused high-risk health behaviours 
to be seen as health problems instead of judicial 
problems, enabling frequent monitoring by local police 
and community representatives. Police members 
indicate consumption places where intervention is 
necessary and also escort patients to mobile units 
for on-site methadone administration. Police officers 
identify syringes and other drug paraphernalia discarded 
in the street and contact Ares do Pinhal to remove 
them. Furthermore, partnership with the police force 
has enabled methadone to be dispensed to patients 
in temporary custody to avoid withdrawal symptoms 
or to patients being detained for a court hearing to 
ensure continuity for the methadone programme when 
patients are released from prison.
Sustainability
The Ares do Pinhal programme has had sustained 
financial support since 1998 from the MoH and the 
municipality of Lisbon and is widely accepted as a 
defining programme in in the city.
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Fig. 21. Ares do Pinhal fact sheet
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REPUBLIC OF MOLDOVA. Strengthening the harm reduction package 
Submitted by: Pirtina, Lucia | Cotelnic-Harea, Tatiana | Bivol, Stela
Centre for Health Policies and Studies (PAS)
Background
Up to the end of 2016, 11 043 new HIV cases had 
been cumulatively registered in the Republic of 
Moldova (including Transnistria), with the number of 
newly registered HIV cases remaining stable over the 
past three years at around 800 cases per year, with no 
major changes in sex distribution (78). The prevalence 
of HIV in 2016 was 0.20%. However, the epidemic is 
concentrated among key populations, mostly people 
who inject drugs in the civilian and prison sectors but with 
increasing rates among of SW and MSM. The available 
data suggest that the epidemic has transitioned from 
an early concentrated epidemic in which the highest 
rates of transmission were among people who inject 
drugs to a more advanced concentrated epidemic in 
which onward transmission to the sexual partners of 
people who inject drugs and other key populations has 
become a source of new infections. HIV prevalence 
among people who inject drugs in urban settings is 
reported to be 14–29% (Fig. 22). According to the 
latest estimate in 2017, there are 36 900 people who 
inject drugs in the country.
A NSP was implemented in the Republic of Moldova 
in 1999. The package of interventions to reduce harm 
associated with injecting drug use included needle and 
syringe exchange; VCT; condom provision for people 
who inject drugs and their sexual partners; targeted 
information; overdose prevention measures; naloxone 
use; vein care; OST, promotion of condom use; and 
education and communication for people who inject 
drugs and their sexual partners. Between 2000 and 
2002, NSPs were extended to four additional territories: 
Bălți, Chișinău, Falesti and Orhei. Implementation of the 
GFATM grant for the 2003–2013 period enabled NSPs 
to be extended to 20 territories (47.6% coverage) and 
in 12 penitentiaries (57% coverage). The package of 
interventions consisted of voluntary saliva-based testing 
for HIV through NGOs; OST (2004, in civilian areas; 
2005, in the penitentiary system); and counselling for 
ART initiation. During this time, the harm reduction 
package supported by the GFATM comprised a 
minimal set of syringes, condoms and the provision of 
information, education and communication; however, 
this was insufficient to fully address all causative factors 
for the HIV epidemic in the Republic of Moldova.
Description of the good practice
To increase the coverage and efficacy of the national 
harm reduction services, the harm reduction 
package was augmented in 2015 to include a 
more comprehensive package of services, with 
additional emphasis placed on sex- and age-specific 
programming; peer-driven interventions; overdose 
prevention; legal aid; activities in prisons; technical 
assistance (evaluation of the OST programme in 
the Republic of Moldova); accreditation for the HIV 
prevention services provided by NGOs; mobilization of 
clients of the harm reduction programmes; outreach 
activities; developing community initiation groups for 
people who use drugs; and training to improve quality 
of care and institutionalize new services (Box 1).
Fig. 22. HIV prevalence rate among people who inject drugs (%) in key urban cities, Republic of Moldova, 2016
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Source: MoH of the Republic of Moldova, 2016 (78).
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Box 1. The current augmented harm reduction package in Moldova from 2017
The package comprises:
• needle and syringe exchange (at the syringe exchange point and via field workers, pharmacies and 
mobile services);
• condom distribution (at the syringe exchange point and via field workers, through pharmacies, mobile 
services);
• community-based testing with rapid HIV tests in association with medical institutions to confirm the 
diagnosis and enrol in treatment if needed (including mobile units);
• counseling, referral and accompaniment to OST services by a social worker or peer educator;
• counseling, referral and accompaniment to specific medical services for hepatitis, STI and TB treatment 
and ART, including distribution of information materials;
• training activities to reduce risk behaviors for people who inject drugs and their sexual partners (including 
in the use of sterile injection equipment and condoms);
• naloxone release and overdose prophylaxis;
• psychological counseling and counseling for social assistance, legal advice, (counseling for social 
support, mentoring, case-management and linking people who inject drugs to other services);
• various other services, including
 - sex-specific information on reproductive health;
 - prevention of violence; prevention and management of overdoses;
 - support and assistance during pregnancy;
 - baby-sitting services to enable women to get involved in activities or benefit from harm reduction 
services;
 - referral;
 - accompaniment to consultations; and
 - payment for specific health services needed for women who inject drugs; and
• peer-to-peer educator accompaniment to the medical site to complete the diagnosis and, if the 
diagnosis of HIV infection is confirmed, accompaniment to the ART centres for medical supervision 
and ART initiation.
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Evidence of impact/efficacy
At the end of 2017, NSPs had been implemented in 
30 territories in the civilian sector (71.4% coverage; 
compared with 47.6% coverage in 2014) and in 
18 penitentiaries, including in Transnistria (85.7% 
coverage, compared with 57% coverage in 2014). All of 
these interventions increased the coverage of services 
for people who inject drugs (Table 7) and of access to 
the continuum of care.
Key behavioural indicators from 2016 show that using 
sterile syringes has become the norm for people who 
inject drugs (proportion who used a clean syringe at 
the last injection: Tiraspol, 98.1%; Chișinău, 97.1%; 
and Bălți, 94.6%). Slower progress has been seen in 
adopting safer sexual behaviours: condom use at the 
last sexual encounter with an occasional partner among 
people who inject drugs averaged 62.4% in Chișinău, 
55.2% in Tiraspol and 54.1% in Bălți.
Table 7. National coverage of harm reduction programmes for people who inject drugs, Republic of Moldova, 
2013–2017
Year 2013 2014 2015 2016 2017
Coverage (%) 28.8 30.8 43.3 49.0 51.0
Fig. 23. Number of persons in key populations tested by NGOs, 2013–2017
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NGO involvement in community testing has contributed 
to the increased number of members of the key 
populations tested for HIV (Fig. 23).
Sustainability
MoH commitment in 2017 led to approval of a specific 
regulation on use of National Health Insurance Company 
funds. In addition, the MoH set priorities for the needs 
to be covered by those funds. Starting in autumn 2017, 
two implemented harm reduction projects financed by 
the National Health Insurance Company covered 20% 
of the need for harm reduction services. The state 
budget is projected to finance 58% of the need for 
harm reduction services by 2020.
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Background
In 2017, there were 692 new HIV cases in Romania. 
According to the Department for Monitoring and 
Evaluation of HIV/AIDS Data in Romania (79), in 2016 
there were 118 new HIV cases through injecting drug 
use, while in 2017 approximately 107 cases were 
reported. The primary mode of transmission is through 
heterosexual intercourse, with an average of 400–500 
new cases per year in the adult population. In 2016, 
there were 100 new HIV cases due to injecting drug 
use of which; 1 case was HIV/HBV coinfected, 82 were 
HIV/HCV coinfected, and nine were HIV/HBV/HCV 
coinfected. In 2017, there were 108 new IDU-related 
cases, with a slight increase in the HIV/HCV coinfection 
rate: all eight new cases of HIV/HCV coinfection 
were related to injecting drug use. Romania provides 
treatment for hepatitis and HIV infection, which is also 
free to all patients diagnosed with HCV who have 
therapeutic indications.
Despite an outbreak of new HIV infections due to 
injecting drug use in the country during 2011–2013, 
rates for infections related to this outbreak have 
continuously decreased from 2014. However, Romania 
is one of four countries in the central part of the WHO 
European Region reporting higher rates of AIDS-related 
deaths (0.4 per 100 000 population; Table 8) (1); nearly 
70% of new infections are late presenters and HIV 
response efforts targeted at key populations remains a 
significant need in the country.
ROMANIA. Integration of HIV and viral hepatitis services for people who inject 
drugs in Romania
Submitted by: Predescu, Mioara1 | Tiliscan, Catalin1 | Streinu Cercel, Anca1 | Sandulescu, Oana1 | Cruceru, Raluca1 | Rodica, Anton1 | 
Vladoianu, Cristian1 | Mărdărescu, Alexandra1 | Fierbinteanu, Cristina2 | Niculaie, Cornelia2
1National Institute for Infectious Diseases “Professor Dr Matei Bals” Bucharest; 2Anti AIDS Society (ARAS)
Table 8. HIV incidence in Romania, 2015–2017
Year HIV incidence (per 100 000 population)
Children Adults
2015 0.28 1.99
2016 0.1 2.19
2017 0.34 2.41
Description of the good practice
A bilaterally supported project between Romania and 
Norway, Strengthening the Prevention and Control of 
HIV/AIDS, HBV, HCV in Romania, was implemented 
from May 2014 to August 2016. The purpose of the 
project was to control HIV, HBV and HCV infections 
in key populations (specifically in people who inject 
drugs) by improving essential prevention services and 
screening/diagnosis services. The objectives of the 
programme were to increase the institutional capacity of 
the National HIV/AIDS Programme; establish a national 
registry to integrate HIV, HBV and HCV data; increase 
the early diagnosis rate for all three viral infections; 
decrease the transmission rate among people who 
inject drugs; and expand access to harm reduction 
programmes. Target groups for the programme were 
people who inject drugs, the Roma ethnic population 
and other populations at a higher risk of HIV infection. 
The National Registry of Patients with HBV and HCV 
(RNHBC) was established in cooperation with the 
National Insurance House and the National Institute 
for Infectious Diseases to ensure that all those tested 
and receiving treatment are adequately recorded and 
that information is accessible by authorized health 
professionals. Approximately 337 general practitioners 
attended training sessions on the virtual platform and 
network. Activities to reduce transmission included 
harm reduction (including a NSP), information and 
education sessions (in person and online) for harm 
reduction, VCT services and media campaigns/an 
online campaign site (80).
Evidence of impact/efficacy
In 2013, the number of IDU-related HIV cases was 290 
but had decreased to 108 in 2017. A general increase 
in the number of HIV infections was probably due to 
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enhanced testing efforts through the programme, 
whereas the reduction in incidence among this target 
group seems to correlate with programmatic efforts.
Establishing the RNHBC
After funding from the Norwegian Financial Mechanism 
ended, one of the most important achievements was 
development of the National Registry for Hepatitis. 
This instrument was developed within the project and 
is one of the most reliable instruments of the National 
Health Insurance House. Currently, Romania provides 
free-of-charge treatment for patients diagnosed 
with HCV infection and therapeutic indications. The 
funds necessary for specific anti-HCV and anti-HBV 
therapies may be correctly predicted and monitored 
at the national level. Physicians that survey and treat 
patients with the HCV and HBV register their cases by 
logging on to the Registry’s database using a personal 
username and password.
Testing and surveillance
During the project (May 2014 to August 2016), 
approximately 37 500 tests were administered 
across eight focus regions in Romania: 12 500 each 
for HIV, HBV and HCV. The total number of people 
screened was 12 500, including members of the Roma 
community. Approximately 1000 people who inject 
drugs received rapid testing for HIV/HBV/HCV infection 
and 163 000 000 condoms and 1 174 110 needles 
and syringes were distributed to people who inject 
drugs. These materials and services were provided by 
the NGO consortium for two years to people who inject 
drugs and Roma communities in Bucharest.
Training and education programmes
For the RNHBC, 337 general practitioners were trained 
to use the online virtual network. In addition, over 
10 000 family practitioners throughout the country 
received online training (comprising four modules; 
each training session had a capacity of 25 people) to 
enhance their knowledge about HIV, HCV and HBV 
infection prevention and control measures. These 
practitioners included family doctors, gynaecologists, 
dermatologists, haematologists, psychologists and 
nurses.
Sustainability
The project has contributed to meeting the objectives of 
Operational Programme 2007–2013 on Employment, 
Human Capital and Social Cohesion and to the 
emerging National Strategy for Health 2014–2020. 
Approximately 85% of project funding was provided 
by the Norwegian Financial Mechanism and 15% by 
the Romanian MoH, which operated the programme. 
Social contracting mechanisms in place in the country 
enabled the Romanian Anti-AIDS Society (ARAS), the 
ALIAT Association and the PARADA Foundation to 
successfully implement project components on behalf 
of the MoH. These NGOs represent an extremely 
important source of data, especially for key populations 
and vulnerable groups such as the Roma population, 
people who inject drugs, MSM and SW.
SLOVENIA. Evolution of CBVCT for HIV infection and STIs for MSM in Slovenia
Submitted by: Križman Miklavčič, Janja1 | Zobarič Trplan, Mateja2 | Ćosić, Mitja2 | Klavs, Irena3
1Ministry of Health; 2DIC Legebitra; 3National Institute of Public Health
Background
Slovenia is a low-prevalence country, in which fewer 
than one per 1000 inhabitants live with HIV. The 
most common mode of transmission is through sex; 
specifically, MSM account for 69% of all new HIV 
diagnoses over a recent 10-year period (2007–2016; 
Fig. 24). During the same period, 470 HIV diagnoses 
were notified to the Slovene National Institute of Public 
Health. The annual number of reported cases was lowest 
in 2010 (at 35; 1.7 per 100 000 population) and highest 
in 2016 (at 56; 2.7 per 10 000 population). Preliminary 
data for 2017 indicate a noticeable decrease in new 
HIV diagnoses among MSM compared with 2016. 
Among 31 new HIV diagnoses in men reported by 22 
November 2017, only 23 were known to be MSM.
Due to the low prevalence of HIV in Slovenia, HIV 
services are centred on prevention and health 
promotion, including safer sex, the use of condoms 
and lubricants, knowing one’s sexual partner, and more 
frequent testing of key populations such as young 
people and MSM. Decentralized CBVCT has been a 
key element of this prevention and promotion strategy 
in the country.
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Description of the good practice
A comprehensive package of targeted prevention 
and testing for HIV and STIs, with linkage to care 
and support, has been implemented in Slovenia with 
the involvement of NGOs, people living with HIV and 
health care workers in settings where HIV prevalence 
is highest. High-quality HIV/STI testing and counselling 
is provided by professional medical and social staff. 
High-quality diagnostics are provided by the Institute 
of Microbiology and Immunology at the Faculty of 
Medicine, University of Ljubljana.
In 2009, Legebitra (an NGO) piloted a community-
based testing programme in association the with 
Institute of Microbiology and Immunology of the Faculty 
of Medicine, University of Ljubljana and Department 
of Infectious Diseases, University Medical Centre 
Ljubljana. Individuals can be tested for HBV, HCV 
and HIV infection, syphilis and oral/anal gonorrhoea. 
Testing for HIV and HBV infection has been available 
since 2009, testing for syphilis and oral gonorrhoea 
was added in 2012 and testing for HCV infection and 
anal gonorrhoea have been available since May 2015.
Through funding from the Norwegian Financial 
Mechanism for 2015–2016, confidential CBVCT 
services (for HIV, HBV and HCV infection, gonorrhoea 
and syphilis) were successfully established in MSM 
meeting venues outside of major cities. Services 
include counselling and providing psychosocial 
support to people living with HIV. 
Slovenia is also a participant in the COBATEST 
Network (12) (for community-based testing) and the 
Euro HIV EDAT project (19). The aim of these projects 
is to generate operational knowledge to better 
understand the role and impact of CBVCT services, 
explore the use of innovative strategies based on new 
technologies, and increase early HIV/STI diagnosis 
and treatment in Europe among the most affected 
groups.
The final ongoing programme, which is aligned with 
WHO recommendations (81), includes confidential 
CBVCT (with standard blood tests) for HIV, HBV 
and HCV infection, gonorrhoea and syphilis at DIC 
Legebitra in Ljubljana, as well as regular testing in 
outreach settings in different regions of Slovenia and 
peer support for people living with HIV. Individual pre- 
and post-test counselling is provided for persons at 
the greatest risk of HIV. In the counselling sessions, 
participants can freely discuss with a counsellor their 
sex lives and ways to reduce the risks of HIV and STIs. 
For every person with a reactive HIV test, the service 
Fig. 24. New HIV diagnoses by transmission mode, Slovenia, 2007–2016
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provider arranges an appointment at the Department 
for Infectious Diseases, Ljubljana University Medical 
Centre for a confirmation test, including the offer to be 
accompanied by a peer counsellor to reduce stress 
and anxiety during linkage to care. People living with HIV 
are also offered psychosocial support from their peers 
to cope with life after a positive diagnosis. Support is 
available 365 days per year; continuous development 
efforts include monitoring relevant policy and legislation 
implementation while remaining sensitive to the needs 
of people living with HIV. Legal support is also provided 
in reported cases of discrimination.
Evidence of impact/efficacy
The services were established in 2009 when 
community-based testing was provided for 50 people. 
In 2017, 1018 people were provided with services 
(total number of all types of tests: 5358). Since 2015, 
the proportion of reactive clients has declined slightly: 
positive test rates were 1.32% in 2015, 1.26% in 2016 
and 0.92% in 2017. Rates of first-time testers have 
been measured since 2016: they were 17.1% in 2016 
and 16% in 2017 (average 16.55%). Linkage to care 
has also been measured since 2016: the rate is 100% 
– meaning that all clients with a reactive HIV test result 
have been included in public health care system for 
confirmatory tests and treatment. Information on the 
confirmation of diagnosis has only been gathered since 
2017: out the nine reactive HIV test results, seven have 
been confirmed (rate of 78%) by laboratory testing at 
the Public Specialist Clinic for Infectious Diseases.
According to ongoing monitoring of user satisfaction 
with the service, the following top five reasons for using 
the service were the “possibility of performing multiple 
tests in one place”; “confidentiality”; the “relaxed 
atmosphere”; “free-of-charge service”; and the 
“possibility to talk with someone who understands”. 
In 2017, the average score for the service was 4.89 
(out of 5), with a total response rate of 49%. For the 
second half of 2017, the response rate was 60% 
(342 out of 570 people tested). Approximately 88% 
respondents responded that they were very satisfied 
with the service, 11.1% that they were satisfied, 0.9% 
that they were neither satisfied nor dissatisfied with 
the service provided; 0% expressed being dissatisfied 
or very dissatisfied with the service. One suggestion 
for improvement was to offer an organized system 
and toolkit for partner notification directly through the 
programme.
The programme shows normalization of testing within 
the MSM population and qualitative development of the 
service as a whole, with impressive satisfaction rates. 
The proportion of late HIV diagnoses among MSM 
had a decreasing tendency between 2012 and 2016, 
coinciding with increasing coverage with HIV testing in 
the community (Fig. 25).
Fig. 25. Percentage of late HIV diagnosesa among MSM, Slovenia, 2007–2016
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Sustainability
Financial support for piloting community-based testing 
programmes was provided by the MoH from 2010 to 
2014. Key resources for developing the programme 
were provided in 2015 and 2016 through the Norwegian 
Financial Mechanism. However, a substantial increase 
in resources for implementing high-quality safer sex 
promotion programmes and early testing among 
MSM has been provided by the MoH from 2017 after 
adoption of the new National HIV prevention and 
Control Strategy 2017–2025.
The MoH of Slovenia finances 93.32% of the 
programme. The remainder of funding is allocated by 
the Foundation for Funding Disability, NGOs and the 
Student Organization of the University of Ljubljana. 
Strategic partnerships have been formed between 
NGOs, health care providers, laboratories and the 
MoH, which guarantees long-term implementation and 
development of the CBVCT programme.
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All people should 
receive the services 
they need, which are 
of sufficient quality to 
have an impact
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Background
Despite measures taken to curb the spread of HIV 
in the country, the number of newly detected HIV 
infections and the total number of people living with 
HIV are increasing greatly in Belarus. In 2007, 990 
new cases of HIV infection were detected (10.2 per 
100 000 population), whereas in 2017 the increased 
to 2468 (25.9 per 100 000 population). The cumulative 
number of HIV infections during the observation period 
increased from 8737 to 24 686; as of 1 January 2018, 
the number of people living with HIV registered in health 
care organizations had reached 19 231. However, the 
mortality rate due to AIDS has not significantly changed 
over the past five years, varying between 2.7 and 
3.1 per 100 000 population. In the current situation, 
interventions aimed at early diagnosis of HIV infection 
and improving both access to ART and ART retention 
rates are becoming the most important elements of the 
national HIV response (Fig. 26).
Description of the good practice
On 1 June 2017, the MoH of Belarus adopted the new 
Clinical protocol for the diagnosis and treatment of HIV 
infection with the aim of providing ART to all people living 
with HIV, regardless of the disease stage and degree 
of immunosuppression, starting from 1 January 2018. 
Adoption of the document was preceded by extensive 
work by a national working group comprised of MoH 
officials, leading national HIV experts, practitioners, and 
representatives of international organizations, people 
STRATEGIC DIRECTION 3. 
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BELARUS. Implementation of the “treat all” approach by ensuring universal 
access to ARVs
Submitted by: Grankov, Viatcheslav1 | Migal, Tatsiana 2 | Skripko, Oleg3
1WHO Country Office of Belarus; 2Ministry of Health of the Republic of Belarus; 3City Infectious Disease Hospital, Minsk
Fig. 26. Number of people living with HIV and number of people receiving ART, Belarus, 2010–2018
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living with HIV and civil society. The working group had 
the task of developing new national recommendations 
for the diagnosis and treatment of HIV infection in 
accordance with the latest WHO recommendations, 
including the “treat all” approach (5), while taking full 
account of national capacities and priorities.
To ensure a smooth transition from the previous 
recommendation of providing ART to all people with 
a confirmed HIV diagnosis and a CD4 cell count of 
500 per mm3 or less to providing ART to all people living 
with HIV regardless of CD4 cell count, an approximate 
schedule of patient recruitment for ART was drawn up 
for each region of Belarus. To accelerate recruitment 
of HIV-positive inmates, specialists from the Infectious 
Disease Service regularly visited penitentiary institutions 
to consult patients and initiate ART. In December 2017, 
several training seminars were held in all regions of the 
country to improve knowledge about ART, attended by 
230 infectious disease doctors, with the support of the 
WHO Regional Office for Europe.
The MoH is purchasing ARVs to provide treatment 
for patients according to the established schedule of 
linkage to treatment and is creating a six-month drug 
reserve (using a timetable showing how many patients 
should be put on treatment each month of the year to 
avoid stock-outs). Following its commitment to ensure 
sustainability for the transition to domestic financing of 
HIV-related activities, Belarus is gradually increasing the 
share of government spending on the purchase of ARVs 
(74.6% in 2017). At the same time, local production of 
generic ARVs has been established, including tenofovir/
emtricitabine/efavirenz – the three-component drug 
recommended by WHO as the preferred first-line 
regimen for ART (5).
ART regimens have been optimized and harmonized 
to bring them in line with WHO recommendations. 
In addition, the MoH, in close cooperation with the 
pharmaceutical industry, representatives of patient 
organizations, specialists of the infectious diseases 
service, public organizations involved in HIV care and 
international partners, is actively working to further reduce 
the cost of ART. This will help to optimize public spending 
for addressing HIV and to ensure the sustainability of 
national HIV control measures. The regional meeting 
on improving access to good quality, affordable ARVs 
and anti-TB drugs in the EECA countries, held in Minsk 
in November 2016, was devoted to this theme. The 
second regional meeting on a similar subject in Minsk is 
planned for November 2018.
Evidence of impact/efficacy
As a result of implementing the “treat all” policy in 
Belarus, the number of persons covered with ART has 
begun to increase and is expected to continue over the 
next few reporting years.
ART coverage for people living with HIV: general 
population
As a result of the “treat all” approach, the number of 
people living with HIV and receiving ART increased from 
8562 at the beginning of 2017 to 11 242 at 1 January 
2018. In the second half of 2017, coverage with ART 
increased from 50.1% to 58.5% of people living with HIV. 
According to planning targets, 19 804 people will receive 
ART by the end of 2018 (Fig. 25).
ART coverage for people living with HIV: 
penitentiary system
The number of people living with HIV and receiving 
ART in penitentiary institutions increased from 651 
on 1 July 2017 to 1008 on 1 January 2018, the latter 
corresponding to 54.8% of all people living with HIV in 
prisons.
Optimization and harmonization of ART regimens
As a result of optimizing ART regimens, 40% of HIV 
patients were receiving tenofovir/emtricitabine/efavirenz 
(recommended first-line regimen for ART) at the 
beginning of 2018. The number of the main treatment 
regimens was reduced from 40 to 11. The number of 
patients receiving individual treatment regimens was 
reduced to 233, thus helping to reduce the financial 
burden for the health care system in the country.
Sustainability
Robust political commitment driven by the MoH 
of Belarus has enabled this policy to be effectively 
implemented throughout the country. The establishment 
of strong relationships with local manufacturers and 
the pharmaceutical industry has enabled the domestic 
production of first-line ARVs, thus allowing people living 
with HIV to receive the support they need while reducing 
the financial burden on the overall health system. 
Optimization of regimens has also reduced the financial 
burden for the health care system in the country. Fig. 27 
shows the gradual increase in public spending on ART, 
with nearly three quarters of the budget now coming 
from the state.
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Background
The overall HIV prevalence in Bulgaria is low (0.07% 
in 2016) and concentrated in key populations (82), 
including people who inject drugs, MSM, the Roma 
population (men), prisoners and SW (Table 9). In 
2001, the Bulgarian Government adopted the first 
National AIDS Strategy and the National action plan 
for prevention and control of HIV/AIDS and STIs 
2001–2007. Supported by the MoH, the National AIDS 
Strategy and National action plan mandated state 
responsibility to ensure HIV testing services and ART 
were guaranteed for all. In 2004, decentralized, low-
threshold rapid HIV testing and counselling services 
combined with harm reduction programmes for 
people who inject drugs were implemented as national 
priorities, including for key populations.
Fig. 27. Proportion of GFATM and state funding for ART, Republic of Belarus, 2010–2018 
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BULGARIA. Development of low-threshold HIV testing services for key 
populations
Varleva, Tonka | Taskov, Hristo | Georgieva, Viara | Zamfirova, Mariya | Hristov, Kristyan
Bulgarian Ministry of Health
Table 9. Average HIV prevalence in key populations, Bulgaria, 2006–2011
People who 
inject drugs
MSM (2007–
2016)
Roma 
men aged 
15–25 
years
Prisoners SW
Prevalence 5.73% 2.95% 2.06% 0.98% 0.82%
Source: National Centre of Infectious and Parasitic Diseases, 2015 (82).
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Description of the good practice
Components of the integrated model for HIV service 
testing and delivery in Bulgaria include health testing 
services within and outside of health care facilities.
Health testing services within health care 
facilities
HIV testing services through provider-initiated testing 
are available in Bulgaria for the general population. 
Some providers offer anonymous, free-of-charge 
HIV testing services with extended pre- and post-
test counselling and psychological support; all offer 
referral to further care. Testing for migrants is available 
conducted by medical specialists in refugee centres. 
These services offer referral to care and additional 
counselling for psychosocial support and risk 
reduction.
HIV testing services outside health care 
facilities
From 2004 to 2008, through GFATM funding, different 
approaches were developed to increase access to HIV 
testing services with a clear focus on HIV prevention 
in target groups, including on-site HIV rapid tests 
(since 2005) via mobile medical units, drop-in-centres 
for people who inject drugs, NSPs, and sexual and 
reproductive health services. Seasonal low-threshold 
HIV testing services near popular seasonal resorts 
were also established, as well as HIV testing services 
in prisons. These services go beyond the health care 
facility package because they offer linkage to ART and 
TB, STI and reproductive care, including OST and 
NSPs as part of the essential harm reduction package 
for people who inject drugs. Health centres for the 
Roma population are community based and extended 
through medical staff.
Highlight: mobile medical units
Mobile medical units, equipped to offer HIV testing 
services as part of prevention services in difficult-to-
reach places, were also implemented through NGOs 
via GFATM grants in Bulgaria. These units are managed 
and used by NGOs that specialize in working with 
Bulgarian key populations. The units host a team of 
medical specialists and outreach staff who provide free 
on-site care. Currently, a total of 11 mobile medical 
units operate in areas with a high disease burden 
in the country. They offer a combination of services 
including STI check-ups, condom distribution, NSPs 
and health education. The units are now widely used 
for providing HIV testing services to young people and 
MSM in discos, bars, clubs, university campuses and 
other similar locations. They also form an essential part 
of local and national HIV testing campaigns. Additional 
funding allocated to the state by GFATM grants enabled 
the geographical expansion of the low-threshold HIV 
testing service network, especially via mobile medical 
units.
Highlight: HIV testing services in prisons
Treatment and services are provided to all inmates in 
accordance with the same guidelines and protocols used 
outside the prison system in Bulgaria. In 2006, the MoJ 
and MoH issued a joint order regulating HIV prevention 
activities, which allowed Regional Health Inspectorate 
teams to visit the prisons twice per month and to provide 
voluntary HIV testing services based on the principles of 
privacy and assured confidentiality. In 2010, the MoJ and 
MoH issued a joint ordinance for medical care in prisons, 
based on national HIV treatment guidelines, which 
also regulated HIV prevention services and ART. As a 
result, HIV testing services are offered to all prisoners 
during the initial medical examination and thereafter as 
part of routine medical care, further motivating inmates 
to access HIV testing services. The MoH provides 
HIV testing and treatment supplies including ART and 
follow-up care. The MoJ provides suitable facilities for 
testing and treatment in prisons to deliver a combined 
package of HIV prevention mechanisms harm reduction 
for people who inject drugs.
Highlight: human resources capacity-building
Before the start of the National AIDS Strategy and 
National AIDS Programme, HIV testing was offered 
at hospitals and public laboratories, often without any 
pre- and post-test counselling and referral owing to a 
lack of training in this area. In parallel with establishing 
the first low-threshold HIV testing services in 2004, a 
long-term programme (2004–2007) supported by a 
GFATM grant was launched for capacity-building of 
counsellors, physicians, psychologists and laboratory 
staff to ensure the provision of comprehensive and high-
quality services for clients. The total number of trained 
personnel increased from 41 in 2004 to 1822 in 2007, 
following implementation of the training programme. 
Of these, 211 are counsellors who provide high-quality 
counselling within low-threshold HIV testing services. 
An additional 1460 physicians, nurses and midwifes 
have been trained to recognize the risk for HIV and 
HIV-related conditions, offer testing, interpret and 
communicate test results, and manage people living 
with HIV.
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Evidence of impact/efficacy
Number of testing sites and number of persons 
tested
Since 2001, the number of locations offering HIV 
testing services has significantly risen, from 41 certified 
laboratories to 158, representing a fourfold increase in 
testing sites as a result of the new low-threshold sites. 
For the first implementation period, on-site health care 
facilities tested between 320 000 and 350 000 persons 
in the general population. For low-threshold HIV testing 
service sites, 1258 persons received HIV testing 
services in 2003; however, 44 220 were accessing 
these services by 2006 – approximately 38 times the 
original number for low-threshold HIV testing services. 
Data from the third implementation period are awaited.
Testing key populations
Before launching the National AIDS Strategy and 
National AIDS Programme in 2001, coverage of HIV 
testing services for key populations was very low. 
Implementation of the integrated model for HIV testing 
services resulted in a 40-fold increase of the number 
of members of key populations receiving HIV testing 
services in five years: from only 410 in 2003 to 17 385 
in 2009 (Fig. 28).
New HIV cases
The number of newly diagnosed cases among key 
populations has increased by 15 times (from nine HIV-
positive persons out of 398 tested in 2004 to 138 HIV-
positive persons out of 17 300 tested in 2009). The HIV 
case detection rate is 15.6 times higher in low-threshold 
HIV testing services compared with traditional health 
care facilities. Since 2009, there has been a steadily 
decreasing trend in the number of new HIV infections 
diagnosed among people who inject drugs (from 56 
in 2010 to 22 in 2016), although similar numbers of 
people tested have been tested (Fig. 29). Number of 
HIV tests and new HIV infections in people who inject 
drugs, Bulgaria, 2001–2016). There is also a fourfold 
decrease in the proportion of people who inject drugs 
out of all new HIV diagnoses (from 46% in 2009 to 12% 
in 2016;).
Fig. 28. Number of people receiving low-threshold HIV testing services, by key population, Bulgaria, 2001–2015
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Output and outcome indicators, along with a web-
based system for individual data collection for HIV 
testing services, were developed in harmonization with 
national HIV prevention and surveillance indicators. This 
includes national guideline optimization and standard 
operating procedures, protocols and checklists for all 
components of low-threshold HIV testing services.
Sustainability
The successful implementation and sustainability of the 
low-threshold HIV testing services model was possible 
thanks to the commitment and coordinated work of 
various institutions and organizations. Consensus 
among the major stakeholders on the objectives and 
priorities of HIV testing service policy was achieved 
through the National Committee for the Prevention of 
AIDS and Sexually Transmitted Diseases to the Council 
of Ministers of the Republic of Bulgaria, established 
in 1996 (83) to build trust and partnership between 
government institutions, local authorities, affected 
groups and NGOs working with them. Robust national 
regulatory consensus through these partnerships in 
combination with a constantly developed national 
strategic plan for the prevention and control of HIV in 
Bulgaria allowed smooth implementation of GFATM 
projects which augmented the success of this low-
threshold HIV testing services rollout. The joint 
partnership between the MoH and MoJ to implement 
progressive HIV testing services in prisons for HIV 
should be commended and may be seen as a growing 
Regional trend to accelerate intersectoral collaboration 
for health. The MoH operates and monitors low-
threshold HIV testing services while the joint effort 
with the MoJ is maintained to operate those within the 
penitentiary system.
The current National AIDS Programme (for 2017–2020) 
is wholly funded by the MoH, which guarantees its 
implementation. The current 2020 strategy envisages 
stronger individualized case management for newly 
diagnosed persons with HIV in the future. Stronger 
collaboration with coinfection surveillance for HBV and 
HCV infection and TB may benefit this practice in the 
future.
Fig. 29. Number of HIV tests and new HIV infections in people who inject drugs, Bulgaria, 2001–2016
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Background
With support from a private association in Finland and 
in cooperation with the prison service and drug and 
alcohol rehabilitation organizations, the Finnish Probation 
Foundation has designed a national harm reduction 
model and training programme for prisons based on 
health education and counselling. The moderators of 
the project were the Probation Foundation, an NGO, in 
cooperation with the Criminal Sanctions Agency. In the 
decades before the project was launched, morbidity rates 
among inmates had been increasing, particularly those 
related to blood-borne infectious diseases, substance 
use and mental health problems. About 50% of all people 
who use drugs are HCV infected; the most commonly 
used drugs are amphetamine, benzodiazepine and 
buprenorphine, often used intravenously. Finnish prisons 
do not currently have NSPs.
Description of the good practice
The health education courses for inmates developed 
during the project are now the permanent working 
method in Finnish prisons throughout the country. The 
aim of the courses is to reduce infectious diseases and 
other health and social risks/harm.
The health education programme includes the following 
interventions:
• an operational model recommendation for prisons 
and a training programme for prison staff to 
reduce the adverse effects of drug use in prisons 
(approximately 200 prison officers have been 
trained);
• a training programme for prisoner health education 
and counselling for leaders of the Health course 
(about 80 nurses/rehabilitation personnel have been 
trained) – the course comprises seven themes:
 - hepatitis;
 - HIV;
 - overdoses and first aid;
 - the risks of injecting drug use and alternative 
ways of using drugs;
 - drugs and mental health;
 - sexuality; and
 - substance use treatment; and
• a harm reduction guide for rehabilitation staff 
working with convicted persons in freedom (6000 
copies have been distributed).
The project emphasized multilevel cooperation between 
staff in health care, substance use rehabilitation, 
surveillance and administration, as well as interaction 
and peer support among inmates. Accepting that a 
drug-free prison may be an unattainable goal is one 
major issue to consider when working on similar 
programmes. Health care in prisons should start 
from the same basis as any other type of health care: 
health care services during imprisonment – including 
counselling services – do not differ from those in the 
community, except for the institutional setting.
Current harm reduction activities in Finnish prisons 
include health education and counselling, testing for 
HBC/HCV and HIV infection, vaccination, and training 
in the promotion of non-intravenous use and in safe sex 
practices to prevent STIs, including making condoms 
available ad continuing ongoing OST.
Evidence of impact/efficacy
The HIV situation in prisons is under control: fewer 
than five new infections are found per year. The main 
indicators were that the project creates a health 
education model to be permanently embedded into 
the prison service and to train personnel for permanent 
positions in the Prison Personnel Training Centre. 
Effects on inmate behaviour were not systematically 
monitored, but some qualitative implementation data 
were gathered (i.e. via inmate interviews). Feedback on 
personnel training was compiled using questionnaires. 
According to the evaluation, the project was 
successful and received positive feedback on ensuring 
transferability and sustainability. In training prison staff, 
the focus was on acquainting staff with harm reduction 
approaches.
Sustainability
The Finnish Probation Foundation designed the national 
harm reduction model and training programme for 
prisons based on health education and counselling with 
support from a private association and in cooperation 
FINLAND. Health education project for people who use drugs in the 
penitentiary system
Submitted by: Knuuti, Ulla1 | Suomela, Maarit2 | Tamminen, Eeva3
1The Criminal Sanctions Agency, Finland; 2Finnish Probation Foundation; 3Health Care Services for Prisoners, Finland
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with the prison service and drug and alcohol 
rehabilitation organizations. When the project started, 
the budget was €280 000 over three years. Thereafter, 
the budget has been about €30 000 per year, from 
internal funding (to cover the cost of materials, courses, 
education, information etc.). The project does not have 
its own budget but is part of the basic functions of the 
Criminal Sanctions Agency; since 2009, 100% of the 
funding has come from internal funding sources.
HA-REACT. Implementation of harm reduction training packages in Latvia and 
Lithuania
Submitted by: Indave Ruiz, Blanca Iciar1,2 | Manzanera, María Teresa1,2 | Mačiulytė, Dovilė3 | Camilleri, Moses4 | Sordo, Luis1,2,5
1Carlos III Institute of Health, Madrid; 2Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid; 
3Republican Centre for Addictive Disorders (RPLC) of Lithuania; 4Foundation for Social Welfare Services of Malta; 5Complutense University of 
Madrid
Background
Latvia has a relatively high incidence of HIV, reported as 
0.50 per 1000 population (adults aged 15–29 years), 
with fewer than 500 new cases in adults and children in 
2016 (84). Lithuania reported an incidence rate of 0.18 
per 1000 population, also with fewer than 500 cases 
in adults and children for the same year (85). The risk 
for HIV among people who inject drugs is high in both 
countries. Injecting drug use was the probable route 
of transmission (for those cases where transmission 
was known) for at least a quarter of the reported 
cases in both countries (Lithuania, 47%; Latvia, 27%) 
(1). Coverage with harm reduction interventions such 
as OST and NSP is also low. In light of this deficit, 
the European Joint Action HA-REACT has been 
developed. HA-REACT aims to contribute to the 
elimination of HIV and a significant reduction in HCV 
and TB infection among people who inject drugs in the 
EU by 2020. Its purpose is to improve the capacity to 
respond to HIV and coinfection risks by providing harm 
reduction services focused on people who inject drugs 
in the EU. Scaling up harm reduction services in the 
focus countries, Latvia and Lithuania, was one of the 
programme’s objectives.
Description of the good practice
The design and implementation of a harm reduction 
training package for care providers and policy-makers 
based on key harm reduction components was 
developed for both countries. Training was directed 
towards community organizations, peer educators, 
health professionals, social workers and decision-
makers in the focus countries. Key objectives included 
promoting good policy dialogue; discussing the benefits 
and disadvantages of harm reduction interventions; 
overcoming reluctance to using harm reduction services; 
building capacity for harm reduction interventions; 
promoting the influence of decision-makers to adopt 
harm reduction strategies; and reducing stigma in the 
policy agenda. Transferability and providing added 
value at the EU level was considered central in the 
design of all tools and materials.
Package and target areas
Promotion of peer interventions was also considered 
and different training elements addressed topics such 
as HCV prevention, the implications of amphetamine 
use for harm reduction interventions, overdose 
prevention, and related stigma and discrimination, 
among others. Target areas and core harm reduction 
interventions were identified based on the successful 
experiences of other European countries.
Priority areas of the harm reduction training programme 
curriculum were as follows:
• OST, overdose prevention and NSPs;
• promotion of peer interventions;
• prevention of HIV and HCV infection, along with 
other infectious disease;
• reduction of stigma and discrimination related to 
people who inject drugs and people who use drugs; 
and
• other growing focus areas such as drug testing/
drug checking interventions in recreational drug use 
settings or take-home naloxone programmes for 
overdose prevention.
Outputs
The outputs were:
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• debate seminars (including debate techniques and 
harm reduction policy decisions);
• study visits (direct observation of successful harm 
reduction intervention experiences); and
• harm reduction intervention workshops (technical 
capacity development).
Debate seminars
The two debate seminars were coordinated by staff 
from the Instituto de Salud Carlos III (ISCIII) Biomedical 
Research Networking Centres (CIBER), Spain. The 
chosen format for the seminars included presentations, 
discussions and small-group work. The content of the 
sessions was adapted to each focus country according 
to their individual political and need-based profiles. 
Tailored agenda included:
• the local harm reduction context;
• target issues – overcoming reluctance towards 
harm reduction and promoting specific interventions 
among professionals;
• sharing good practice from other countries; and
• improving the existing harm reduction services in 
Lithuania and Latvia;
Experts were invited to give presentations from each 
focus country, as well as from HA-REACT partners and 
collaborating institutions from EU and neighbouring 
countries, such as the ECDC, EMCDDA and the 
Eurasian Harm Reduction Network. Gap and barrier 
analyses were completed to determine the optimal list 
of professional attendees representing NGOs, CSOs, 
health care institutions and key policy-makers.
Study visits
All study visits included presentations, discussions 
and direct observation of successful experiences/
best practices. Two visits were organized in Spain and 
a third in Prague. Agendas of all study visits included 
visits to several harm reduction services: Mobile 
outreach units for methadone distribution and outreach 
services; night shelters; a pharmacy participating in the 
Opioid Substitution Treatment and Needle Exchange 
programme; local police departments; supervised 
drug consumption rooms; and low-threshold drop-in 
centres. The local experts and authorities described 
the status of harm reduction programmes, including in 
group discussions.
Harm reduction intervention workshops
Several workshops were designed to enable attendees 
to observe, practice and discuss the different harm 
reduction interventions. Two training courses consisting 
each of the following three workshops were organized 
(one in Lithuania and one in Latvia):
• a workshop on OST;
• a workshop on other harm reduction interventions; 
and
• a workshop on overdose prevention.
International experts were identified and invited to 
participate, together with experts from the focal countries 
as trainers and facilitators in the different workshops. 
All workshops applied a participatory methodology and 
included lectures, discussions, small-group exercises, 
individual assignments, a video, question and answers 
sessions, demonstrations, practical sessions (hands-
on practice), small- and large-group exercises, and role 
play and simulation.
Evidence of impact/efficacy
All activities were evaluated using a standardized 
evaluation questionnaire, with promising results. 
Seminars achieved maximum evaluation scores of 93% 
in Riga (Latvia) and 88% in Vilnius (Lithuania). The study 
visits achieved a maximum evaluation score of 91% 
in Spain in 2016 and of 90% in Prague. Continuous 
evaluation of the training courses is still in progress. All 
who attended the seminar in Riga said they were willing 
to reflect the contents of the seminar in the workplace 
(strongly agree, 64%; agree, 36%) and 91% of the 
participants at the Vilnius.
The focal countries are currently integrating harm 
reduction interventions in their systems and 
professionals are engaging and, hopefully, mobilizing to 
make changes based on the information shared during 
training. Particular interest has been shown in naloxone 
programmes for overdose prevention and supervised 
drug use. Enrollment of people who inject drugs to 
such programmes has been discussed and, hopefully, 
will be promoted. Efficacy data for the programme are 
under analysis.
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Sustainability
Each arm of the training programme prioritized 
collaboration with all local institutions in the focus 
countries. The training of trainers methodology (also 
used by WHO) enabled professionals of all cities 
and focal cities in Latvia and Lithuania to participate. 
Agendas, reports and evaluation materials will be 
freely available after the conclusion of the project so 
that countries interested in the training package can 
replicate it with minimal resources. The harm reduction 
training package should be adapted based on the 
country context and available resources.
HA-REACT. Harm reduction services in mobile outreach units: an example from 
Latvia
Submitted by: Indave Ruiz, Blanca Iciar1,2 | Manzanera, María Teresa1,2 | Fremaine, Agnese3|Kaupe, Ruta4 | Sordo, Luis1,2,5
1Carlos III Institute of Health, Madrid; 2Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid; 3Latvian 
Centre for Disease Prevention and Control; 4DIA+LOGS; 5Complutense University of Madrid
Background
HIV risk among people who inject drugs is high in Latvia, 
as in many other European countries (1). The first IDU-
related HIV case was diagnosed in 1995 (86) and HIV 
transmission through injecting drug use is currently a 
significant cause of premature death (87). Coverage with 
both OST and NSPs is low (at 10% and <50 per person 
who injects drugs, respectively) (88). In this context, 
decentralized testing services are particularly needed 
in the country. Until 2017, there was only one mobile 
outreach unit (MOU) offering testing and linkage to care 
services.
Description of the good practice
A new MOU was introduced in Latvia in January 2017 
with the aim of reducing the incidence of HIV and other 
blood-borne infections among people who inject drugs, 
with special focus on so-called hidden populations (i.e. 
those not currently in contact with health services). 
DIA+LOGS, a NGO, was chosen to implement this 
MOU, developed in the context of the Joint Action 
proposal on HA-REACT and supervised by the Centre 
for Disease Prevention and Control of Latvia. This 
MOU provides harm reduction services such as NSPs, 
condom distribution, rapid HIV testing and counselling 
for people who inject drugs in Latvia’s capital city Riga 
and its surrounding areas. The preparation period lasted 
approximately one year (2016). The most relevant 
activities were consolidating political commitment 
behind implementation of the MOU and coordinating 
this enterprise through local and national authority 
involvement.
During the same period, DIA+LOGS was in charge 
of community involvement. This NGO is well known 
and respected among people who inject drugs. After 
a year of preparation, the MOU started working for 
23 hours/per week, distributed over four days. The 
MOU workforce and its functions included one nurse 
(14 hours/week); one social worker (23 hours/week); 
three outreach workers (23 hours/week) and one driver 
(23 hours/week). Target areas were identified and 
intervention sites were selected based on three criteria: 
(i) places where injecting drug use was most prevalent in 
the region; (ii) areas where no harm reduction services 
existed or were not provided; and (iii) places where harm 
reduction interventions were more difficult to implement 
owing to stigmatization. In the first six months of activity, 
the MOU performed 398 consultations with 93 different 
clients, distributed 432 condoms and 8436 needles/
syringes and completed approximately 143 HIV tests. 
Even better results were achieved in the following three 
months owing to integration into the MOU of a research 
project on HIV testing managed by the Centre for 
Disease Prevention and Control of Latvia.
After the first six months, external professionals 
assessed the MOU based on structured interviews of 
clients and NGO workers and opinions from the Centre 
for Disease Prevention and Control of Latvia, which 
provides medical support, including an HIV testing 
service. A SWOT (strengths, weaknesses, opportunities 
and threats) analysis by the researchers identified the 
qualities required for a strong MOU programme:
1. preliminary research to determine the target 
population should be done before implementing 
MOUs.
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2. selection of a good NGO for implementation based 
on the following criteria:
a. is well known/experienced in the area to act 
as a crucial icebreaker for people who inject 
drugs;
b. is experienced in collaborating with local 
authorities and communication pathways 
between this NGO, supervisors, municipalities 
and clients (people who inject drugs and their 
relatives);
c. understands the social context and should be 
able to adapt their activities to changes; and
d. is impressively staffed and demonstrates 
robust harm reduction competencies;
3. involvement of all local municipalities in the process;
4. social contracting services between local public 
health institutions and NGOs to allow active 
dialogue between theory and practice, supported 
by empirical studies and evidence;
5. monitoring and evaluation and quality assurance 
strategies that are defined before implementation;
6. standardization, including standard operating 
procedures and security protocols;
7. involvement of local authorities (especially police);
8. overdose prevention services (naloxone) be 
available in all units; and
9. sustainable financing mechanisms integrated 
throughout the projects.
Evidence of impact/efficacy
The MOU was designed to promote the health and safety 
of people who inject drugs. The large and increasing 
number of needles exchanged suggests that the MOU 
could be playing a decisive role in preventing HIV and 
hepatitis C among people who inject drugs, although 
data are still being analyzed. A MOU was shown to be 
a relatively low-cost method of meeting the immediate 
needs of people who inject drugs, including first aid, 
condom provision and relevant information, but has 
proven especially useful for providing access to health 
and other community services for this population. For 
many clients, the MOU represents their first contact 
with health services in general and with HIV prevention 
programmes in particular (primary or secondary 
prevention), thus facilitating linkage to care. Quantitative 
data on service provision during the first six months of 
operating the MOU enabled us to perform a descriptive 
analysis of its function (Table 10).
Implementation of the MOU has increased the distribution 
of needles by 5% since 2015. In 2015, 88 new cases 
of HIV were attributed to injecting drug use in the 
country; project designers expect the MOU to have an 
important impact in this population. Current data reveal 
strong uptake among people who inject drugs, and the 
coming final evaluation will determine the requirements 
for scaling up and for benchmarking against new HIV 
infections.
Sustainability
The Latvian Centre for Disease Prevention and Control 
plans to continue funding the MOU after the end of the 
HA-REACT Project. Purchase of another MOU is also 
Table 10. MOU indicators, DIA+LOGS, Latvia, January – October 2017
Indicator (n) Jan Feb Mar Apr May Jun Jul Aug Sept Oct
Consultations 14 52 39 42 42 48 44 36 72 99
Individual clients 14 52 39 42 42 48 44 36 72 99
New clients 9 30 65 57 57 79 20 20 49 27
Secondary clientsa 0 0 0 0 2 0 0 0 0 0
Syringes and needle distributed 80 656 1480 445 1955 2010 1810 1005 1005 413
Syringes and needles returned 0 5 150 60 383 380 507 490 320 0
Condoms distributed 163 711 370 222 366 424 432 262 296 291
HIV tests performed 13 36 24 33 25 30 31 28 63 83
a Clients who are not reached directly by the MOU (i.e. they do not attend the MOU) but are provided with needles/syringes through one of its clients.
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planned. The MOU service has also been included in 
the new National HIV prevention plan for 2018–2020. 
DIA+LOGS has confirmed that it will seek funding 
opportunities to continue the work of this MOU. Cross-
border knowledge sharing with other Member States, 
such as Estonia, has already begun. For example, 
professionals from DIA+LOGs were invited to share 
their experience of running the MOU in an Estonian 
workshop in December 2017.
ITALY. La Bussola: a handbook for protecting the rights of people living with HIV
Submitted by: Luzi, Anna Maria1 | Pugliese, Lucia1 | Schwarz, Matteo1 | Suligoi, Barbara1
1Istituto Superiore di Sanità (National Institute of Health), Rome, Italy; 2Avvocatura Foro Palermo, Italy
Background
In 2016, 3451 new HIV diagnoses were reported in 
Italy (an incidence of 5.7 per 100 000 population). Most 
people diagnosed with HIV in 2016 were male (76.9%); 
the average age was 39 years for men and 36 years 
for women. In 2016, 35.8% of newly diagnosed people 
were foreign nationals. Among them, 65.5% were 
heterosexual (women, 34.9%; men, 30.6%). 
Description of the good practice
A handbook has been developed for individuals who 
have received a positive HIV diagnosis and may feel 
disoriented in managing their new chronic condition, 
as well as for caregivers attempting to support people 
living with HIV in Italy. Targeted primarily to people 
recently diagnosed with HIV in Italy, the handbook, La 
Bussola (The Compass) aims to raise awareness of 
the rights of people living with HIV, including the tools 
available to them in Italy (89).
The handbook is designed for all people, including 
foreign nationals, who may use it as a tool to obtain 
urgent and essential care services from the Italian 
health system. The online version of the handbook 
was sent to the entire network of public STIs/infectious 
disease diagnostic centres (a network of about 700 
public centres across all 21 Italian regions), as well as 
to numerous NGOs actively providing assistance to 
HIV-positive people.
After receiving a diagnosis of HIV seropositivity, it 
is necessary to be aware of the social security and 
welfare benefits provided by local legislation, including 
the eligibility requirements for receiving the necessary 
care in an infectious disease centre and for exemption 
from out-of-pocket expenses. Further, under Italian law, 
HIV-seropositive persons should not be discriminated 
against in the pre-selection criteria for employment 
nor after employment. Finally, concerning travelling 
expenses, it is necessary to understand which health 
services are paid for or subsidized by the host country.
The La Bussola handbook addresses these and other 
legal issues relevant for people living with HIV in Italy via 
sections based on the following 14 frequently asked 
questions:
1. What does it mean to become a person now living 
with HIV?
2. Am I obliged to communicate my HIV-positive 
status to my partner?
3. What do I need to do to obtain free access to care 
and medications related to my HIV status?
4. Does the HIV-positive status confer any social 
benefits?
5. What are the social benefits granted to the 
HIV-positive person for whom legal disability is 
recognized?
6. Are there any differences between regions related 
to granting health care to HIV-positive people?
7. Can the HIV-positive status limit access to work 
activities?
8. Can the HIV-positive status limit access to 
education and sports?
9. Under what exceptional conditions may an 
employer ask a worker to undergo HIV testing?
10. Can data concerning the HIV status of a person 
be communicated to third parties by the health 
personnel?
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11. Can an employer investigate the health status of a 
person who is applying for a position?
12. Can employment agencies investigate the health 
status of persons requesting their services?
13. When legal disability is recognized, can an 
employer and/or an employment agency request 
clarification on the cause of the disability?
14. Does the HIV-positive person travelling abroad for 
work/study/tourism encounter any limitations in 
accessing other countries and/or in taking ART 
with them?
Evidence of impact/efficacy
This practice is in its initial stages and being implemented 
in the country. Therefore, data on reach and usage are 
not yet available.
Sustainability
D evelopment and maintenance of the handbook is 
fully financed by public resources from the National 
Institute of Health (Istituto Superiore di Sanità) and is 
expected to be available long term. It will be translated 
into English and updated every two years.
ITALY. A handbook on access to health care for foreign citizens and migrants, 
Second Edition
Submitted by: Luzi, Anna Maria1 | Pasqualino, Gaetano Mario2 | Pugliese, Lucia1 | Schwarz, Matteo1 | Suligoi, Barbara1
1Istituto Superiore di Sanità (National Institute of Health), Rome, Italy; 2Avvocatura Foro Palermo, Italy
Background
In 2016, 3451 new HIV diagnoses were reported in Italy, 
representing an incidence of 5.7 per 100 000 residents. 
Most people diagnosed with HIV in 2016 were men 
(76.9%); the average age was 39 years for men and 
36 years for women. In 2016, 35.8% of newly diagnosed 
people were foreign nationals. Of these, 65.5% were 
heterosexual (women, 34.9%; men, 30.6%).
This good practice addresses the growing problem 
of migrant14 and refugee health in Italy following 
the unprecedented level of migration into the WHO 
European Region. The Italian National Health System 
ensures that all people in the country, including migrants, 
receive a minimum level of assistance regardless of 
their specific conditions. Access to HIV treatment and 
prevention programmes falls within this minimal level of 
assistance and is therefore ensured to all the people in 
need. In relation to migrants, it is essential to distinguish 
between the different groups and types of migrants, in 
accordance with their status under Italian law.
Description of the good practice
The main purpose of the handbook, Access to care for 
foreigners, is to provide information on accessing health 
14 The handbook is divided into six sections distinguishing migrants according 
to their status as (i) holders of a regular residence permit; (ii) migrants who do 
not have a regular residence permit; (iii) migrants from countries that entered 
bilateral agreements concerning healthcare with the Italy; (iv) EU citizens; (v) 
migrants with international protection; and (vi) models of the different docu-
ments/certificates.
and social services to foreign living legally and illegally 
residing on Italian territory.15 The handbook, published in 
two editions over two years, is the result of collaboration 
between the AIDS Unit and the Research Communication 
and Training Unit of the National Institute of Health (90), 
with legal support from the Palermo Forum (specializing 
in immigration law). The starting point for this work was 
data collection by the National Institute of Health over 
many years through the AIDS Unit and the HIV/AIDS and 
STI Telephone Service. The collected information and 
data showed that the migrant population generally has a 
low socioeconomic status.
The handbook is structured into chapters (the first four 
are summarized below) and includes a list of primary 
centres for immigration, classified by type and function, 
with photo reproductions of forms and other documents 
such as health service access requests, the health 
insurance card and residence permit.
Chapter 1. Access to care for migrants: 
contains information and procedures for 
accessing the national health care system and 
obtaining a health insurance card, including 
registration costs and details of the different 
types of residence permits. This chapter is for 
15  Including foreign persons coming from countries with which Italy has 
entered into bilateral international agreements, as well as persons coming 
from the EU.
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persons who already have a valid residence 
permit.
Chapter 2. Access to social and health care 
for foreign persons who do not have a valid 
residence permit: outlines how to access 
urgent and necessary care for foreign persons 
who do not have a regular residence permit, 
including the procedure for requesting the 
release of the STP (Straniero Temporaneamente 
Presente) code, which is needed to receive 
urgent and necessary care, and the rights of 
foreign people who are awaiting regularization 
of their status in the country.
Chapter 3. Access to social and health care 
for foreigners according to bilateral treaties 
entered into by Italy and individual countries: 
contains a full list of treaties between Italy and 
partner countries concerning bilateral access to 
social and health rights for the citizens of both 
signatory countries, including a FAQ (frequently 
asked questions) section.
Chapter 4. Access to social and health care 
for citizens of the EU: contains references to 
the legal framework governing access to care 
for those EU citizens who exercise their right to 
move within the EU territory, including a list of 
the main forms that need to be obtained in the 
home country to request access to health care 
in Italy or any other EU country to which the 
person intends to relocate.
Evidence of impact/efficacy
The online version of the handbook has been 
distributed throughout the country via the Italian 
National Focal Point. This is a group of experts from 
public institutions and nongovernmental and volunteer 
organizations representing migrant communities in 
several Italian regions with the aim of studying migrant 
flows as they relate to the health needs of foreign 
populations. Over the past 14 years, this permanent 
working group has worked in collaboration with health 
professionals to promote national and international 
epidemiological research and projects in the field of 
HIV prevention. Special attention has always been 
paid to migrant populations and training courses for 
psychosocial and health professionals have been 
organized regularly.
Sustainability
Development and revision of the handbook are 
fully financed by public resources from the National 
Institute of Health. The handbook will be translated 
into English and updated every two years.
ITALY. Testing for syphilis and HIV, HBV and HCV infection in Italy: new 
guidelines for serological screening in public drug treatment services
Submitted by: Suligoi, Barbara1 | Luzi, Anna Maria1 | Colucci, Anna1 | Fanales Belasio Emanuele1 | Mulieri, Ilaria1 | Pugliese, Lucia1 | 
Raimondo, Mariangela1 | Salfa, Maria Cristina1 | Manna, Gaetano2 | Di Stefano, Adele2
1Istituto Superiore di Sanità (National Institute of Health), Rome, Italy; 2Gruppo Tecnico Interregionale Dipendenze (Regional Representatives 
of Public Drug Treatment Services)
Background
About 70% of people who use drugs and attending 
public drug treatment services in Italy are not being 
tested for HIV, HBV and HCV infection, despite an 
estimated high prevalence of these infections among 
people who use drugs in the country (8%, 35% and 
60%, respectively) (91).
Description of the good practice
New guidelines aimed at promoting the serological 
screening and the early diagnosis of HIV, HBV and 
HCV and syphilis in public drug treatment services 
were developed by the National Institute of Health in 
collaboration with Drug Prevention Policy Department 
and regional representatives of drug treatment services 
(Fig. 30) (92). Briefly, the new guidelines recommend 
actively offering serological testing for these infections to 
people who use drugs, both new and old clients, every 
six to 12 months, along with targeted pre- and post-test 
counselling, specific prevention measures, and follow-
up treatment and care for those who need it.
The new guidelines include an overview of the 
epidemiology of HBV, HCV and HIV infections; 
prevention measures for these infections; a description 
of the procedures and criteria for serological testing, 
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highlighting the importance of testing for both new 
attendees and old clients; four summary sheets on 
the key aspects of serological screening for each 
infection; and a specific chapter on testing people 
who use drugs in vulnerable groups (prisoners, 
migrants, young people and minors). The guidelines 
also suggest an innovative communicative-relational 
model to improve the uptake of serological testing for 
drug-related infections is suggested.
When the final version of the new guidelines was 
ready, a two-day training course on use of the new 
guidelines was organized in 2016. Forty health 
care professionals working in public drug treatment 
services from all Italian regions and representatives of 
the community of people who use drugs were invited. 
The programme included plenary sessions, interactive 
discussion, role play and exercises/discussions 
in working groups. Results of the working group 
discussion were incorporated into the final version of 
the new guidelines. Specific outputs included specific 
recommendations for implementing serological testing, 
practical suggestions for overcoming organizational 
issues and a list of indicators to measure the effective 
implementation of the new guidelines and their impact 
on harm reduction.
Key indicators include the:
• number of clients tested for HBV, HCV and HIV 
infection;
• number of pre and post-test counselling;
• proportion of clients tested for HBV, HCV and HIV 
infection among all attendees;
• number of clients testing positive for any infection;
• prevalence of each infection among new and old 
clients;
• number of clients who tested positive who were 
linked to care for the specific infection; and
• proportion of health care workers trained in 
serological screening among those of the team.
The new guidelines were published in March 2018 on 
the websites of the National Institute of Health and 
the Drug Prevention Policy Department and will be on 
the MoH website soon. The guidelines are expected 
to be fully implemented by all drug treatment facilities 
in Italy in the second half of 2018. Drug treatment 
centres will measure the implementation level for the 
new guidelines annually using indicators reported in 
the final part of the guidelines. Overall, the rate of 
serological testing for every infection will indicate the 
corrective actions to be taken by each centre.
Evidence of impact/efficacy
The practice was primarily intended to improve 
uptake of testing for HBV, HCV and HIV infection and 
syphilis among people who use drugs. The effect on 
actual testing rates among people who use drugs 
will be monitored once the guidelines have been fully 
implemented across the country. However, some 
preliminary results are promising: The EMCDDA 
has proposed publishing a short version of the new 
guidelines (in English) on the EMCDDA website as a 
model of awareness and capacity-building in drug 
treatment centres that can be of use to other European 
countries. Furthermore, representatives of public drug 
treatment centres have recognized the relevance of 
the guidelines and recommended implementation 
of periodic training on effective communication and 
counselling for health professionals working in drug 
treatment centres.
Additional expected benefits of the practice in this key 
population are:
• collection of more accurate and granular data 
(information will be reported on an individual basis) 
on infections other than HIV, such as HBV and HCV 
infection and syphilis;
• strengthening national HIV surveillance data through 
more accurate detection of new HIV diagnoses 
among people who use drugs;
• raising awareness on the relevant spread of these 
infections among people who use drugs;
• development of communication and relationship 
skills among health care workers based on the 
use of innovative tools and procedures aimed at 
encouraging the uptake of serological testing in 
drug treatment centres (the new guidelines describe 
in detail the skills to be developed in terms of self-
awareness, empathy and active listening);
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• enhancement of NSPs, to be extended to prisoners 
and migrants; and
• increased linkage to care, retention in care and 
coverage with ART.
Sustainability
Public drug treatment centres provide annual data on 
HIV prevalence and incidence to the MoH, the National 
Institute of Health and the Drug Prevention Policy 
Department. Over the next few years, this requirement 
will lead to reinforcement, at no cost, the application 
of the new guidelines to obtain reliable epidemiological 
data on HIV and other drug-related infections.
The guidelines are expected to be updated every five 
to seven years.
Fig. 30. The new guidelines.
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LITHUANIA. Initiation of national regulation of low-threshold services
Submitted by: Čaplinskas, Saulius | Krupenkaite, Rima | Čaplinskienė, Irma | Seselgis, Algirdas | Pakalniskiene, Jurgita | Jakaitiene, Radvile
Ministry of Health of the Republic of Lithuania
Background
Targeted prevention measures of HIV infection were 
introduced in Lithuania following the first reported case 
of HIV in the country in 1988. In the first years of HIV 
epidemic, the main focus of the HIV response was 
on organizational goals: in 1989, the Lithuanian AIDS 
Centre was established to coordinate the national HIV 
prevention strategy; and in 1990, and the first National 
AIDS Prevention and Control Programme was launched. 
In Lithuania, as in other countries in the Region, harm 
reduction measures (in particular, NSPs) have been 
heavily debated both in society and among decision-
makers. The initiation of low-threshold programmes 
was led by a national institution, the Lithuanian AIDS 
Centre, which launched the a pilot NSP in the capital 
city of Vilnius in 1991. At that time, injecting drug 
use was rarely discussed and was not considered 
a problem of national concern. To understand the 
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peculiarities of injecting drug use behaviours, the 
Lithuanian AIDS Centre tried to establish contact with 
the IDU community with the help of volunteers. In this 
way, pilot needle and syringe exchange activities began 
with no legal basis, although the first HIV cases in the 
injecting drug use community were only identified in 
1994 and harm reduction was not widely discussed. 
With hindsight, it is clear that Lithuania launched NSPs 
together with other services to prevent the spread of 
HIV among people who inject drugs, in a timely manner. 
To strengthen the decentralized response to HIV in 
key populations, Lithuania developed low-threshold 
services through active involvement of the country’s 
local regions including regulation by the MoH. This 
highlighted the need (i) for a harm reduction services in 
society; (ii) to raise the awareness of decision-makers, 
especially in the local regions; and (iii) to regulate unified 
and clear standards for low-threshold services.
Description of the good practice.
In 2006, the MoH of Lithuania regulated low-threshold 
services by releasing an Order of the Minister of Health 
(entitled Description of low-threshold service provision). 
The ministerial order defined specific terms (e.g. needle 
and syringe exchange, risk behaviours, stationary and 
mobile services, types of service clients); the purpose and 
tasks of low-threshold services, along with mandatory 
services; the forms of service provision (stationary 
and mobile units); the needle and syringe exchange 
ratio; the qualification requirements for personnel and 
premises; and requirements for collecting and handling 
waste and controlling infections. In addition, the 
ministerial order detailed the requirements for eligible 
institutions (public institutions and NGOs) to establish 
a low-threshold service site and where they should 
be set up, that is, areas where high-risk groups meet 
(i.e. in the target group environment), thus ensuring 
geographical accessibility to customers. Budgeting 
for low-threshold services was also regulated by the 
ministerial order. Essential injecting paraphernalia (e.g. 
syringes, needles, condoms, alcohol wipes, waste 
containers) have been since purchased centrally 
from the state budget and distributed among all low-
threshold services. The national regulations for low-
threshold services have also strengthened advocacy 
for sustained financing.
The clearly defined national standards for low-threshold 
services have increased public awareness of HIV 
response measures, such as NSPs, and should reduce 
stigma among key populations, strengthen strategic 
information, and improve communication and social 
support for behaviour change for people who inject drugs 
(including people living with HIV). The legal framework for 
low-threshold services set the basis for the involvement 
of community organizations (i.e. NGOs) in providing 
the low-threshold services, along with financial support 
from the state. Of the 14 low-threshold service sites in 
Lithuania, five were set up by NGOs.
Evidence of impact/efficacy
The procedure for low-threshold service provision was 
established under Order No. V-584 of the Minister of 
Health of the Republic of Lithuania, 5 July 2006 (93). 
The national regulations for low-threshold services do 
not contradict ethical standards and have received 
support from relevant national and local authorities, 
including local regional leaders and NGOs.
Fig. 31 shows the decreasing proportion of people 
who inject drugs among all newly diagnosed people 
living with HIV in Lithuania. This trend is coincident 
with the continued development of low-threshold 
harm reduction services for people who inject drugs.
Sustainability
The national regulations for low-threshold service 
provision procedure have strengthened the case 
for sustained financing. Funding for low-threshold 
services (including for injecting paraphernalia needs) is 
included in the long-term national planning document, 
National Drug Control and Drug Addiction Prevention 
Programme action plan, and the Order of the Minister 
of Health is the official implementation body for the 
new national regulations for low-threshold services. 
The national regulations for low-threshold services 
have also strengthened advocacy for sustained 
financing (i.e. long-term funding of the low-threshold 
service measures is foreseen); the creation of new 
low-threshold services with EU financial support (from 
2018) is scheduled. Full transition to state funding 
is recommended to ensure the local sustainability of 
these services.
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PORTUGAL. The Portuguese Community Screening Network
Submitted by: Simões, Daniel1 | Freitas, Rosa1 | Rocha, Miguel1 | Meireles, Paula2 | Barros, Henrique2
1Grupo de Ativistas em Tratamentos (GAT), Coalition Plus Community Research Laboratory; 2Instituto de Saúde Pública da Universidade do 
Porto (Institute of Public Health, University of Porto)
Background
In Portugal, 1030 new HIV diagnoses in 2016 were 
notified, of which approximately 56% were late.16 These 
findings underline the barriers to testing in the country. 
Sex between men was the second highest mode of 
transmission in Portugal in 2016, corresponding to 
35.7% of all new HIV diagnoses;17 for the first time 
since 1984, MSM represented 50% of all new HIV male 
cases, reflecting a consistent increase over time in both 
the absolute number and relative contribution. Sharing 
of injecting paraphernalia was the cause of less than 
3% of new cases in Portugal in 2016. Over a third of 
new HIV diagnoses occurred in people born outside the 
country, of whom three quarters were from sub-Saharan 
African countries. An estimated proportion of over 80% 
of newly diagnosed individuals in 2015 lived in the 
larger urban areas. Broadly speaking, the Portuguese 
risk profile varies but so does access to testing, further 
reinforcing the importance of developing a testing 
strategy targeting the most affected populations such 
as migrants, MSM, SW and people who inject drugs 
(prevalence estimates for the latter three groups reach 
10%) (94–99).
16 Defined as a CD4 cell count of below 350 per mm3 (55%) or presenting 
with an AIDS-defining event regardless of the CD4 cell count (1%).
17 With heterosexual transmission being the main reported transmission route 
(57.1%).
This asymmetry highlights the requirement for services 
tailored to the needs of target populations, as well as 
the creation of an epidemiological data surveillance and 
dissemination system to obtain high-quality strategic 
information about the epidemic(s). Data collection on 
HBV and HCV infection is scarce and testing in key 
groups was uncommon. With the establishment of 
the Portuguese Community Screening Network, these 
tests became available through CBOs.
Description of the good practice
The Network seeks to: (i) implement and expand 
decentralized access to testing for HBV, HCV and HIV 
infection and syphilis, while ensuring effective support 
and monitoring along the process of linking people to 
care between CBOs and the Portuguese National Health 
System; and (ii) provide data for second-generation 
surveillance of the incidence of these infections and 
their respective predictors among people testing at 
these CBOs. In regulatory terms, lay providers can 
perform rapid tests in Portugal. Currently, member 
organizations of the Network employ a mixture of health 
professionals and lay workers, who perform the rapid 
testing (depending on the composition of the teams). 
Peers are also integrated into some teams for testing. 
All persons providing testing services are trained under 
Fig. 31. Transmission routes among newly reported HIV cases, Lithuania, 1988-2017
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the Network, which at the moment is the only structure 
in the country providing training for NGOs in HIV 
prevention and screening, as well as for viral hepatitis 
and syphilis. A major challenge for the screening 
Network was the lack of Portuguese guidelines for 
community-based screening. The approach chosen 
by partners was based on the most up-to-date 
international guidelines of reference institutions, CDC, 
ECDC and WHO (87,100,101); it was developed in 
collaboration with EU-funded projects dedicated 
to community-based testing, such as COBATEST 
(17) and Euro HIV EDAT (19). Based on these 
recommendations, a procedural manual was created 
to provide guidance on the physical infrastructure 
required for performing screening tests; the obligations 
of those conducting them; information required on the 
screened infections, screening protocols and models, 
and/or on counselling before and after a test; the 
referral process; and legislation and quality control. All 
guidance is in line with WHO’s essential 5Cs for HIV 
testing services (consent, confidentiality, counselling, 
correct results and connection) (87). The manual was 
written in a language accessible for all people who 
received training: health care professionals, lay workers 
and peers.
The first round of contacts to form the Network focused 
on organizations with which the promoter had previous 
contact, as well as organizations with pre-existing HIV 
screening projects (self-directed or financed through 
the National Programme for HIV and TB). After the first 
stage, organizations that were providing community-
based screening throughout the country were contacted 
and/or contacted the Network. The Network started 
with 13 partner organizations and 18 testing sites (at 
the inception of the programme) and by the end of 
2017 encompassed 18 organizations and 25 testing 
sites. Nine other organizations have requested to enter 
the Network but, due to current financial limitations, the 
response to new organizations has been slower.
The Network thus provides training in community-based 
screening for health professionals and lay providers, 
rapid testing kits, medical consumables, screening 
algorithms and data collection tools. The Network 
offers combined rapid and point-of-care testing for 
anti-HIV 1/2, the Hbs antigen, anti-HCV antibodies 
and anti-Treponema pallidum antibodies, according to 
individual criteria, which maximizes opportunities for 
early diagnosis in key groups. All tests used are finger-
prick rapid tests, have a specificity and sensitivity of 
over 95%, and are approved for use in the EU. Data 
collection tools are available both online and via a 
printed structured questionnaire. Provision of tablets 
with mobile Internet access enables participants to fill 
in the online questionnaire during the testing session. 
Additionally, a coordinated online data collection and 
centralized data analysis system (by the Institute of 
Public Health of Porto University) provides organizations 
with monthly access to a standardized report on the 
screening activity. This reduces the data management 
burden but has also allowed the progressive analysis of 
each project by providing organizations with monthly 
updates required to make for ongoing adjustments.
Clients are first invited to respond to an anonymous 
questionnaire, which generates a unique identifier 
code that enables follow-up at subsequent visits in 
any member centre (and thus creating a multicentric, 
community-based prospective cohort). The 
questionnaire includes triage questions to assess 
which test(s) should be offered to each person. Pre-
test counselling is voluntary (as the testing model is 
based on pre-test information), lasts for approximately 
five minutes and focuses on explaining how the testing 
sessions are structured, the tests themselves and the 
questionnaire. Participants are always invited to ask 
questions. While waiting for the test results (a maximum 
of 30 minutes after the finger-prick, depending on the 
tests performed), persons are invited to ask questions or 
to speak about the infections or other specific concerns 
they may have. As member NGOs work in a targeted 
fashion, many of the tested persons are members of 
the key population that the organizations work with; 
thus, the testers have specific knowledge on the 
corresponding risk behaviours, prevention strategies 
and complementary interventions/referrals. Following a 
reactive test between result, referral is offered by the 
testing centre to a specialty appointment in a hospital, 
with a member of staff to accompany the person to the 
first appointment to help navigate the hospital and face 
any barriers that arise. If necessary, the person is also 
referred to complementary support services (social, 
migration, drug treatment services). In the case of a 
negative result, the relevant prevention interventions 
are made available according to risk behaviour(s): these 
include condom distribution, safe drug use materials, 
information on other relevant services and testing sites, 
and information on PEP.
Most organizations offer escorted referral to care. 
In some organizations, more structured support is 
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offered to extend escort provision until the person feels 
comfortable navigating the system alone. In 2018, 
Grupo de Ativistas em Tratamentos (the screening 
network promoter) initiated a new project in its testing 
centres, as well as in two hospitals in Lisbon, whereby 
a trained peer will offer continuous support in linkage to 
care, adherence and retention in care. The trained peer 
works as a case manager for newly diagnosed persons 
from key populations. Peers will also be present as 
part of the medical teams of partner hospitals and will 
support and accept referrals from doctors for patients 
with adherence/retention difficulties.
Implementation of external quality control measures 
ensured the proper delivery of screening tests and use 
of appropriate reagents. The external quality control 
programme was coordinated by the National Health 
Institute Doutor Ricardo Jorge (the Portuguese National 
Institute of Health (INSA), a reference laboratory. 
The process consists of sending a panel of samples 
with unknown reactivity to all organizations, which 
then analyse and return the results to the reference 
laboratory. Cross-analysis allows the performance of 
each screening centre to be assessed by an external 
entity. Additionally, visits to the testing sites are part 
of the supervision programme to check laboratory 
conditions, storage conditions, regulatory compliance, 
among others. A checklist was developed in the initial 
phase by a team at São João Hospital, based on WHO 
criteria; to act as a guide for the external auditor. A report 
of each visit was done and sent to the organization, 
including suggestions for improvement, if applicable.
Evidence of impact/efficacy
The results have led to improved knowledge on 
epidemics in the national territory and on the quality 
of community testing in Portugal. Over the 2016–2017 
period, over 2000 tests were reactive, of which 156 
were for more than one infectious agent (Table 11; 
Fig. 32, left). For HIV, there were 205 reactive tests in 
2016 and 267 in 2017 (total of 472). However, if only 
HIV tests had been offered, then 1540 reactive tests for 
infections other than HIV would have not been detected 
(Fig. 32). Additionally, an alarmingly high number of 
persons tested in the Network had never been tested 
for one of the four screened infections. Of those tested 
for the each infection at the first visit, the proportion that 
had not been tested previously ranged from 37.7% for 
HIV testing to 57.5% for HBV testing. The project was 
effective at targeting key groups: approximately 60% of 
the more than 27 000 people tested in 2016 and 2017 
at any of the CBOs included in the Network were from 
one or more key population groups (MSM, people who 
inject drugs, SW and migrants; Fig. 32, right).
Over 70% of all people with a reactive test accepted 
the referral and linkage to care service offered by the 
CBOs (Table 11). Preliminary results demonstrate 
that peers/lay workers performed similarly to certified 
health professionals in performing tests and offering the 
correct test(s) and performed better for acceptance of 
referral to care for people who inject drugs (although 
this was lower for migrants).
The project ran a community-based data collection 
system, which enabled harmonized data collection 
and generation of both national-level indicators (for 
increasing knowledge about these infections in key 
populations in the country) and of more granular 
data (each organization has easy access to their own 
data and regional analysis is possible), which was 
managed by a reference public health institute. These 
data, analysed by target group/region, can be used to 
improve the targeting of interventions and prevention 
programmes, while increasing the skills and reliability of 
peer/lay workers in performing the tests.
Table 11. Screening results, Portugal, January 2016 – December 2017
Type of test Tests performed 
(n)
Total persons 
tested (n)
Reactive tests, 
n (%)
Persons who 
accepted referral, 
n (%)
HIV infection 31 217 27 412 471 (1.7) 362 (76.9)
HCV 
infection
18 298 16 848 469 (2.8) 345 (73.6)
HBV 
infection
15 123 14 089 348 (2.5) 280 (80.5)
Syphilis 25 508 22 485 838 (3.7) 634 (75.7)
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Sustainability
The bulk of investment in the Network was necessary at 
the early stage for questionnaire and database design; 
training preparation; contact gathering; establishing 
project documentation structure(s); ethics committee 
review and data protection approvals; and establishing 
the initial partner Network. Maintenance of the project 
requires a lower annual financial investment, even with 
the increase in member organizations and a continuous 
scale-up of testing activities. The Network received 
financial support from the EEA Grants Programme 
(Public Health initiative) between April 2015 and July 
2016 (102). The partnership between the screening 
Network and AIDS Health care Foundation provided 
a rapid (one-minute) HIV screening test within distinct 
contexts. As the support ended in July 2016, the 
Network is still working (but with a very limited budget): 
providing tests, medical consumables and data 
collection tools, as well as database management, 
reporting and feedback. As a consequence of the 
economic crisis in Portugal, the National Programme 
for HIV, Viral hepatitis and Tuberculosis has not 
increased its support to CSOs. The Network has not 
received any public funding from the Portuguese State. 
At the moment the project is privately funded through 
its promoter and partners, thus limiting its capacity and 
potential for growth.
Fig. 32. Number of reactive tests and number of people reporting risk behaviours, Portugal, 2016–2017
HIV
HCV HBV MSM PWID
Syphilis Migrants SW
Left panel: number/percentage of reactive tests for single and multiple infectious agent(s) at any of the 25 community-based structures from January 2016 to 
December 2017.
Right panel: individuals who reported behaviours which placed them as members of one or more key populations, of the 28 127 persons tested between January 
2016 to December 2017.
RUSSIAN FEDERATION. A complex, three-pronged, patient-oriented health 
care model for HIV-positive adolescents
Submitted by: Voronin, Evgeny 1 | Afonina, Larisa2 | Kovalenko, Tatyana1 | Gulshina, Valeria3
1National Clinical Infectious Disease Hospital of MoH of the Russian Federation; 2Applied Research Centre for Prevention and Treatment of 
HIV Infection in Pregnant Women and Children of Ministry of Health of the Russian Federation; 3Department of Organization of Health-care 
Services for Infectious Diseases of Public Health Importance of Ministry of Health of the Russian Federation
Background
Despite the worldwide progress made in reducing 
the HIV burden, the problem of HIV infection among 
adolescents remains acute owing to an increase in the 
proportion of adolescents among HIV-positive children, 
high mortality rates and lower ART efficacy caused by 
to lower adherence. According to UNAIDS (in 2017), 
young people aged 15–24 years have the lowest 
rates of HIV status awareness (under 50%), coverage 
with ART (40%) and achievement of an undetectable 
viral load (30%) compared with all other age groups. 
Studies show that the lowest level of adherence to ART 
is among adolescents aged 10–16 years, followed by 
adolescents aged 16–18 years.
82
Compendium of good practices in the health sector response to HIV in the WHO European Region
The Russian Federation has the highest number of 
new HIV infections in the WHO European Region. 
Data for June 2017 from the National Clinical 
Infectious Diseases Hospital show that the proportion 
of children aged 10–17 years among perinatally 
infected HIV-positive children was 41%. According 
to data for 2017, half of HIV-positive adolescents 
received second-line ART and a fifth of adolescents 
received third- or fourth-line ART. Addressing HIV 
in adolescents requires a complex and multifaceted 
approach owing to a variety of health and social 
determinants. In addition to the medical problems 
associated with a chronic disease requiring lifelong 
treatment, adolescents face serious social problems 
(stigma and discrimination) in addition to the typical 
problems of adolescence (related to physiological, 
psychological and social characteristics of the age 
group). Working with adolescents without considering 
the individual links of this complex chain of cause and 
effect inevitably leads to failure, resulting in reduced 
adherence to follow-up and ART and possibly to poor 
morbidity and mortality outcomes.
At the all-Russian round table event, “Adolescents and 
HIV. Problems and solutions” (May 2017, Moscow), 
HIV-infected adolescents from the most affected areas 
expressed two main problems: insufficient attention 
and understanding on the part of health workers 
and poor interpersonal communication between 
adolescents due to stigma.
Description of the good practice
Among other specialized care approaches, the 
Russian Federation has developed a comprehensive, 
three-pronged patient-centred model of care for HIV-
positive adolescents. All components of the model are 
inextricably linked and continuously implemented by 
an interdisciplinary team, together with adolescents 
and their families. The main goal of the model is to 
improve the quality of life of HIV-positive adolescents 
and increase life expectancy by disclosing and 
accepting HIV status; increasing adherence to 
follow-up and treatment; and reducing morbidity and 
mortality rates. The basic characteristics of the model 
include advisory activities, care and support.
Component 1: comprehensive cognitive, mental 
and neurological assessment
The comprehensive assessment involves conducting 
medical and psychological examinations to design 
a patient-tailored prevention and management plan 
addressing both medical and social support and 
integration needs.
In addition to standard medical examinations, 
neurological examinations included evaluation of 
cognitive dysfunctions and specialized investigations, 
where needed and by indication only.18 According 
to a specific database of the results of complex 
medical examinations of 130 HIV-infected children, 
the following changes were detected in the absence 
of any clinical manifestations of HIV: every third 
child had vasculopathy and every tenth child had 
HIV encephalitis, hydrocephalus and developmental 
anomalies.
Examination of psychological characteristics included:
1. a clinical interview;
2. a personality diagnostic questionnaire designed 
for adolescents; and
3. a questionnaire for adolescents about parents.
A survey conducted in the same group of children 
revealed that only 30% of adolescents lived with 
both (biological) parents;19 thus, the vast majority 
of HIV-infected adolescents also had psychological 
issues: in 90% of children, character attenuations 
were identified as a criterion for psychological risk 
and need of psychological support; and 45% of 
children were at risk of social inadaptation. Half of the 
adolescents reported a lack of harmonious relations in 
the family. High adherence to ART (defined as taking 
all prescribed ARVs)20 was observed in only 40% of 
adolescents and correlated with harmonious family 
relationships and no risk of social inadaptation.
Analysis of rehabilitation and social integration 
pathways and targets suggests that 34% of families 
are in dire need of psychological support; 46% of 
families need psychological support, but to a lesser 
extent; and 20% of families (the best adapted) need 
less extensive psychological rehabilitation pathways.
18 Brain magnetic resonance imaging is indicated in special cases: in children 
with advanced stages of HIV-infection and/or with cognitive disorders and/or 
based on physician decision due to specific medical concerns.
19 Other adolescents lived with only one biological parent, in the custody of 
relatives, in the custody of non-relatives or in the children’s home.
20 Adherence is defined here by the authors: high, 100% intake of prescribed 
antiretrovirals (and a viral load of <50 copies/ml); lowered, 80 –100% intake of 
prescribed antiretrovirals; and low, <80% intake of prescribed antiretrovirals.
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Component 2: comprehensive multidisciplinary 
care
The care package includes all necessary medical 
aid and individualized psychological support. Care is 
provided regularly according to individual needs and 
includes clinical, laboratory and instrumental evaluation 
of the course of HIV infection and ART effectiveness; 
ART adherence support; HIV education; support for 
disclosure of HIV-positive status (preparation, the act 
of disclosure, post-observation); support for disease 
acceptance; child–parent relationship support; and 
horizontal interpersonal (i.e. sibling or peer) relationship 
support.
These are provided through art therapy, sand play 
therapy, sensory workshops and classes, training 
courses and other creative activities.
Component 3: multidisciplinary activities
The activities include promoting, implementing and 
strengthening horizontal interpersonal relations 
among HIV-positive adolescents (through consultative 
meetings, workshops, training courses, camps, round 
table discussions, and sporting and cultural events). 
Such activities are held on a continual basis.
Developing good communication skills is vital for HIV-
positive adolescents to mitigate the fear of serostatus 
disclosure in situations where peer–peer interaction is 
common and disclosure of disease status may not be 
fully understood. Fear of serostatus disclosure may lead 
to minimal social interactions and, in some cases, social 
isolation. Help provided to HIV-positive adolescents in 
this area allows them to not only master the necessary 
social skills but also experience successful interactions 
with peers.
Small-group counselling gives adolescents an 
opportunity to discuss issues related to their HIV-positive 
status, as well as those related to stigma and sexual 
development. Another objective of such counselling is 
to overcome obstacles to ART adherence.
In August 2017, the Applied Research Centre for 
Prevention and Treatment of HIV Infection in Pregnant 
Women and Children at the National Clinical Infectious 
Disease Hospital in St. Petersburg (a Federal 
Government institution) organized a summer training 
camp for adolescents from territories of the Russian 
Federation with the highest HIV burden. As a special 
activity focused on prevention of potential psychological 
and medical conditions, all adolescents were offered 
interventions related to the three components of the 
comprehensive care approach (described above). 
The following types activities were included: individual 
counselling, group game therapy (including a training 
element), creative activities and relaxation sessions in 
the sensory room.21
In the framework of the All-Russian information and 
testing campaign, Stop HIV/AIDS, the specialists of 
the Republican Infectious Diseases Hospital/Scientific 
and Practical Centre for Prevention and Treatment of 
Pregnant Women and Children, together with their 
colleagues from United Kingdom, held a training 
workshop in November 2017 in St. Petersburg. The 
workshop was attended by specialists working with 
HIV-positive adolescents and adolescents living with 
HIV themselves. The workshop provided detailed 
information on all three components of the model, 
including several multidisciplinary group training 
sessions involving clinicians, psychologists and HIV-
positive adolescents. Feedback from participants 
was considered for the further implementation and 
strengthening of model components.
Evidence of impact/efficacy
Implementation of the comprehensive assessment, 
treatment and care/support model improve qualitative 
diagnostic testing for medical, social and psychological 
problems in adolescents. This is useful for identifying 
and addressing the medical causes of mental disorders; 
mastering social skills and gaining experience of 
successful interaction with peers; understanding the 
causes of decreased adherence to follow-up and 
treatment; building a person-centred programme for 
supporting adolescents; and harmonizing the psycho-
emotional state of HIV-positive adolescents with that 
of peers.
Furthermore, complex multidisciplinary diagnostics 
within the framework of Component 1 conducted by 
specialists of the National Clinical Infectious Diseases 
Hospital showed that all HIV-infected adolescents 
need continuing social adaptation and psychological 
support. After the intervention, there was an increase 
of almost 50% in self-esteem levels and a similar 
reduction in anxiety levels, along with decreased 
21 A sensory room is a therapeutic space with a range of equipment that 
provides children with personalized sensory input and helps then calm and 
focus themselves so that they are better prepared for learning and interacting 
with others. Relaxation and activation stimuli as light therapy, sound therapy, 
aromatherapy and tactile therapy are used.
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attention/memory impairment. Based on the results of 
secondary diagnostics conducted after implementing 
interventions specified in the model, positive effects 
were seen in important parameters: for example, 
increased self-esteem and decreased levels of anxiety, 
attention impairment and memory impairment (Fig. 33).
While implementing the model, adherence to ART a was 
found to correlate with the quality of family relationships. 
Assessment of the individual psychological features 
Fig. 33. Results of secondary diagnostics following a three-prong intervention, Russian Federation
Fig. 34. Viral load in adolescents with lowered adherence to ART before and after implementing the care model, 
Russian Federation
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of HIV-infected adolescents in this study found 
that harmonious family relationships are especially 
important for adolescents with a lower socioeconomic 
and social status. Fig. 34 shows a substantial increase 
in viral suppression at three to six months of follow-up 
after the intervention. This outcome demonstrates the 
effectiveness of treatment; one of the most important 
contributory factors to treatment adherence was the 
provision of timely psychosocial support interventions
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Sustainability
The practice is fully funded by the Russian Federation. 
At the country level, this model is planned to be 
implemented into the work of all Regional AIDS 
Centres. At the local level, the model is included in the 
work programmes of the Federal institution, Republican 
Infectious Diseases Hospital/Scientific and Practical 
Centre for Prevention and Treatment of Pregnant 
Women and Children, affiliated to MoH of the Russian 
Federation. The project is expected to continue for the 
next three years, with monitoring and evaluation of 
programme results based on analyses of viral load and 
ART adherence.
UKRAINE. Improving HIV case-finding and access to treatment among people 
who inject drugs: the Optimized Case-Finding for HIV (OCF) and Community 
Initiated Treatment Intervention (CITI) scale-up project
Submitted by: Smyrnov, Pavlo | Denisiuk, Olga | Slobodianiuk, Kateryna | Kuznetsova, Julia
International Charitable Foundation “Alliance for Public Health”
Background
Ukraine has the second highest HIV incidence rate in the 
WHO European Region and the HIV epidemic is heavily 
concentrated among people who inject drugs and 
their sexual partners. The HIV epidemic began in 1987 
among people who inject drugs in the southern and 
eastern regions. There are 346 000 people who inject 
drugs in Ukraine with an HIV prevalence rate of 22.6% 
according to a national IBBS from 2017 (unpublished 
data). People who inject drugs in Ukraine continue 
to have substantial HIV seroconversion rates and a 
significant number of heterosexual cases are still linked 
to people who inject drugs today. The HIV transmission 
risk among people who inject drugs is high, particularly 
if their peers include undiagnosed HIV-positive people 
who inject drugs, people who inject opiate-based drugs 
and previously incarcerated people who inject drugs. 
In 2006, the International Charitable Foundation (ICF) 
“Alliance for Public Health” initiated the widespread use 
of HIV rapid diagnostic tests through CBOs within HIV 
prevention programmes. According to the 2015 IBBS, 
despite the provision of HIV rapid diagnostic tests, only 
38.5% of people who inject drugs had been tested for 
HIV the previous year. In 2015, ICF “Alliance for Public 
Health” initiated a new testing strategy22 to provide 
uninterrupted access to HIV screening at outreach 
locations (38). The approach, which combines self-
testing with self-testing directly assisted by peers 
to lower the testing threshold, proposes further 
interventions to reach key populations that are either 
not yet tested or not aware of their serostatus. At the 
22  The testing strategy (Directly assisted self-testing): individuals who are 
self-testing for HIV receive an in-person demonstration from a trained provider 
or peer before or during HIV self-testing, with instructions on how to perform 
the self-test and how to interpret the result. This assistance is provided in 
addition to the manufacturer’s instructions for use and other materials found 
inside HIV self-testing kits.
same time, programme data on the results of rapid HIV 
testing performed with harm reduction activities among 
people who inject drugs in Ukraine for 2010–2015 
suggested a case-finding challenge: the detection of 
fewer HIV-positive cases every year.
Description of the good practice
Scale-up of the Optimized Case-Finding for HIV (OCF) 
and Community Initiated Treatment Intervention (CITI) 
project was designed in collaboration with the CDC 
and United States President’s Emergency Plan for 
AIDS Relief (103), with the aim of improving case-
finding, the HIV testing strategy and treatment access 
for seropositive people who inject drugs.
The OCF strategy combines experience gained from 
previous network studies, outreach activities and HIV 
screening projects.23 It is based on active contact tracing 
and recruitment of the extended risk/social networks of 
HIV-positive participants. The project uses a two-step 
recruitment model that starts with positive index cases: 
patients who test positive are invited by coupons from 
outreach staff at HIV screening services. Once at the 
OCF site, they are asked to invite three people who they 
think may be at risk of HIV (thus forming an extended 
risk network). These contacts are then offered to invite 
three of their contacts (regardless of serostatus) and 
encourage these partners to undertake rapid testing for 
HIV at the OCF site with the assistance of a contact 
tracing/case-finding specialist. Participants receive 
incentives of US$ 2 per visit and $ 1 for each person 
they recruit for testing. Anyone can participate every 
23 Risk Network peer-driven intervention (implemented by Alliance Ukraine 
from 2009), Project Protect (implemented by the National Disease Research 
Interchange and Alliance from 2010) and Project TRIP (implemented by the 
National Disease Research Interchange and Alliance from 2013).
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six months unless they become seropositive, in which 
case they become an index case to start the second-
step recruitment process. A real-time Syrex Cloud is 
used for programme monitoring to record each client, 
each test result and linkage to care information, as well 
as for scanning the QR (quick response) codes (i.e. 
2-dimensional bar codes) on referral coupons (104). The 
case finder also attaches all HIV-positive clients to a CITI 
case manager and follows up the client’s progress into 
treatment. Case managers provide additional support 
at all further stages: confirmation of HIV-positive results 
in regional health facilities, provision of additional 
diagnostic procedures (if needed) and administration of 
timely ART. CITI combines peer navigation, outreach 
case management and community support services to 
achieve better treatment uptake and better outcomes 
for HIV-positive people who inject drugs. CITI is 
designed to support HIV-positive clients for up to five 
months after registration. Testing at the sites includes 
motivational and peer support counselling. Rapid 
transfer of blood samples to the AIDS centre laboratory 
ensures that HIV-positive clients receive ART by the 
second visit.
Objectives of the CITI case manager are to:
• assess the client’s condition, needs and motivation, 
and determine his/her strengths;
• identify key barriers that prevent clients from 
accessing ART;
• analyse the available resources and services;
• design an assistance/support plan;
• coordinate social and medical services and 
represent client interests at health care institutions;
• monitor performance and implementation; and
• measure the performance goals of case 
management and terminate related services.
Evidence of impact/efficacy
The OCF strategy reached 48 522 people who inject 
drugs and their partners with HIV screening services 
in between January 2016 and December 2017. The 
average HIV-positive yield among the OCF peers 
reached 17% in 2017. Programmatic data for 2016 
suggest that the service continuum within the strategy 
from early initiation of ART to support of adherence 
among HIV-positive members of key populations is 
improved compared with standard practice (Figs 35 
and 36).
Fig. 35. Scope of OCF/CITI outreach
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CITI facilitated early treatment access for active people 
who use drugs.
• The average time from rapid testing for HIV to CITI 
enrolment was one to three days (50% of clients 
were enrolled the same day).
• The average time from enrolment in CITI to 
registration was 20 days.
• The average time from enrolment to ART initiation 
was 29 days.
Sustainability
Results of the project are planned to be used for 
lobbying for continuous expansion of the project in 
conjunction with local authorities into regions where 
there is currently no case management for HIV-
positive people who inject drugs. Data on OCF/CITI 
effectiveness will be also used for advocating for CITI 
to be included into the national package of services 
funded by government.
Fig. 36. Comparison of CITI case management and standard practice in referral of clients who tested positive 
for HIV, 2016
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All people should 
receive the services 
they need without 
experiencing financial 
hardship
©UNAIDS
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Background
The annual HIV infection incidence in Croatia is about 
two per 100 000 population, underscoring Croatia as a 
relatively low-prevalence country. The dominant mode 
of HIV transmission is through sex between men; 64% 
of all registered cases are MSM and, in the last several 
years (2014–2017), more than 80% of newly diagnosed 
cases were MSM. A small increasing trend has been 
seen in the number of newly diagnosed cases of HIV 
infection in the past few years, which may be partly 
explained by a true increase in the number of infections 
as well as by increasing the number of tests following 
the introduction of voluntary, free and anonymous 
counselling and testing for HIV in eight Croatian cities 
since 2004. In the past five years, the average number 
of annually reported HIV cases was 100 (range 77–
116), showing an increase of around 150% compared 
with pre-2004.
Prior to the implementation in 2004 of the GFATM 
project Scaling Up HIV/AIDS Response in Croatia, 
anonymous and free counselling and HIV testing were 
not available. HIV testing services were available at 
several locations but required a medical referral, a health 
insurance card or a direct payment for the service. 
Second-generation surveillance of HIV infection had 
not been implemented. No bio-behavioural research 
had been conducted within the framework of HIV 
surveillance that aimed to monitor HIV or STI prevalence 
and risk behaviour in key populations. Systems 
for monitoring and evaluation also had only been 
partially implemented. There were no systematically 
organized educational  public health campaigns to 
inform the general public or key populations about 
health risks. Before the GFATM project, there was 
also no systematic and comprehensive psychosocial 
care available for people living with HIV. Through the 
project, which was funded by the GFATM, Croatia 
received funds for the implementation of some priority 
areas of the national HIV/AIDS prevention strategy and 
programme. The MoH was the primary recipient of the 
GFATM donation and was the project coordinator (the 
total amount of the donation for the period 2003–2006 
was US$ 4 945 192).
The GFATM donation contributed significantly to the 
financing of activities aimed at improving HIV/AIDS, 
HBV, HCV and STIs surveillance system(s) through 
establishing voluntary, anonymous and free HIV testing 
sites, promoting health education, supporting national 
campaigns to reduce risk behaviours, conducting bio-
behavioural research, providing psychosocial support 
for persons affected by HIV, initiating harm reduction 
programmes and NSPs for people who inject drugs 
and creating a system for collecting indicators and 
monitoring and evaluating HIV/AIDS programmes/
activities. These services garnered intersectoral 
collaboration and support, including a large contribution 
from NGOs and CSOs involved in HIV prevention 
activities targeted at key populations in Croatia (e.g. 
MSM, SWs, migrants and people who inject drugs).
Description of the good practice
After successful implementation of the GFATM 
project in 2003–2006, the country reached almost a 
100% transition to financing a toolbox of activities via 
domestic resources. Despite limited resources owing 
to the long-term financial crisis in Croatia, all GFATM 
project components were fully transitioned to domestic 
financing sources except for one (105). Sources are 
primarily allocated from the state budget through the 
MoH. Another source for financing activities is income 
from state lottery games;24 this is used for prevention, 
24  Based on the Law on Games of Chance, Official Gazette No. 87/09, 
35/13, 41/14 and 143/14 and by-laws, the government decree on criteria 
for defining users and the mode of allocation of part of the revenue from the 
games of chance for each year.
STRATEGIC DIRECTION 4.
Financing for sustainability
CROATIA. Financial sustainability of the GFATM HIV/AIDS project: the Croatian 
experience of increasing domestic resources
Submitted by: Nemeth Blažić, Tatjana1 | Kosanović Ličina, Mirjana Lana2| | Jelavić, Melita2| Jovović, Iva3| Begovac, Josip4 | Skoko Poljak, Dunja5
1Croatian Institute of Public Health; 2Andrija Štampar Teaching Institute of Public Health; 3CSO Flight; 4University Hospital for Infectious Disease 
“Dr Fran Mihaljević“; 5Croatian Ministry of Health
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early detection and treatment, for rehabilitation of 
drug users, for harm reduction programmes and for 
collaboration with CSOs/NGOs The financing model 
and the legal framework for contracting and financial 
monitoring were provided through tender processes 
with the MoH (one-year or three-year projects/
programs for state institutions and social contracting of 
CSOs) and through standardized criteria and selection 
procedures (selection committee with multidisciplinary 
members). A portion of preventive activities (the work 
of the VCT and sexual health centre at the Croatian 
Institute of Public Health) were also funded by the 
Croatian Health Insurance Fund for the last few years. 
Similarly, part of the HIV/AIDS and STIs surveillance 
activities, national campaigns, volunteer counselling 
centres, and research are also funded jointly by local 
communities (rarely; only in some parts of the country), 
the private sector (very rarely), international projects and 
donations and European projects (e.g. Joint Actions: 
Quality Action in HIV Prevention (106), HA-REACT (78), 
INTEGRATE (107) and European Social Fund project 
Healthy Living (108)).
To ensure a smooth transition from international to 
domestic funding, it was vital to establish political 
commitment and consensus and then integrate this 
consensus into the Croatian National Program for HIV/
AIDS Prevention strategy. In addition, it was necessary 
to have robust cooperation between the health care 
sector and NGOs and the establishment of a legal 
framework and an institutional support model and 
system of civil society development and funding, as 
well as monitoring and evaluation of NGOs, including 
public/standardized procurement techniques for 
transparent allocation of funds from the state budget.
Evidence of impact/efficacy
Implementation of the GFATM project made a 
positive contribution towards developing a national 
response by building partnerships and collaboration 
and investing in human resources: a functional 
network of experts has been established, including 
a common communication channel via email on the 
national level (aids-hr@googlegroups.com); during the 
implementation of the GFATM project, people gained 
new and useful knowledge and skills, and new services 
were introduced; cooperation among stakeholders 
improved, and formal and informal partnerships were 
established.25
Sustainability
The framework within national strategic documents 
and institutional support of cooperation between 
health institutions and CSOs have made a significant 
contribution to this effort, accomplished by including 
objectives, activities and stakeholders in the Croatian 
National HIV/AIDS Prevention Program and therefore 
enabling continuous national funding, implementation 
and efficiency monitoring. In addition, it shows that 
GFATM not only provides financial resources but also 
makes a positive contribution towards developing 
a national response by building partnerships and 
collaboration and by investing in human resources 
and building capacities of CSOs. Partners involved 
in the implementation of the National HIV/AIDS 
Programme or who provide support for implementation 
or development of resources26 work in cooperation, 
enabling synergy to achieve the common goal of all 
the stakeholders. Areas for CSO/NGO engagement 
include HIV testing and counselling, training of experts, 
anti-discriminatory programs, psychosocial support, 
education and prevention among adolescents, 
prevention for MSM, prevention for people who 
inject drugs, including harm reduction programs 
and prevention in the general population. Along with 
national funding, one of the additional opportunities for 
sustainability is participation in EU projects and using 
EU funds for cofinancing activities.
25 For example, between the Croatian Institute of Public Health or county pub-
lic health institutes and the CSOs Iskorak, the Croatian Association for HIV 
and Viral Hepatitis (CAHIV) and the Association for Improvement of Quality of 
Life (NGO Flight), as well as the NGOs HELP (which helps youth, and people 
with drug-related problems) and Hepatos Rijeka.
26  For example, the MoH, the Ministry of Science and Education, the Ministry 
for Demography, Family, Youth and Social Policy, the public health institutes, 
the national insurance fund, the University Clinic for Infectious Diseases “Dr 
Fran Mihaljević”, the WHO office in Croatia, the Croatian Institute for Health 
Insurance, the  Office for Combating Narcotic Drug Abuse and the Office for 
Cooperation with NGOs, as well as CSOs that are specialized, trained and 
have experience in the field of HIV prevention (the NGOs Flight, HELP, Terra, 
Institut, Croatian Red Cross, Iskorak, Hepatos Rijeka and CAHIV).
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Background
The HIV epidemic in Kazakhstan is at a concentrated 
stage. HIV prevalence among the general population 
is 0.1%. The prevalence of HIV infection is 117.7per 
100 000 population. The HIV incidence was 16.2 per 
100 000 population in 2017 and 15.4 per 100 000 
population in 2016 (109).
ART was implemented in Kazakhstan between 2003 
and 2004. The first clinical guidelines for diagnostics, 
treatment and medical care provision for HIV infection 
and AIDS was published in 2004. According to the 
guidelines, ART initiation was recommended for 
those with a CD4 cell count of less than or equal to 
200 per ml. Less than 6% of the 4000 people living 
with HIV and registered at AIDS centres received ART. 
ARVs were procured through GFTAM funding and the 
list of available drugs was poor, with only one or two 
treatment lines available.
From 2009 onwards, the government took full 
responsibility of ARV procurement from the national 
budget, thus ensuring the sustainability of HIV 
interventions in the country (Fig. 37). According 
to 2016 WHO recommendations, ART should be 
initiated immediately for patients with a confirmed 
positive diagnosis of HIV infection, irrespective of the 
CD4 cell count. In 2017, a new clinical protocol was 
adopted in Kazakhstan, known as the “test and treat” 
strategy, in which ART is initiated in accordance with 
the Consolidated guide to the use of antiretroviral 
drugs for treatment and prevention of HIV infection: 
recommendations from a public health perspective (5).
At around the same time, the cost of first-line ART 
in Kazakhstan per person in 2016 was calculated as 
$ 946–3140, depending on the treatment scheme. 
Although the country made significant progress in 
ART provision to all those in need, the cost of ARV 
procurement by the state was higher than the global 
median cost, which greatly limited the number of 
people who could receive ART (110).
Description of the good practice
In April 2016, the MoH commissioned all responsible 
agencies to consider procuring drugs at a lower price 
through the United Nations Children’s Fund (UNICEF) 
Within the framework for carrying out these instructions, 
joint meetings were held with specialists from the 
Pharmacy Committee of the MoH of Kazakhstan, the 
Republican Center for AIDS Prevention and Control 
of the MoH of Kazakhstan  and Samruk Kazyna 
Pharmacy,27 the sole distributor of medicines procured 
for the provision of free medical care in Kazakhstan. 
Comparative data on the cost of ARVs in Kazakhstan 
and the UNICEF price proposal were presented at the 
meetings. Calculations were presented, showing that 
predicted savings from procurement through UNICEF 
in the allocated financial resources for purchasing 
ARVs would make it possible to increase the amount of 
drugs purchased and thus increase coverage with ART 
for people living with HIV. As a result of the meetings, 
Samruk Kazyna Pharmacy took responsibility for 
negotiating with UNICEF to purchase ARV drugs.
Since ART provision to all those in need is a national 
priority, it was decided to hold a online video conference 
conference with specialists from UNICEF (Copenhagen, 
Geneva and Astana offices), Samruk Kazyna Pharmacy 
(Astana), the Republican AIDS Centre, UNAIDS, the 
CDC, and the KazUnion of people living with HIV 
(Almaty) to clarify all questions from UNICEF, Samruk 
Kazyna Pharmacy and other international organizations. 
Discussions included the conditions for concluding 
the agreement between UNICEF and Samruk Kazyna 
Pharmacy and other topics, including the necessity for 
100% prepayment of the order, the currency contract, 
the means of delivery of drugs from the manufacturer 
in the Republic of Kazakhstan, violation of transport or 
factory packaging, and timing for the supply of drugs 
in Kazakhstan. Once answers to the outstanding 
questions were received from UNICEF, Samruk Kazyna 
Pharmacy informed the UNICEF Head Office that it 
intended to purchase 11 types of ARVs for Kazakhstan.
27 In February 2009, the Government of the Republic of Kazakhstan decided 
to establish SK-Pharmacy Company within the structure of the National 
Welfare Fund Samruk-Kazyna JSC (Government Decree No. 134, dated 
February 11, 2009). Rights of possession and uses of absolute share of 
Samruk Kazyna Limited Liability Partnership were transferred by the Republic 
of Kazakhstan’s Government Decree No. 516 dated May 25, 2013 to the 
Ministry of Health of the Republic of Kazakhstan. 
Kazakhstan. Improving access to ART for people living with HIV
Submitted by: Baiserkin, Bauyrzhan | Kassymbekova, Sairankul
Republican Centre for AIDS Prevention and Control of the Ministry of Health of Kazakhstan
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Evidence of impact/effectiveness
Purchase of the 11 types of ARVs through the UNICEF 
mechanism reduced the procurement price for ARVs 
by 2–40 times and reduced the budget expenditure 
by half. Owing to the price reduction, the cost of 
first-line ART in Kazakhstan (tenofovir/emtricitabine/
efavirenz) decreased from $ 3140 to $ 100 per patient. 
This financial savings enabled coverage with ART for 
people living with HIV to double from 7000 patients by 
the end of 2016 to 12 000 by the end of 2017 (Fig. 38). 
Furthermore, four new ARVs with high treatment 
efficacies and good safety profiles were added to the 
list of drugs with a guaranteed volume for free medical 
care (including dolutegravir28).
A total of 16 types of ARVs are now included in the 
list of medicines and medical products for provision of 
citizens within the guaranteed volume of free medical 
care and within the system of compulsory medical 
insurance (111).
Regarding the UNAIDS 90–90–90 targets (112), by 
the end of 2017 about 80% of the estimated number 
28 In May 2018, WHO issued a statement concerning a potential risk of neural 
tube defects in infants born to women taking dolutegravir at the time of con-
ception (59). As more countries have scaled up ART optimization efforts and 
include or plan to include dolutegravir-containing regimens in their national 
protocols as the preferred first-line option, WHO issued a briefing note in April 
2018 on the clinical advantages of and programmatic information about the 
new fixed-dose combination tenofovir/lamivudine/dolutegravir (60). Additional 
and diverse analyses are planned for July 2018 to expand on the original 
data, which originated from a single country.
of people living with HIV knew their HIV status and 
were registered at AIDS centres. Around 55% of these 
patients were receiving ART and 55% have achieved 
viral suppression. While this practice makes great 
strides towards optimizing the second 90–90–90 target 
(i.e. 90% of people who know their status are on ART), 
the country still needs to scale up activities to reach the 
90–90–90 targets by 2020.
Sustainability
All HIV/AIDS interventions are monitored and 
sustained via government funding, including activities 
such as development and implementation of clinical 
protocols for HIV treatment and care, centralized ARV 
procurement, and monitoring of ART effectiveness. 
Support for this practice at the national level is reflected 
in various national decrees.29
29 The Decree of the Government of Kazakhstan dated 8 November 2017, 
no. 719, On amendments to the Decree of the Government of Kazakhstan, 
dated 30 October 2009, no. 1729; On approval of the rules for procurement 
of medicines, preventive (immunobiological, diagnostic, disinfecting) drugs, 
medical products, devices and equipment and pharmaceutical services nec-
essary for providing the guaranteed volume of free health care in the system 
of mandatory social health insurance, and the Decree dated 8 July 2015, no. 
515, On approval of rules for procurement of services for the storage and 
transportation of medicines and medical products and devices by a single 
distributor to ensure the guaranteed volume of free health care in the system 
of mandatory social health insurance and on introducing amendments and 
additions to some decisions of the Government of Kazakhstan, and in Chap-
ter 16, Section 8, of The procedure for procurement from a single source or 
through international organizations established by the General Assembly of 
the United Nations, as approved by the authorized public health body and 
on the basis of international treaties (agreements) ratified by the Republic of 
Kazakhstan, as well as international treaties signed for implementation.
Fig. 37. Financing for ART, Kazakhstan, 2005–2017
0
20
40
60
80
100
0 0
7 8
100 100100 100
93 92
0 0
2005 2006 2007 2008 2009 2017
State Budget GFATM
P
ro
p
o
rt
io
n 
o
f 
A
R
T
 c
o
st
s 
(%
)
93
STRATEGIC DIRECTION 4. Financing for sustainability
Background
GFATM support in Montenegro from 2006 to 2015 
resulted in a continued low prevalence (0.03%) of 
HIV among the general population in the country and 
a remarkably low prevalence of HIV among two key 
populations: 1.1% in people who inject drugs, and 
0.5% in SWs. However, as in many countries in central 
Europe, MSM transmission is significantly increasing 
(12.5% prevalence in 2014). This increase made the 
country re-eligible for GFATM financing in 2016. At 
the end of the grant in June 2015, the Montenegrin 
government took over financing of services provided in 
public sector, including full funding for expanded ART, 
OST and VCT. However, no formal structure permitted 
CSO implementation of the HIV prevention activities. 
Consequently, lack of NGO manpower disrupted the 
implementation of established preventive services 
within CSOs. Less than a year after the end of the 
GFATM support, provision of the NGO-led prevention 
services in Montenegro was nearly terminated. The 
remaining grant funds were used to procure a one-
year stock of prevention commodities, including 
needles, syringes and condoms. Two NGOs, CAZAS 
and Juventas, continued providing some preventive 
services by limiting their package and scope of 
services, which resulted in a considerable reduction 
of the coverage/recipients among key populations. 
Compared to 2015, Juventas reported an almost 65% 
decrease in unique client reach of MSM in the first 
half of 2016, compared with 2015, while the burden 
among this population fuels the epidemic. Similarly, 
CAZAS reported a one-year termination of the work 
of its drop-in centre for people who inject drugs, 
from July 2015 to June 2016, with limited outreach 
work confined to the capital of Podgorica. The EU 
country report on Montenegro from 2016 empirically 
documented that “efforts were made to implement 
the National HIV Strategic Response but sustainable 
funding is still not ensured”. These harsh realities and 
dialogues laid the ground for a new commitment to 
secure HIV funding through the state.
Description of the good practice
Funds provided through the Commission for allocating 
funds from games of chance by the Ministry of Finance 
in 2016 partially filled the funding gap, covering 
between 20% and 25% of the previous GFATM 
contributions for HIV prevention services. Then, in 
2016, due to the successful advocacy of Juventas, 
the Montenegrin parliament passed a legislative act to 
allocate €100 000 for NGOs “that provide services for 
supporting people living with HIV/AIDS and affected 
populations”. This set the first precedent for explicit 
commitment to funding HIV prevention services 
Fig. 38. Estimated coverage with ART among people living with HIV, Kazakhstan, 2011–2017
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MONTENEGRO. Transition to domestic funding of the HIV response through 
social contracting of NGO/CSO service provision
Submitted by: Brajovic, Mina1 | Cicic, Alma2 | Golubovic, Vladan3
1WHO Country Office Montenegro; 2Institute for Public Health; 3Country Coordinating Mechanism Secretariat
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through NGO implementation to key populations. 
The same allocation has been included in the 2017 
state budget. Nevertheless, these allocations were 
sufficient to cover only 40% of the overall national 
yearly deficit. Therefore, the CCM decided on the 
basis of the GFATM board decision from December 
2016 to submit a new GFATM funding request in the 
amount of €556 938 to mobilize new and catalyse 
existing funds for remaining gaps.
In 2015, the year of closure of the HIV Round 9 
Grant, NGOs and CSOs united in advocating for 
the sustainability of HIV/AIDS services aimed at 
key populations. This advocacy campaign primarily 
targeted decision-makers to mobilize the transition but 
also educated the wider public about the successes 
derived from the national HIV response in Montenegro. 
The messages emphasized (i) the irreplaceable role of 
CSO service provision and (ii) the difference in cost 
between prevention (€6–€8 per person per month) 
and treatment for HIV (€1200–€1500 per person per 
month) and hepatitis C (€1500–€2000 per person per 
month).
Evidence of impact/efficacy
A key obstacle in Montenegro following the transition 
from the GFATM financing was the absence of a social 
contracting mechanism which would allow NGOs to 
continue delivering prevention services. Thus, the 
OSFs and the UNDP provided bridge funding to invest 
in the development of sustainable systems for HIV 
prevention and treatment support. With OSF support, 
Juventas and CAZAS were nominated to work with 
the MoH on the development of a social contracting 
mechanism that would allow government financing 
of civil society-led prevention interventions. The 
MoH launched its first open public call for proposals 
for HIV prevention programmes in November 2017, 
with €80 000 allocated for prevention services for 
key populations, €10 000 for support to people living 
with HIV and €10 000 for procurement of necessary 
commodities. Amendments to the law determining 
the state budget for both 2016 and 2017 were 
adopted by the Montenegrin parliament, demanding 
state budget allocation to sustain existing and grow 
durable solutions for financial contributions to HIV/
AIDS services for key populations.
The conditional GFATM (2017–2019) allocation only 
permits funds regarding service delivery. Therefore, 
the civil society sector in Montenegro plans to bolster 
advocacy efforts, through both the CCM and joint 
advocacy strategic plans. For example, CAZAS is 
currently implementing a social contracting capacity-
building project with OSF funds and will seek further 
OSF support to enhance management and service 
delivery capacities.
By allocating yearly earmarked funds of €100 000 
from the government/MoH (between 35% and 40% 
of overall needs for NGO-led preventive services) 
and becoming re-eligible for the GFATM support, 
Montenegro is able to sustain a low prevalence of HIV. 
According to the new law on NGOs from 2017, 0.3% 
of the state budget is earmarked for NGO projects in 
general, an additional 0.1% is dedicated to protection 
of people with disabilities and another 0.1% is 
allocated for co-funding EU-supported projects.
Sustainability
The current estimate for the need for preventive HIV 
services is around €300 000. This includes the costs 
of renting premises for drop-in centres for MSM, SWs 
and people who inject drugs, as well as the centre 
for people living with HIV, outreach work among key 
populations, salaries of staff and outreach workers, 
operating costs of the services and other costs 
incurred. Through consensus between Montenegro 
and GFATM, the government and the MoH plan to 
gradually increase their share of the costs for HIV 
prevention services among key populations, through 
social contracting of the NGO/CSO sector. The 
MoH has already allocated a budget line for 2018 
in the amount of €125 000 for this purpose and 
most probably will continue to increase the annual 
allocations. The current agreed projection is to slightly 
increase the proportion of state funding each year to 
maintain the current level of support. As part of the 
implementation arrangement, national authorities 
monitor programme and management costs of the 
social contracting mechanism by allocating additional 
Montenegrin funds.
Investments by the UNDP will help improve the legal 
framework for this funding mechanism, assuring that 
the MoH is operating in line with new countrywide 
requirements for sectoral reviews related to the 
financing of civil society. Additional efforts to secure 
the support of local authorities are planned. This will 
be necessary to provide NGOs free premises for the 
operation of their service and thus further savings 
by eliminating rent expenses. The funds saved will 
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be used to provide service delivery. Although in its 
preliminary stages, the advocacy work of NGOs/
CSOs and the intersectoral consensus gained in the 
country, along with continuous support from a variety 
of donors, have paved the way to full domestic funding 
for Montenegro in the years to come.
REPUBLIC OF MOLDOVA. Financing of harm reduction services for key 
populations by the National Health Insurance Company 
Submitted by: Parfentiev, Dumitru1 | Osoianu, Iurie1 | Serbulenco, Aliona2 | Oltu, Iulian3 | Climasevschi, Iurie4 | Iatco, Ala5
1National Health Insurance Company; 2State Ministry of the Ministry of Health, Labour and Social Protection; 3Hospital of Dermatology and 
Communicable Diseases; 4Center for Health Policies and Studies; 5Union for HIV Prevention and Risk Reduction
Background
According to national statistics, 11 877 HIV cases 
(including 3728 in Transnistria) were cumulatively 
registered by the end of 2017. Around 800 new cases 
(including 230 in Transnistria) have been registered each 
year for the last three years, with no major changes 
in the sex distribution. In 2016, the prevalence of HIV 
in the Republic of Moldova was 0.20%. However, the 
epidemic is concentrated among key populations: 
mainly, people who inject drugs, in both the civilian 
and the prison sectors, but with increasing rates 
among SWs and MSM. Available data suggest the 
epidemic has transitioned from an early concentrated 
epidemic, in which the highest rates of transmission 
were among people who inject drugs, to an advanced 
concentrated one, in which onward transmission to 
the sexual partners of people who inject drugs, and 
other key populations, has become a source of new 
infections. According to the latest estimates, there are 
36 900 people who inject drugs (including 10 800 in 
Transnistria), 17 800 SW (3500 in Transnistria) and 
17 100 MSM (4100 in Transnistria).
The IBBS survey among risk populations was carried 
out for the first time in the Republic of Moldova in 
2009–2010, using respondent-driven sampling 
methodology. The same methodology was used during 
the studies conducted in 2012–2013 and 2016–2017, 
assuring data comparability. This methodology enabled 
the recruitment of both beneficiaries of harm reduction 
programming and members of key populations. 
However, data from studies conducted in 2003, 2004 
and 2007 cannot be compared, owing to methodology 
variance. Fig. 39 shows HIV prevalence among MSM, 
SWs and people who inject drugs, in 2009, 2013 and 
2016.
Prevention service coverage of key populations 
increased between 2014 and 2017 (see Table 12).
Fig. 39. IBBS survey results on HIV prevalence among MSM, SWs, and people who inject drugs, Republic of 
Moldova, 2009, 2013, and 2016
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Description of the good practice
Before 2017, HIV prevention services for key 
populations were exclusively financed by an external 
source, the GFATM. In alignment with the National AIDS 
Programme for 2016–2020 and the national Transition 
and Sustainability Plan, a gradual shift in the financing 
of prevention services from GFATM to domestic 
funding was proposed. For 2016 it was expected that 
two projects (approximately €50 000 each) would be 
funded from domestic resources. Unfortunately, this 
proved difficult, as a strong financial and procurement 
regulatory mechanism had not yet been put in place.
In 2016, the Union for HIV Prevention and Risk 
Reduction initiated a dialogue with representatives from 
the GFATM, UNAIDS, WHO, the MoH, the NHIC and 
the Coordination Unit of the National AIDS Programme, 
to mobilize the development of a legal/regulatory 
framework for the financing of harm reduction services 
from the state budget. As the result, a financing and 
procurement mechanism whereby procurement would 
be sourced from the NHIC prophylaxis fund was 
developed and agreed upon by all the stakeholders.
As a result, at the beginning of 2017, a joint order of 
the MoH and the NHIC for the approval of regulation 
regarding the financing of harm reduction services by 
the NHIC prophylaxis fund was endorsed, setting HIV 
harm reduction programmes as health priorities. The 
regulations included:
1. the financing principles of the projects;
2. permitted modalities of project presentation and 
selection;
3. the projects’ financing conditions, which stipulate 
that the funding applicant:
a. must be a non-profit-making institution/
association registered in the Republic of 
Moldova;
b. must have had, in the 2014–2017 period, 
a minimum of three years of experience in 
implementing projects similar to those for 
which funding is requested;
c. must have had past project management 
experience worth at least €7500 per project;
4. guidelines for monitoring and evaluating sources 
of financing.
Moreover, the procurement mechanism requires that 
services are provided through accepted standards, 
thereby defining the standard service package, the 
manner of provision, the monitoring and evaluation 
framework(s), and so on. Those standards were 
reviewed in 2016 and approved through the Ministry 
of Health, Labour and Social Protection, and the 
first call for proposals from qualifying applicants was 
announced on 14 August 2017.
In response, four local NGOs with experience in the 
field of HIV prevention services applied. Two projects 
were selected for funding: (i) Inițiativa Pozitivă received 
€47 600 to cover a total number of 718 beneficiaries 
(including MSM, SWs and people who inject drugs) in 
the central region of the Republic of Moldova from 2017 
to 2018, and (ii) Tinerii pentru Dreptul la Viață received 
€48 000 to cover a total number of 1000 beneficiaries 
(only people who inject drugs) in the northern region of 
the country during the same period.
Evidence of impact/efficacy
The shift from global to domestic financing is of high 
importance, especially as the resources from GFATM 
for the 2018–2020 period were reduced by 40%. The 
reductions mostly affected the prevention programmes. 
Along with these challenges and changes in the external 
Table 12. Prevention service coverage of key populations, Republic of Moldova, 2014–2017a
Key population  Coverage (%)
2014 2016 2017
People who inject drugsb 30.8 49.0 51.1
SWc 24.6 39.3 46.8
MSMc 14.7 22.3 26.9
a Estimated. b Needle exchange. c Condom distribution.
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funding landscape, the sizes of key populations have 
increased: from an estimated 30 200 people who inject 
drugs in 2014 to an estimated 36 900 in 2017; from 
an estimated 12 000 SWs in 2014 to an estimated 
21 300 in 2017; and from an estimated 13 500 MSM 
in 2014 to an estimated 17 100 in 2017. Consequently, 
the gap between the amount of resources available 
for prevention and the number targeted for coverage 
grew exponentially. Thus, domestic financing is timely 
and a vital first crucial step towards the full budget 
coverage needed to reach the desired targets and 
reduce the HIV epidemic among these key populations. 
Despite national efforts to mobilize domestic funding, 
the amount of funding available is still inadequate. 
Leveraging domestic financing through the identification 
of a proper financing and procurement regulatory 
mechanism will make it possible to increase the access 
of key populations to harm reduction measures and 
coverage, including service provision outside the formal 
health system (all prevention services, including HCV, 
HIV and syphilis testing, are provided by NGOs). It will 
also contribute to the decentralization of the funding 
mechanism by the NHIC.
It is too early to discuss the impact of this practice, 
but the HIV incidence in the key population is expected 
to decrease because of the increased coverage of 
key populations with harm reduction services in the 
Republic of Moldova.
Sustainability
Joint approval/regulation by the MoH and the NHIC is 
fundamental to this practice. The NHIC is also interested 
in contracting NGOs active in the field for harm 
reduction services for HIV, and the representatives of the 
Republic of Moldova expect long-term implementation 
of similar activities. In addition, the NHIC has shown 
interest in funding another project for €50 000 in 2018, 
demonstrating its ongoing commitment for further 
project implementation.
THE FORMER YUGOSLAV REPUBLIC OF MACEDONIA. Transition to 
domestic funding for a consolidated HIV response
Submitted by: Senih, Andrej1 | Bozinoska, Elizabeta2 | Stevanovic, Milena3
1Stronger Together, Association for Support of People Living with HIV; 2Health Education and Research Association (HERA); 3University Clinic 
for Infectious Diseases and Febrile Conditions
Background
Up to the end of 2017, there have only been a total 
of 358 diagnosed cases of HIV and 83 registered 
AIDS-related deaths in the former Yugoslav Republic 
of Macedonia, underscoring the fact that it is low-
prevalence country (113). Studies continue to show the 
country has been able to prevent an epidemic among 
people who inject drugs (114); this is probably because 
of the very early introduction of NSPs (115), the scale-
up of OST, and relatively good service coverage, thanks 
to decentralized services (116). Similarly, services 
targeting female SWs are also available across the 
country, relying almost exclusively on service delivery 
NGOs, and this has a correlation with an extremely low 
prevalence.However, the former Yugoslav Republic of 
Macedonia has faced a continuous increase of HIV 
prevalence among MSM during the last five years, with 
the latest prevalence data showing 5.4% (2018)and at 
least 84% of newly diagnosed cases being reported in 
this group in 2016 (117). Compared to those for the 
other key populations, services for MSM have been, 
indeed, at least brought to scale, a fact that has been 
outlined and addressed in a new draft national strategy 
until 2021.
Description of the good practice
The former Yugoslav Republic of Macedonia lost its 
eligibility status for GFATM national grants in 2013, 
based on its classification as an upper middle-income 
country with a low HIV burden of disease. A special 
working group was appointed by the MoH to oversee a 
series of initial analyses and consultations to transition 
to domestic resources with proactive support from the 
CCM secretariat. However, CSO advocacy emerged 
independently from these national-level processes to 
catalyse this transition.
Beginning in 2014, a civil society platform for joint 
advocacy was formed by all 15 HIV-programme-
implementing NGOs and CSOs from across the 
country to ensure the successful transition from donor 
to national funding for HIV programmes that targeted 
key populations. The platform initiated a series of 
strategic actions, including uniform collaboration 
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with the MoH on developing procedures and criteria 
for the social contracting of NGOs under national 
funding, demanding and supporting processes for 
data gathering, budget estimations and planning 
of the annual national HIV programme for the years 
2015 to 2018, engaging members of the parliament 
(including the prime minister) and initiating a public 
hearing in the Parliamentary Commission on Health. 
The platform called on the government to ensure 
domestic transition, allocate funding and establish 
a contracting mechanism for CSOs. During the four 
years of transition planning and work in the former 
Yugoslav Republic of Macedonia, civil society resorted 
to street actions and protests against budget cuts 
while engaging with media to raise the issue as a 
public health concern. CSOs also worked with political 
parties in the pre-election period at the end of 2016, 
which resulted in 12 of them signing a declaration of 
commitment to allocate national funds for sustaining 
the HIV response. Key factors for success were the 
early initiatives taken by the CCM and, independently, 
by CSOs, the dialogue with the MoH, working with 
political parties, organizing protests during critical 
moments and campaigning. Gathering data for budget 
and programme planning and for advocacy, that is, 
support from the GFATM, in particular with financing 
key studies, were also fundamental building blocks.
Evidence of impact/efficacy
By the last quarter of 2017, the state had allocated 
significant funds from the national budget for 2018 
to atone for gaps following withdraw of the GFATM 
support and by requesting the MoH to develop a 
long-term mechanism for contracting CSOs in 2018 
as implementers of the national HIV programme. This 
work resulted in the recognition of NGOs/CSOs as 
implementers of HIV services targeting key populations 
within a government-funded national HIV programme 
in 2015 and formalization of eligibility criteria and 
procedures for selection of CSOs as implementers 
of HIV programmes by the MoH in 2016. Moreover, 
the signed declaration of commitment by 12 political 
parties prior to parliamentary elections in December 
2016 served as the basis for obtaining high-level 
political commitment on the HIV issue. Following the 
September 2017 decision to sustain funding, the 
MoH piloted the social contracting mechanism to 
deliver services through CSOs in the last quarter of 
2017 (Fig. 40).
This practice ensured that more than 15 000 
beneficiaries from key populations access and maintain 
access to life-saving services for HIV. While GFATM 
support was instrumental in establishing the practical 
base for diversified services in the HIV response, the 
former Yugoslav Republic of Macedonia was able to 
adopt these services into their own political, social 
and economic situation, with impressive results. The 
augmentation of the role of NGOs and CSOs in the 
development and implementation of national policies 
in the health sector cannot be understated. The formal 
recognition of CSOs in implementing health services 
for preventive programmes is the first example of its 
kind for the MoH. In 2018, the MoH signed annual 
agreements with all 15 NGOs involved in HIV service 
delivery among key affected populations (118).
Sustainability
The 2018 Annual Work Plan of the National HIV 
Commission prioritizes the long-term initiatives to 
sustain the practice. NGO and CSO successes were 
intricately linked to sustained and trusted funding by a 
variety of country mechanisms. Although funding came 
primarily from the state budget, additional sources 
of funding were instrumental. The AIDS Health Care 
Foundation continued its support for the secretariat 
of HIV; this support was shared between the Health 
Education and Research Association (HERA) NGO 
and Stronger Together. The Open Society Foundations 
of the former Yugoslav Republic of Macedonia 
lead a crucial role supporting the HIV platform and 
financing targeted advocacy interventions. In addition, 
the International Planned Parenthood Foundation 
continued their funding of HERA for the initiation of 
national transition processes for the sustainability of 
HIV services beyond the GFATM.
With this strong start, it is expected that CSOs and 
NGOs will become further engaged in areas such 
as TB prevention and treament, and sexual and 
reproductive health services in the country.
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According to national surveillance data for 2015, there 
are 347 000 people who inject drugs in Ukraine. Of these, 
42 247 are registered as patients suffering from “mental 
and behavioural disorders due to opioid use” as of 1 
January 2017. Among countries in the WHO European 
Region, Ukraine has one of the largest burdens of HIV-
related diseases. The key role in the development of the 
epidemic is played by key populations, among whom 
people who inject drugs have the highest HIV prevalence 
rates (about 22%), with the dominant subgroup being 
opioid users. Therefore, the development of HIV 
services provided to people who inject drugs (i.e. NSPs 
and substitution maintenance therapy) is of particular 
relevance for the country.
Description of the good practice
Substitution maintenance therapy programmes have 
been used and expanded in Ukraine since 2004. During 
more than 10 years of the programme’s existence, 
costs related to procurement of drugs and their logistics 
management were fully covered by international 
donors, namely by the GFATM. To date, Ukraine has 
one of the largest substitution maintenance therapy 
programmes in the EECA region, and it covers 10 189 
patients as of 1 January 2018. Despite the need for 
substitution maintenance therapy, the government only 
funded the functioning of service points, allocating no 
funds for purchasing substitution maintenance therapy 
drugs, and this jeopardized the sustainability and further 
Fig. 40. Annual spending of the national HIV programme in The former Yugoslav Republic of Macedonia, 
2014–2018
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UKRAINE. Reducing the economic burden associated with substitution 
maintenance therapy through expansion of dispensing drugs for self-administration
Submitted by: Kuzin, Ihor | Lyashko, Viktor | Ivanchuk, Irina
Public Health Centre of the Ministry of Health of Ukraine
Background
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development of the program, owing to a decrease in 
donor funding.
In 2016, an active advocacy campaign was conducted 
with the participation of the Public Health Centre, the 
All-Ukrainian Network of People Living with HIV and 
other partners to allocate funds from the state budget 
for the procurement and logistics management of 
substitution maintenance therapy drugs. In 2017, 
sufficient quantities of drugs were purchased to cover 
the needs of all existing patients. Since the end of 2017, 
drug logistics management (delivery and storage) is 
also funded from the state budget.
Considering the long time it takes to provide substitution 
maintenance therapy and the fact that the majority of 
patients have received long-term treatment and are 
stable, active efforts were made during 2015 to change 
the regulatory framework so that drugs could be 
delivered to stable patients for self-administration. For 
this purpose, negotiations were held with the Ministry 
of Internal Affairs and other interested parties to change 
the existing regulations. The necessity of conducting 
negotiations with the Ministry of Internal Affairs (police 
forces) was due to the fact that, according to Ukrainian 
regulations, although substitution maintenance therapy 
services provision is determined by the MoH, all draft 
legislation should be done in conjunction with law 
enforcement agencies, since drug use regulations 
are considered to fall under the responsibility of 
both ministries. Previously, representatives of law 
enforcement agencies opposed the introduction of 
self-administration practices, justified by the significant 
risks of drug misuse and its leakage into the illicit 
market. In order to obtain the approval of the Ministry 
of Internal Affairs, active work was carried out, lasting 
approximately one year, by providing information and 
education about the implementation of substitution 
maintenance therapy programmes, the experience of 
issuing drugs for self-administration in other countries, 
approaches and measures to prevent misuse and 
proper cooperation between health care and police 
institutions.
At the beginning of 2016, changes to the regulatory 
framework came into force which made it possible to 
actively deliver substitution maintenance therapy drugs 
to stable patients, provided that certain criteria were 
met (i.e. having been in the substitution maintenance 
therapy programme for at least six months, the 
absence of violations of the rules of participation in the 
programme, abstinence from other drugs, as confirmed 
by the results of monthly tests for six consecutive 
months).
At the beginning of 2018, 64.7% and 33.5% of patients 
who were on buprenorphine and methadone therapy, 
respectively, received drugs for self-administration for 
up to 10 days, under the necessary supervision. Three 
forms of self-drug administration are now present in 
the country: (i) patients receive drugs from local health 
care centres (predominant mode), (ii) stable patients 
with prescription opioid dependence receive drugs in 
pharmacies and (iii) patients receive drugs as part of at-
home hospital services in cases where they cannot visit 
the health care centre on a daily basis due to health 
concerns.
Evidence of impact/efficacy
Data from 1 January 2018 show that the proportion 
of patients receiving substitution maintenance therapy 
drugs for self-administration varies in different regions 
of the country. Almost all regions in Ukraine are 
actively implementing this practice, but the scale of 
its implementation has significant regional variations. 
It was assumed that the state funding would ensure 
the continuity of treatment of already existing patients. 
However, thanks to an active advocacy campaign, 
funding was obtained to ensure the continuity of 
treatment while expanding scope. Thus, during 
2017–2018, the programme will be expanded to 
cover approximately 2000 additional people, an 
additional 20% of those already receiving treatment. 
When the practice of dispensing medications for self-
administration was introduced, it was not expected that 
its introduction would happen with such haste, as a 
variety of opinions encountered within law enforcement 
agencies and even individual medical workers were 
common. However, over the course of two years, 
it was possible not only to introduce the practice of 
dispensing drugs for self-administration but also to 
significantly expand the self-administration practice, 
covering 64.7% of all patients receiving buprenorphine 
and 33.5% of all patients receiving methadone in 
Ukraine. 
Buprenorphine: 
Out of 26 regions in Ukraine (24 oblasts, Kyiv city, and 
Crimea), 695 (64.7%) patients receive buprenorphine 
pills for self-administration; some regions have reached 
and are approaching 100% implementation, 13 regions 
have a rate over 50%, and 9 are still below a rate of 
20%. 
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Methadone: 
Out of 26 regions in Ukraine (24 oblasts, Kyiv city, and 
Crimea), 2984 (22.5%) patients receive methadone pills 
for self-administration; no regions have yet reached 
100% implementation, 7 regions have a rate over 50%, 
and 8 are still below a rate of 20%.  
Sustainability
The introduction and expansion of the practice of 
dispensing drugs for self-administration does not 
require additional resources from international donors. 
Rather, the practice allows resources for medical 
institutions to be saved, thus reducing the financial 
burden of the state for the delivery of harm reduction 
programming. Considering a large burden of HIV in 
Ukraine falls within the key population of people who 
inject drugs, this practice is a timely, domestically 
financed, strong example for other Member States 
in the EECA region to consider when adjusting their 
national HIV programmes and policies in the future.
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Background
The HIV in Europe initiative was instrumental in the 
European working group that proposed a consensus 
definition of late presentation of HIV infection for the 
purpose of facilitating efforts to understand and remedy 
this problem through surveillance and research in 2010 
(119). The definition was quickly adopted by national 
surveillance institutions and international public health 
bodies such as WHO and ECDC, and it enabled 
comparisons across countries, health care settings 
and key risk groups. It was soon evident that, in spite 
of improvement in the field of HIV testing and treatment 
across Europe, in 2012, around half of newly diagnosed 
HIV cases were so-called late presenters (with a CD4 
cell count of <350 cells per mm3), including 30% of 
cases with advanced HIV infection (a CD4 cell count of 
<200 cells per mm3) (120). This became the starting 
point for launching European HIV–Hepatitis Testing 
Week as a way to increase focus on HIV testing and 
thus help to reduce the proportion of people living with 
undiagnosed HIV and reduce the proportion of late 
presenters.
Description of the good practice
European Hepatitis–HIV Testing Week was launched 
by the HIV in Europe initiative in 2013 as a platform to 
help promote and increase testing and to encourage 
people throughout Europe to become aware of their 
HIV and/or hepatitis status (121). Now in its sixth 
year, and the fourth time hepatitis testing has been 
included, European Hepatitis–HIV Testing Week will 
take place from 23 to 30 November 2018 with a pilot 
second testing week in May 2018 to encourage testing 
activities throughout the year. The ultimate goal of 
European HIV–Hepatitis Testing Week is to make more 
people aware of their HIV and/or hepatitis status and 
reduce late diagnosis by communicating the benefits 
of testing and by supporting ongoing dialogue between 
all partners in the HIV and hepatitis communities to:
• encourage people who could be at risk of HIV or 
hepatitis to get tested;
• encourage health care professionals to offer 
an HIV or hepatitis test as part of routine care in 
specific settings and conditions (in line with present 
European guidelines);
• support and unite organizations to scale up HIV and 
hepatitis testing and share lessons learnt between 
countries;
• make government bodies aware of the individual, 
societal and economic benefits of HIV and hepatitis 
testing initiatives and how to evaluate testing 
practices; and
• help end the HIV and hepatitis epidemics by 
preventing onward transmission to others through 
early diagnosis and treatment.
The week offers partners across Europe the unique 
opportunity to unite to increase awareness regarding 
the benefits of HIV and hepatitis testing. European HIV–
Hepatitis Testing Week is relying on three core groups of 
partners to help ensure it achieves its aim: government 
bodies, health care professionals and CSOs. These 
partners may be active within the HIV and/or hepatitis 
fields or work with communities at an increased risk 
and can help ensure promote HIV and hepatitis testing 
and timely access to treatment as a national priority.
STRATEGIC DIRECTION 5. 
Innovation for acceleration
EUROPEAN TESTING WEEK. A regional initiative to advocate and promote 
testing for viral hepatitis and HIV
Submitted by: Combs, Lauren1 | Raben, Dorthe1 | Collins, Ben2 | Simões, Daniel3 | Von Lingen, Ann-Isabelle4 | Farrell, Jason5 | Pasanen, 
Sini6 | Dominković, Zoran7 | Kifetew, Chamut8 | Power, Lisa9 | Dedes, Nikos10 | James, Cary11 | Noori, Teymur12 | Dutarte, Maria4 | Daamen, 
Caroline12 | Gogia, Marine4 | Begovac, Josip13 | Kovacs, Tudor14 | Van Montfoort, Tonni15 | Zakowicz, Anna16 | Delpech, Valerie17
1Centre of Excellence for Health, Immunity and Infections (CHIP); 2International HIV Partnerships; 3Grupo de Ativistas em Tratamentos; 
4European AIDS Treatment Group; 5Correlation Network; 6AIDS Action Europe; 7Iskorak; 8Terrence Higgins Trust; 9HIV Justice Network; 
10Positive Voice; 11European HIV–Hepatitis Testing Week; 12European Centre for Disease Prevention and Control; 13European AIDS Clinical 
Society; 14International Lesbian, Gay, Bisexual, Transgender, Queer and Intersex Youth and Student Organization; 15European Network of 
People Who Use Drugs; 16AIDS Health Care Foundation; 17Public Health England 
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To participate in European HIV–Hepatitis Testing Week, 
organizations are asked to register on the website. 
Participants that sign up for the European HIV–Hepatitis 
Testing Week indicate that they intend to take action 
to contribute to achieving the aims of the testing week 
to increase the proportion of people who are aware of 
their HIV and/or hepatitis status. There is no minimum 
requirement for those who sign up for the testing 
week, and it is entirely up to the participants how the 
local campaign will be executed. Some of the possible 
activities include hosting testing week events/activities, 
raising awareness among key populations regarding 
the importance of HIV and/or hepatitis testing, lobbying 
government bodies on the importance of improved 
access to HIV and/or hepatitis testing, recruiting other 
organizations to sign up and helping to create a list of 
places in their country where individuals can access free, 
confidential and voluntary HIV and/or hepatitis tests. 
After the conclusion of European HIV–Hepatitis Testing 
Week, all registered participants are asked to complete 
a post-testing week online evaluation survey.
Unfortunately, not all countries implement a policy of 
ensuring timely access to free care and treatment for 
those who test positive for HIV and/or hepatitis. As a 
result, as part of the work, European Hepatitis–HIV 
Testing Week supports participating partners in ongoing 
efforts to lobby government bodies to employ health 
care policies that meet European guidelines, including 
access to treatment. In 2017, European HIV–Hepatitis 
Testing Week supported a joint statement developed by 
an alliance of key and most affected populations and 
regional groups and networks calling for organizations, 
clinics, health care providers and policy-makers to ensure 
access to effective, comprehensive, rights-based, safe, 
anonymous and voluntary HIV and hepatitis testing for 
everyone to promote early diagnosis and linkage to care. 
Additionally, since its initiation, European HIV–Hepatitis 
Testing Week has built a public platform on social media 
for participating partners to interact on the international 
level. The majority of European HIV–Hepatitis Testing 
Week participants use social media to promote related 
events/services; however, participants also report that 
they use social media to promote testing advocacy, share 
other testing week activities from affiliated organizations 
and interact with the local/international communities.
Evidence of impact/efficacy
Based on testing statistics and feedback from 
implementing partners, the annual evaluation of the 
European HIV–Hepatitis Testing Week focuses on how 
valuable the testing week platform and associated 
materials are in helping to scale up access to testing at 
a local level. Additionally, a dossier of evidence for HIV 
and hepatitis has been developed to help organizations 
lobby, organize and evaluate their testing activities. The 
dossiers of evidence are updated regularly to include 
data on the current state of HIV and hepatitis in Europe 
in addition to guidance on how partners can find and 
add their local and country epidemiology to make it 
context specific.
European HIV–Hepatitis Testing Week has partnered 
with NAM aidsmap (122) and the ECDC to create the 
European Test Finder (123). The European Test Finder 
is a search engine where users can find their nearest 
testing centre where they can access testing for HIV, 
hepatitis and STIs. The aim of this service is to increase 
visibility and access to information on where to find 
testing services. In 2017, the Test Finder was available in 
44 countries throughout Europe and has been translated 
into 16 languages.
In 2017, there were 640 partner organizations who 
signed up for the testing week. The majority of the 
partners were from western Europe (see Fig. 41). 
Most of the organizations in the Other category were 
multinational.
Additionally, of those who completed the post-testing 
week evaluation survey, the vast majority have reported 
from 2015–2017 an estimated increase in testing by at 
least 50% or more during testing week in comparison to 
the amount of testing that they conduct on a daily basis 
(Fig. 42).
Respondents of the evaluation survey also are asked 
if they target specific groups for their testing week 
activities. The vast majority report targeting the general 
population, MSM and youth; however, there have been 
increases in activities that are targeted towards patients 
with STIs, towards immigrants originating from countries 
with generalized HIV/HBV/HCV epidemics and towards 
people with indicator conditions (Fig. 43).
Since 2015, when hepatitis was added as a key focus 
area, the number of participants implementing combined 
activities for HIV/HBV/HCV has also been on the rise.
Sustainability
The HIV in Europe initiative fundraises to run the platform 
(webpage, materials, coordination) and secures support 
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from private funders. Unfortunately, HIV in Europe is 
not in a position to offer any direct financial support to 
participating partners. This means that the testing and 
advocacy activities depend on the participants’ own 
resources. The European Hepatitis–HIV Testing Week 
initiative supports participants by offering a range of 
template materials, ideas for testing activities, a platform 
for sharing experiences and a condensed compilation 
of the evidence and European guidelines available 
on HIV and hepatitis testing. In particular, Toolkit 1 
outlines guidance on how organizations can raise 
funds for their activities through applying for grants with 
pharmaceutical companies or local trusts, partnering 
with local health providers and/or the local government, 
Fig. 41. Geographical distribution of European Hepatitis–HIV Testing Week participants by parts of the WHO 
European Region (West, Centre and East)
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Fig. 42. Reported estimated increase in testing of at least 50% or more, 2015–2017
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working with NGOs and conducting local fundraising 
events (Fig 44). Additionally, Toolkit 1 provides guidance 
on how to develop applications and proposals to apply 
for funding. These can be found on the Materials page 
of the European HIV–Hepatitis Testing Week website 
(124). The European Hepatitis–HIV Testing Week has 
established an internationally recognized initiative that 
many have come to look forward to every year. A testing 
week will continue to be held every year with the aim 
of encouraging testing, increasing serostatus awareness 
and reducing late diagnosis, which is a persistent 
obstacle for the HIV response in the WHO European 
Region. 
Fig. 43. Targeted populations for European Hepatitis–HIV Testing Week activities, 2015–2017
0%
10%
20%
30%
40%
50%
60%
70%
80%
2015 2016 2017
MS
M
Pe
op
le 
wh
o i
nje
ct 
dr
ug
s
Se
x w
or
ke
rs
Mi
gr
an
ts 
an
d 
mo
bil
e p
op
ula
tio
ns
Pr
iso
ne
rs
Pa
tie
nts
 w
ith
 se
xu
all
y  
 
tra
ns
mi
tte
d 
inf
ec
tio
ns
Pr
eg
na
nt 
wo
me
n
Ge
ne
ral
 p
op
ula
tio
n
Yo
uth
Im
mi
gr
an
ts 
or
igi
na
tin
g f
ro
m 
    
   
    
co
un
trie
s w
ith
 ge
ne
ral
ise
d 
    
HI
V/
HB
V/
HC
V 
ep
ide
mi
cs
Pe
op
le 
pr
es
en
tin
g w
ith
 an
    
 H
IV 
ind
ica
to
r c
on
dt
ion
Ot
he
r
Fig. 44. Cy Checkpoint, AIDS Solidarity Movement Cyprus.
©Logan Bellew
107
STRATEGIC DIRECTION 5. Innovation for acceleration
Background
The Robert Koch Institute estimates that 12 700 people 
in Germany are unaware of being infected with HIV as 
of the end of 2016. In Germany, about half of all patients 
newly diagnosed with HIV are late presenters.30 The 
average time between HIV infection and HIV diagnosis 
is about five years among MSM, and six to seven years 
among heterosexuals. Compared to that for MSM, 
the probability of late presentation for diagnosis is 
significantly higher for migrants (odds ratio (OR) 2.93; 
95% confidence interval (CI) 2.2–3.9), heterosexuals 
(OR 1.51; 95% CI 1.16–1.97) and patients with 
unknown transmission risk (OR 2.16; 95% CI 1.69–
2.77) (125).
Detecting HIV may be difficult since the presentation 
of acute and chronic infection varies considerably. It is 
crucial for the timely diagnosis of HIV and other STIs 
that physicians deal with sexuality and sexual health 
in an unprejudiced manner that ensures the respect of 
all patients and people living with HIV. Only then will 
patients openly report about the health risks associated 
with HIV and other STIs, making it possible to administer 
the appropriate testing to obtain diagnoses. However, 
many physicians do not feel sufficiently trained for this 
form of communication (126–128). Moreover, an evasive 
response by professionals to these diseases may pave 
the way for discrimination against the corresponding 
patients at hospitals and medical practices.31
Description of the good practice
Good communication about sexuality and transmission 
pathways is key for timely diagnoses of STIs, but many 
physicians are not adequately trained. This educational 
communication training programme for doctors and 
medical students aims to fill this gap and to counteract 
discrimination and stigmatization of MSM (particularly 
when HIV infected), SWs, their clients and other 
marginalized groups.
Deutsche AIDS-Hilfe (a German AIDS service 
organization) developed, in collaboration with national 
30 Defined as having a CD4 cell count <350 per mm3 or clinical AIDS (a CDC 
category C event) at the time of the first reported positive HIV test.
31 A 2012 survey among people with HIV revealed that 19% of the respon-
dents had been denied medical treatment on account of their HIV infection in 
the year before the survey.
experts representing key national organizations and 
institutions, a continuous education programme for 
physicians (129); this programme was later expanded 
to universities/medical students.
The education programme is aimed at:
• establishing and improving physician–patient 
communication regarding aspects of sexuality and 
sexual practices;
• improving the understanding of living environments 
of people living with HIV to counteract stigmatization 
and discrimination in the public health sector; and
• promoting collaboration between physicians and 
local HIV/AIDS service organizations as well as 
other counselling centres.
The content of the education programme includes:
• how to obtain an HIV/STI-related sexual history 
theoretically and through practice; 
• identifying weaknesses in communication 
techniques and offering learning experiences to 
improve them; 
• reviewing clinical knowledge, especially regarding 
the diagnosis and transmission routes of HIV/STIs 
(syphilis, gonorrhoea, chlamydia, hepatitis A/B, 
HPV) where necessary; 
• explaining the living environments of people living 
with HIV and the relevant target groups for HIV/STI 
prevention in an easy-to-understand manner; and 
• explaining the forms of discrimination (in particular, 
in health care).
Methods
Workshops for physicians are offered as in-house 
training to organizers of medical quality circles, or 
in relation to general practice days (regular regional 
meetings of physicians), at congresses or at clinics/
hospitals.
GERMANY. Let’s talk about sex: HIV/STI prevention in medical practice
Submitted by: Leibnitz, Mirja | Taubert, Steffen
Deutsche AIDS-Hilfe
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Workshops usually take one and a half to four hours. 
The seminars comprise a theoretical further education 
module dealing with the diagnosis of HIV/STIs, and a 
practical module dealing with sexual history and talking 
about sexuality. Upon request, advanced modules can 
be added, such as communication of medical findings, 
female-specific issues, sex and sexuality in the ageing 
population(s) and dealing with HIV at the medical practice. 
The interactive chemsex workshops involve exercises 
and role play in small groups and offer opportunities to 
discuss personal attitudes, for example towards morally 
controversial topics such as promiscuity or unusual 
sexual practices. Physicians and medical students are 
introduced to different so-called Lebenswelten (social 
environments, choices and ways of living) by LGBT 
referees and trainers. If possible, people living with HIV 
are invited to the workshops for testimonials.
Scope
The project was launched in 2010 with the first 
workshop for physicians. Since then, 131 workshops 
have been conducted. The workshops are attended by 
an average of 14 physicians, which adds up to a total of 
1833 participants throughout Germany. The workshops 
are most popular among general practitioners and 
gynaecologists.
At the medical schools of Charité Berlin, Frankfurt/Main 
and Lübeck, a total of eight educational courses for 70 
lecturers were conducted between 2012 and 2017. 
The educational courses enabled lecturers to teach the 
education module, which is now offered at these three 
universities as an obligatory course that is one to three 
hours long. A one-day seminar (eight semester hours) 
has been conducted at the universities in Cologne, 
Dresden, Essen, Freiburg, Leipzig, Mainz, Munich, 
Münster, Rostock and Witten/Herdecke. The total reach 
of medical students in the period 2013–2017 was at 
least 2800.
Evidence of impact/efficacy
The evaluation of the seminars for doctors using a 
questionnaire completed at the end of the workshop 
reveals a high level of satisfaction among the participants, 
and the event is regarded as being highly beneficial. 
Altogether, 1213 questionnaires were returned, which 
is equivalent to a response rate of 72%; 95% of the 
participants rate the workshop as very useful or mostly 
useful for their work. The average rating given for the 
instructors’ competence and ability to present the 
contents is 1.2 [scale from 1 (very good) to 5 (poor)]. 
The average overall rating given for the event is 
1.37 (representing the period from October 2010 to 
December 2017).
Qualitative evaluation results of the project show efficacy 
and the need for physician–patient communication 
concerning sexuality, sexual practices and transmission 
pathways to improve diagnosis, treatment and 
prevention. Although comparable data is not available, 
the feedback from workshop participants shows a clear 
enhancement of knowledge about and willingness to 
conduct HIV/STI testing and to improve communication 
skills regarding the topic of sexuality and sexual practices 
towards patients.
The regularly conducted evaluations of the whole-day 
seminars at medical universities showed an average 
rating of 1.1 for the instructors as well as 1.2 for the 
overall seminars (scale from 1 (very good) to 5 (poor)). 
Particular praise was given to the interactive role play, 
exercises and discussions, the balance of theoretical 
and hands-on content, the atmosphere of open 
dialogue and the discussion of sexuality, which is usually 
lacking or completely absent in medical studies. Many 
medical students specifically asked for longer/more 
education modules on this subject area as well as more 
in-depth education on how to take a sexual history. 
At the annual conference of the German Association 
for Medical Education on 23 September 2017, the 
education module for universities was voted the “most 
convincing contribution to the direct improvement of 
patient care”.
Sustainability
The development, implementation, outreach and 
continuation of the workshops and seminars has only 
been possible because of the excellent collaboration 
and partnership with experts from the Deutsche 
Arbeitsgemeinschaft niedergelassener Ärzte in der 
Versorgung HIV-Infizierter (German Association of 
Practicing Physicians Treating HIV-Infected Patients), 
the Deutsche STI-Gesellschaft (German STI Society), 
the Deutsche AIDS Gesellschaft (German AIDS 
Society), the German Competence Network for HIV/
AIDS and the Federal Centre for Health Education, 
Deutsche AIDS-Hilfe. Currently, financial support from 
the Federal Centre for Health Education and the Private 
Health Insurance Association, Verband der Privaten 
Krankenversicherung (the primary donor), allows all 
workshops to be free of charge. Financial sustainability 
of the communication trainings targeting physicians 
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could be achieved by charging workshop participants 
in the future. The seminar module for students has 
been implemented in the curricula of a number of 
universities throughout Germany, and it is expected 
that more universities will implement it as part of their 
curricula. This ensures that the practice is maintained 
at university level. Additionally, the seminar structure of 
the teaching module for students has been added to 
the best-practice examples (Longkomm Toolbox) of the 
project for the development of a national longitudinal 
communication skills curriculum for undergraduate 
medical education (130).
GERMANY. Your Health, Your Faith: HIV prevention with and for African faith-
based communities in Germany
Submitted by: Gangarova, Tanja | von Unger, Hella | Petry Kababiito, Lillian | Petry, Manfred | Kazadi, Pastor Paul | Biaggiocy Ennin, Pastor Jim
Deutsche AIDS-Hilfe
Background
Migrants are  disproportionally  affected  by  HIV/
AIDS  in  Germany,  with  about  every  third  new  HIV 
diagnosis  given  to  a person who  has  immigrated  to 
Germany  (131). More  than  half  of  HIV  new  diagnoses 
among  migrants  in  Germany  are  people  from 
sub-Saharan  African  countries. Because infections 
are not just brought from the countries of origin but 
also occur in Germany, HIV prevention services must 
be better tailored to the needs of migrants. To date, 
these groups and their communities are only minimally 
involved in HIV prevention and research. Community-
based participatory research provides a valuable tool 
for building capacity and enabling migrant communities 
to create knowledge for HIV prevention and health 
promotion in their (faith) communities.
Description of the good practice
Your Health, Your Faith (2016–2018) is a three-year 
participatory research project that aims to improve 
the involvement of African faith-based communities in 
HIV research and prevention services. The project is 
conducted by the National AIDS Service Organization 
in collaboration with partners from different African 
communities, African pastors, AIDS service 
organizations (ASOs)32 and researchers from the 
Institute of Sociology, Ludwig Maximilian University of 
Munich.
The project participants are trained and supported in 
five German cities. HIV prevention trainings for African 
pastors have been conducted, enabling them to 
communicate preventive messages in a frame of church 
ceremonies without external support. The pastors 
involved in the project train other African pastors willing 
to become active in this filed. The trainings cover two 
32 Aidshilfe Saarbrücken, AIDS-Hilfe Hamburg, Aidshilfe Düsseldorf and health 
authorities/public health centres in Berlin and Bremen.
topics: HIV-related knowledge and methods, that is, 
how to use the bible to enable the communication 
about health-related issues in African churches. The 
idea behind is to empower more African pastors and 
enable them to communicate HIV-related messages 
and take on more responsibility for their communities.
Teams of African activists, African pastors and ASOs 
have been built in each city. Together, they developed a 
concept for preaching preventive messages in church 
settings and developed scenarios for a mobile theatre 
group. Passages from the bible were identified to enable 
African key persons or the pastor to communicate 
preventive messages, for example:
• “My people are destroyed for lack of knowledge”, 
Hosea 4:6 (knowledge will help us protect ourselves 
from HIV); and
• “Love your neighbour as yourself” Mark 12:30–31 
New International Version, Matthew 22:39 (solidarity 
with HIV-positive people is God’s will).
The main messages of the sessions are:
• get tested! (late presenters are a big problem in 
these German communities);
• take pills when you are sick! (some Africans living 
with HIV do not initiate ART because they believe 
that god (or praying) will cure them); and
• solidarity with HIV-positive people (don’t judge, 
don’t exclude).
As part of the events in the church, the pastor gives 
a sermon. Afterwards, there is an open discussion. 
ASOs or public health authorities are also involved in 
the discussion. A mobile theatre group is part of the 
project and can be booked by every organization or 
church. The scenarios address HIV-related topics. The 
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interactive approach of the pastors and the usage of 
supportive performative prevention methods have 
proven themselves; the theatrical performances enable 
the communication on taboo topics such as HIV/AIDS.
The project seeks to embed HIV prevention services 
for and with migrants into a broader concept of health 
promotion. HIV/AIDS is generally not the only or the 
most important health concern of the communities. The 
chance of sparking interest and starting a conversation 
is greater when the main concern is promoting the well-
being of migrants, in relation to HIV/AIDS and beyond. 
A topical embedding of HIV prevention in health 
promotion, women’s health, young people’s health, 
pregnancy counselling and information on access 
to the health care system has proven helpful. The 
implementation of further events and media (videos, 
booklets, etc.) for African pastors and communities is 
planned for 2018.
The project believes that sensitive topics such as HIV/
AIDS should be addressed in an appropriate form, 
especially in church settings. What is appropriate 
depends on the situation, the context and the 
participating persons. It is important in this process to 
find a balance between respectful communication and 
the overcoming of taboos. A culturally sound approach 
should not contribute to silence and stigmatization; 
instead, it should make it possible to talk about HIV 
and eliminate the stigma.
HIV prevention in faith-based communities is possible 
and promising. In 2016–2017, 30 multilingual events 
were held in various African churches, reaching 
approximately 3000 people. The number of African 
clients using the services of ASOs in the cities involved 
in the project is further reportedly increasing.
The events in churches are evaluated after each event. 
The pastor, the ASO and the migrant organization write 
a joint report, which is collected by the National AIDS 
Service Organization. In addition, every six months, 
evaluation meetings (across locations) take place in 
Berlin. The results of the first phase of the project were 
evaluated in a participatory and cross-case manner, 
and quality standards for prevention events in African 
churches have been developed.
Indicators of success include:
• contact with an African church is established 
through an African community member/key person 
with training in HIV prevention;
• an event is planned collaboratively (involving the 
African church, an African HIV activist/key person 
and a representative of a German HIV NGO or a 
local health authority);
• the event takes place in a church setting and is 
documented;
• organizers and participants evaluate the event in a 
positive light; and
• the partnership is expected to continue, and more 
events will be planned.
A video about the project (in German) is available 
(132).
Evidence of impact/efficacy
Contacts have been established in five cities, and 
30 events were jointly planned, took place and were 
documented. In the evaluations (oral and written), the 
great majority of events were considered to have been 
successful; in only one or two cases, problems were 
encountered, and it was thought that these could be 
resolved through follow-up meetings. The project has 
received requests from other African churches and 
pastors in Germany, with them showing their willingness 
to participate in the project. However, there are some 
limits to the degree of cooperation between African 
churches and ASOs: social workers cannot always 
take part in the weekend events, the distribution of 
condoms is not allowed in church settings, and the 
organization, implementation and evaluation of events 
in African churches must be financially compensated. 
A method of project documentation is currently being 
developed and will be published in order to spread 
the knowledge gained in the frame of the project 
and make it accessible and useful for others such as 
ASOs, other African pastors and interested African 
communities. It will summarize the methods used, the 
messages sent, lessons learnt, and so on.
Sustainability
From the beginning, long-term sustainability has 
been the foremost premise of the Your Health, Your 
Faith project and was taken into consideration in 
the design of the project. Efforts have been made 
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on-site to ensure that the findings of the project can 
be and are being implemented, for example through 
the development and stabilization of structures and 
networks (cooperation between African churches, 
ASOs and self-organized migrant organizations). 
These networks and structures will still exist after 
finalizing the project and can be used for the further 
development of HIV prevention for and with African 
communities. The project has been presented to 
local authorities in each of the involved cities to 
ensure sustainable financing at the municipal level; for 
example, in Berlin and Essen, the project has already 
been introduced to local authorities to ensure long-
term financing after the nationwide model project has 
finished.
NETHERLANDS. 4mezelf.nl: an online sexual health intervention designed to 
support MSM directly after HIV diagnosis
Submitted by: Heijman, Titia | Davidovich, Udi
Public Health Service of Amsterdam
Background
Men who have just been diagnosed with HIV have 
specific needs concerning their adjustment to the 
new realities in their lives. One important aspect of 
adjustment relates to managing their sexual health. 
Recently diagnosed MSM are in the midst of adjusting 
to the new and very diverse implications that their 
HIV status has for their sexuality, including issues and 
implications of infectiousness and treatment, issues 
of self-worth, perceptions of attractiveness, romantic 
attachment to others, future (sexual) relationships, 
disclosure of the HIV status to others, STIs in relation 
to HIV, the need to gain new knowledge in complicated 
issues regarding treatment and safe sexual behaviour 
in the era of ART and many others. Formal interaction 
with health professionals, or the medicalization of 
social processes, is relatively undesirable for recently 
diagnosed MSM.
Description of the good practice 
A website that addresses many of the issues recently 
diagnosed (less than one year) MSM deal with, placing 
strong emphasis on managing their sexual health was 
developed (see Fig. 45). The Internet provides a low-
threshold and safe environment to deal with sensitive 
issues. This so-called safety of distance can facilitate 
help-seeking behaviour and disclosure, as shown in 
previous research. In the fragile emotional times typical 
after HIV diagnosis, users can benefit from the fact that 
they can follow the intervention at their own pace, in 
the comfort of their home or location of choice and with 
minimal disclosure to third parties or strangers in the 
form of medical professionals. Moreover, the Internet 
makes it easier to offer the intervention modules on a 
tailored basis. Intervention memory that knows when 
users logged on/off allows them pick up again where 
they left on their return. However, men were able to find 
their information in one visit only if necessary.
Fig. 45. 4mezelf advert. ©GGD Amsterdam 
Over 4mezelf.nl
De website richt zich op emotionele ondersteuning 
en seksuele gezondheid na de hiv diagnose.
steun voor 
als je nét 
weet dat 
je hiv hebt.
Een initiatief van de GGD Amsterdam in 
samenwerking met de Hiv Vereniging 
Nederland, Soa Aids Nederland, Hiv 
specialisten en consulenten. 
www.4mezelf.nl
The content of the interventions modules was based 
on results from a formative qualitative study conducted 
earlier for this project among MSM who had recently 
been diagnosed with HIV (133). The content of the 
website is theoretically grounded in the Information–
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Motivation–Behavioural Skills model developed by 
Fisher and Fisher. The website was launched in March 
2013 and is currently still running.
Evidence of impact/efficacy
By January 2014, 1535 unique individuals had visited 
the website, with a total of 2587 visits. From September 
until January 2014, the number of unique visitors was 
around 200 per month. In this period, approximately 
120 MSM diagnosed with HIV visited and made active 
use of the site. Around 72 of them identified as being 
recently diagnosed with HIV. Since the website serves 
only a limited number of men (estimated 300 per year), it 
was mainly marketed through STI clinics and HIV clinics 
in the Netherlands. The website was introduced at the 
STI clinic of the Public Health Service of Amsterdam in 
March 2013 and, in August 2013, it was offered as an 
additional tool to other STI clinics and HIV treatment 
centres in the Netherlands.
A leaflet was developed and handed out by the nurse 
or doctor in direct contact with a man belonging to the 
target group (recently diagnosed with HIV). Following an 
evaluation of the website for usability and acceptability 
in 2014, access to the website was simplified to 
allow its use without passwords. Furthermore, links 
to the website were strategically integrated in existing 
websites for MSM, such as Mantotman and Time2test.
Website statistics showed that the main visited topics 
included monitoring health, and sex and relationships 
(the other topics were talking about HIV status, STIs 
and dealing with emotions after diagnosis). On average, 
there were 1.6 visits per unique visitor. The topics were 
considered to be highly useful; however, few men 
(n = 48) participated in the questionnaires. Although the 
website could be used as a one-time programme, 56% 
stated that they intended to visit the site again.
The programme addressed a small but important 
target group and succeeded in structural integration 
into existing websites.
Sustainability
The website has been integrated into Mantotman, 
Time2test, HIVnet.org and the site of the Public Health 
Service of Amsterdam. The website is directed to a 
small Dutch subpopulation (MSM recently diagnosed 
with HIV) but its content can be adjusted to benefit also 
other groups.
NETHERLANDS. Testlab: a low-threshold, online-mediated HIV and STI testing 
service for MSM
Submitted by: Zuilhof, Wim1 | Davidovich, Udi2
1STI Netherlands (SOA AIDS Nederland) and Rotterdam Public 
Health Service; 2Public Health Service of Amsterdam
Background
MSM comprise the population with the highest rates 
of HIV and STIs in the Netherlands. MSM in the 
Netherlands also have high rates of Internet and smart 
phone use, which makes them suitable for online 
interventions. HIV/STI testing by online interventions 
serves high-risk populations who might be more 
reluctant to go the general testing services. It provides 
an opportunity for anonymity, it delivers messages 
efficiently and users can choose their own time for 
testing.
Description of the good practice
Testlab is an online service for testing for HIV, 
chlamydia, gonorrhoea and syphilis. Testlab is built 
within the national online HIV and STI prevention 
portal for MSM, http://www.mantotman.nl.
Men visiting the Mantotman website can initiate 
a Testlab testing request. Once initiated, men go 
through initial eligibility screening online. In order to 
use Testlab, men must not have active symptoms of 
STIs, been warned by a sex partner about an STI or 
had sexual risk behaviour in the prior 72 hours, in line 
with the current national protocol. Such cases are 
referred to direct testing at the STI clinic for further 
diagnosis or the potential prescription of PEP. Men 
with symptoms are asked to come directly in person 
that day to the STI clinic to go through rapid testing 
and commence with same-day treatment. Non-
symptomatic men who been warned by a sex partner 
about an STI or had sexual risk behaviour in the prior 
72 hours are allowed to continue with the test.
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Men who are HIV positive and only wish to screen for 
other STIs can opt out of the HIV test. After finishing the 
online questionnaire, they receive a referral letter that 
they can download. With this referral letter, men can 
present themselves for testing in a network of testing 
points that are scattered around their city and are very 
likely to be situated in the vicinity of the clients’ place of 
work or living area. There, after presenting their referral 
letter at the testing location, the local nurse will draw 
blood for HIV and syphilis and men will self-swab their 
throat and anus and provide urine to establish throat, 
rectal and urethral samples for testing for chlamydia 
and gonorrhoea.
The testing point will then send the materials to an 
affiliated testing lab, which, in turn, will report the testing 
results to the STI clinic of the Public Health Service. 
The appointed physician there will then determine the 
diagnosis and upload the results online in a secured 
environment. The client can then login online and retrieve 
the results. This was the case in 98% of the test results 
for 2017. This entire process takes approximately five 
working days for all STIs tested for, from the moment of 
testing at the testing point.
Testlab users with a positive test result are then asked 
to present themselves (with a provided online referral 
letter) at the STI clinic as soon as possible, for further 
diagnosis and treatment. Data for the number of 
successful follow-up visits following a positive test result 
are not yet available. Men who received a negative test 
result do not need to take any further action. They 
were successfully screened without physically seeing a 
doctor or having to visit an STI clinic.
Evidence of impact/efficacy
The service provides a viable alternative for the often-
long queues and time-consuming visits at STI clinics 
and minimizes the interaction with health-providing 
services, as these are sometimes perceived as barriers 
for testing by risk groups. The service is, further, a very 
suitable method for STI screening among HIV-positive 
men. HIV-positive men who do not use condoms 
are advised in the Netherlands to test often (every 
three months) for STIs, even when there are no overt 
symptoms. This service offers them a quick and low-
threshold way to regularly and often screen for STIs 
while opting out for the HIV test.
The service succeeded as a low-threshold testing 
service that attracts a large number of MSM for 
testing across the Netherlands. The total number of 
Testlab consultations since 2009 reached 28 611 by 
2017, increasing every year (Fig. 46). The service is 
Fig. 46. Annual number of Testlab consultations, the Netherlands, 2009–201
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now offered in the regions of Amsterdam, Drenthe, 
Friesland, Groningen, Rotterdam, South Gelderland 
and The Hague. The service minimized personnel costs 
per negatively screened individual, as men who were 
found to be negative for STIs did not have to make use 
of the nurses at the STI clinics.
Sustainability
The service is offered free of charge and is integrated 
into the structural national STI care provided in the 
Netherlands. Its contribution is now seen as a viable 
permanent addition to the pallet of STI care options 
offered in the Netherlands for risk populations.
Fig. 47. A screenshot from vrijlekker.nl
Source: vrijlekker.nl (136).
NETHERLANDS. Reducing sexual risk behaviour among youth: development 
and evaluation of a tailored, single-session online intervention
Submitted by: Davidovich, Udi
Public Health Service of Amsterdam
Background
In the Netherlands, half of all young people under the 
age of 25 years report having had sexual intercourse 
by the age of 19 years (134). This national survey also 
showed that condom use among young people is low 
for casual contacts. One in 10 boys and one in six 
girls under the age of 25 years have been tested for 
an STI, and 5% of boys and 6% of girls for HIV. Data 
from STI clinics in the Netherlands show that STI rates 
are as high as 19.5%. The most prevalent infection is 
chlamydia, which is often asymptomatic (135).
Description of the good practice
The intervention, the website http://www.vrijlekker.
nl (see Fig. 47), was developed based on over 200 
qualitative interviews conducted with youth and 
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investigating barriers to safe sex and STI screening. 
Based on these interviews, training modules were 
developed which participants could follow online. These 
modules aimed at counteracting the individual barriers 
for safe sex and STI screening as well as providing 
first steps in removing impeding elements in the 
participant’s sexual network. The training was designed 
as a single online session aimed at inflicting cognitive 
change during one contact moment. The Information–
Motivation–Behavioural Skills model, developed by 
Fisher and Fisher, was used as the theoretical basis of 
the intervention. The training included filmed coaches 
that guided users throughout the intervention, thematic 
films, interactive text with personal feedback and 
sexual network tools. The modules were offered on a 
tailored basis to match each user’s own cognitive and 
behavioural risk profile, which was established via an 
automated online questionnaire.
Evidence of impact/efficacy
Over 170 000 unique persons used the intervention 
during its first year; in the years thereafter, more than 
200 new users continue to do so every week.
An evaluation was conducted comparing a control 
group recruited online from a social media channel 
that was popular at the time and from an existing 
youth panel. This was done prior to the launch of the 
intervention. The intervention group was recruited later 
on online from several social media channels (see also 
Fig. 48 for the evaluation time frame). The control and 
intervention groups were demographically matched 
prior to comparison. Behavioural outcomes were 
compared at the six-month follow-up. The evaluation 
included 2944 participants, of whom 1553 completed 
the follow-up (mean age 19, SD 2.4).
Fig. 48. Evaluation time frame33
Time −1   Time 0   Time +1
Control (six months)       Intervention (six months)
33  The control group was recruited six months prior to the intervention launch 
(Time −1), and this is the time when the control baseline was measured. 
At the intervention launch (Time 0), the follow-up for the control group was 
conducted, and the baseline for the intervention group was measured. Six 
months later (Time +1), the follow-up measures for the intervention groups 
were conducted. 
The intervention group had used condoms significantly 
more often with their most recent casual partner (OR 
1.82; 95% CI 1.08–3.04) and/or with their steady 
partner (OR 2.17; 95% CI 1.48–3.18) than the control 
group at the six-month follow-up. The evaluation of the 
intervention demonstrated that offering adolescents 
and young adults a single-session intervention online 
which is empirically and theoretically sound and which 
is aimed at addressing the individual barriers for safer 
sex and STI screening resulted in a desired behavioural 
change. Usability and acceptability measures further 
indicated it was highly liked and used by the participants.
Some schools in the Netherlands have adopted the site 
as part of their routine sexual education programme. 
The large traffic bulk to the website and its in-depth 
usage point at an effect beyond the designated 
campaign time, which was set at one year. As a result, 
the intervention is continuously being offered online, 
at http://www.vrijlekker.nl. In addition, the success of 
this approach encouraged the Public Health Service 
of Amsterdam to further invest in the development of 
online and mobile representations of its services in a 
manner specifically designed for youth.34
Sustainability
The website and its automated tailored counselling 
features are offered free of charge and have been 
integrated into the structural online STI care that is 
provided by the Public Health Service of Amsterdam. 
The advantage of an automated online counselling 
service such as http://www.vrijlekker.nl is that the 
continuation of its activity requires only a minimal 
financial investment.
34 Some websites are examples (137,138).
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Background
MSM are disproportionately affected by HIV in Norway, 
as in other developed countries. The Norwegian 
Institute of Public Health reports a decrease in new HIV 
diagnoses in Norway of 30% since 2008. In 2017, 213 
individuals were diagnosed with an HIV infection. Men 
accounted for 73% (n = 155) and women accounted 
for 27% (n = 58) of these cases. Of the 155 men 
diagnosed with HIV in 2017, 88 of them were MSM. 
MSM with backgrounds from developing countries are 
overrepresented in the Norwegian HIV statistics; they 
accounted for 60% of the MSM cases in 2017.
There is limited data on HIV testing among MSM in 
Norway. Norwegian data are typically based on non-
representative Internet studies, and these indicate that 
approximately seven out of 10 MSM have ever taken 
an HIV test. However, there is reason to believe that 
the number is lower when considering probability 
surveys from comparable countries, such as in the 
United Kingdom. British population-based studies 
show that 50–60% of all MSM have ever been tested 
for HIV and that the proportion taking a yearly HIV test 
is considerably lower, 15–25%.
Increasing levels of HIV testing is a considerable 
challenge, and efforts in this respect should be as 
diverse as the individuals constituting this sexual 
minority. Based on the situation described above and 
inspired by similar projects in France and the United 
Kingdom, Gay and Lesbian Health Norway started 
applying for public funding of a pilot project on low-
threshold HIV testing targeting MSM in 2004. After 
being granted funding by the Oslo municipality in 
2011, Gay and Lesbian Health Norway invited major 
stakeholders35 to participate in a reference group 
during the planning and implementation of the pilot 
project. The inclusion of all these relevant partners and 
their contributions was of great significance for the 
start-up of the project and its longevity. The positive 
impact of the project was evident for stakeholders 
after presentation of evaluation data approximately six 
months into the pilot project, illustrating the project’s 
35  Including the Norwegian Institute of Public Health, The Norwegian Direc-
torate of Health and the Infectious Diseases Ward and the Department of 
Microbiology at Oslo University Hospital, as well as the Olafia Clinic, Norway’s 
largest sexual health clinic.
ability to reach the targeted population such as MSM 
rarely or never testing for HIV as well as MSM with 
backgrounds from developing countries.
Description of the good practice
Sjekkpunkt was launched in December 2012, as 
the first innovative low-threshold rapid HIV testing 
services outside the formal health system targeting 
MSM in Norway. As such, Sjekkpunkt contributed 
to an increased diversity in HIV testing services and 
possibly an increase in HIV testing rates among MSM 
in Norway. Besides HIV rapid testing, the consultations 
at Sjekkpunkt include conversations about HIV risk 
factors and behaviour change.
Sjekkpunkt is designed to address barriers in other 
existing HIV testing services in the formal health system, 
by lowering the threshold of taking an HIV test. The 
project targets MSM but, regardless of sex and gender 
identity, everyone who approaches the testing service 
is offered an HIV test. The low-threshold approach is 
ensured by availability and convenience (i.e. location, 
opening hours, outreach work, HIV rapid tests) and 
anonymity (requiring no names or social security 
numbers to get tested). Furthermore, Sjekkpunkt 
is administered by peers, in this case, other MSM, 
both HIV-positive and HIV-negative, working as lay 
service providers performing the tests/consultations. 
Concerning quality control, the peer workers go through 
a standardized training programme conducted by 
internal and external trainers. All volunteers are followed 
up on a regular basis after they start conducting tests 
by employees at Gay and Lesbian Health Norway.
The peer-driven approach is meant to leverage non-
judgemental and non-clinical conversations about HIV 
risk factors and behaviour changes. The approach 
also makes access to MSM or men-only venues 
easier, where Sjekkpunkt offers HIV testing, such as 
gay saunas and sex clubs. This is part of the project’s 
outreach component, in addition to monthly testing at 
hotels in other major cities in Norway outside the capital 
Oslo. Sjekkpunkt also offers monthly HIV testing at gay 
bars, clubs and cruising areas and weekly testing at a 
gay sauna in Oslo. Besides this, Sjekkpunkt provides 
drop-in testing at the main office of Gay and Lesbian 
NORWAY. Sjekkpunkt: a low-threshold HIV testing service targeting MSM
Submitted by: Bjørnshagen, Vegar | Moseng, Bera Ulstein
Gay and Lesbian Health Norway
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Health Norway in the Oslo city centre (open Monday 
to Saturday).
The testing service aims to be as neutral and discrete as 
possible, by not having an LGBT profile and having no 
pronounced indications of being a place for HIV testing, 
with all the possible connotations this might entail. For 
example, the main testing site is located in a building 
with other organizations and companies, and a visit to 
the building therefore does not imply that you are there 
to take an HIV test. Neutrality, discretion and anonymity 
might be attractive features for hard-to-reach groups, 
such as men who have sex with both men and women, 
and MSM who are not open about their homosexuality. 
The testing service is marketed on neutral digital 
spaces, such as Facebook and Google AdWords, to 
reach MSM not identifying with the LGBT community 
or MSM who otherwise do not interact on gay social 
media where the testing site is also marketed.
The aforementioned strategies, with the combination 
of being present at gay venues and gay social media 
as well as aiming for a neutral profile with anonymous 
testing spaces, were chosen to address possible 
barriers to HIV testing and to recruit openly gay and 
bisexually identified MSM as well as more hard-to-
reach groups to HIV testing.
Evidence of impact/efficacy
Since Sjekkpunkt was launched in the end of 2012, the 
number of HIV tests conducted at the testing service 
has increased on a yearly basis (Fig. 49).
The number of positive HIV tests per year diagnosed 
in Sjekkpunkt (Fig. 49) represents 7–15% of the HIV 
cases among MSM in Norway in this period. Individuals 
receiving a positive HIV test at Sjekkpunkt are linked to 
care at the nearest infectious diseases ward. In 2017, 
seven of the eight individuals testing positive were 
confirmed linked to care.
All users of Sjekkpunkt are asked to participate in an 
anonymous survey. Results from this survey are used 
to evaluate the testing service. Approximately 2.5% of 
the users of Sjekkpunkt are not from the MSM group 
(i.e. they are women, or men who only have sex with 
women). Data from 2017 describing the HIV testing 
history of MSM users36 at Sjekkpunkt found that 16% 
36 The sample is restricted to men reporting ever having had sex with another 
man and not having visited Sjekkpunkt more than once during 2017 (n = 
997).
Fig. 49. HIV testing data from Sjekkpunkt, Norway, 2013–2017
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had never been tested and that 40% had not been 
tested within the last year (Fig. 50).
Sustainability
Sjekkpunkt is funded by the Norwegian Directorate of 
Health and the Oslo municipality, and maintenance of 
the testing service is dependent upon a continuation of 
this example of a successful cooperation between civil 
society and the public sector.
The sustainability of Sjekkpunkt also requires continuous 
collection and analysis of user data on sexual behaviour, 
sexual orientation, HIV testing history, alcohol and drug 
use, and so on, to evaluate whether the testing service 
reaches the intended target groups. This is done using 
a questionnaire including validated measures tested in 
representative studies regarding sexual health, such as 
the National Survey of Sexual Attitudes and Lifestyles 
(Natsal), the National Health and Nutrition Examination 
Survey (NHANES) and The National Longitudinal Study 
of Adolescent to Adult Health (Add Health).
Fig. 50. HIV testing history of MSM at Sjekkpunkt, 2017
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SPAIN. The DEVO Network: a community-based initiative
Submitted by: Fernàndez-López, Laura1,2 | Rifà, Benet3 | Mansilla, Rosa3 | Colom, Joan3 | Casabona, Jordi1,2 | 4The DEVO Network Group
1Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agència de Salut Pública de Catalunya (ASPCAT); 2CIBER 
Epidemiología y Salud Pública (CIBERESP); 3Subdirecció General de Vigilància i Resposta a Emergències de Salut Pública, ASPCAT; 
4Actuavallès; Creu Roja Tarragona; Ambit Prevenció; AssexoraTgn; ACASC; Associació Antisida Lleida; SAPS-Creu Roja; STOP-SIDA; Gais 
Positius; Centre Jove d’Atenció a la Sexualitat Barcelona (CJAS); Associació Comunitaria Anti Sida de Girona (ACAS); Projecte dels Noms-
Hispanosida
Background
In Spain, the trend in the rate of new HIV diagnoses 
has remained relatively stable in recent years, with 
an estimated 9.44 cases per 100 000 population in 
the year 2015. Sexual transmission between MSM 
represents 53.6% of new diagnoses and increased 
from 47.5% in 2009 to 56% in 2015. Late diagnosis 
represented 46.5% of new cases in 2015, and 27.1% 
of them were diagnosed with advanced disease (139).
Prevention and early diagnosis and treatment thus 
comprise the main strategy to reduce the impact of 
the HIV epidemic. CBVCT services are considered 
an effective tool for HIV testing, especially for key 
populations (86). These centres offer their services 
outside of conventional health centres, on a voluntary 
basis and with the active participation of the community 
both in the design and in the implementation of 
interventions and strategies. These types of centres 
119
STRATEGIC DIRECTION 5. Innovation for acceleration
generally operate on their own premises or through 
outreach interventions (e.g. on the street, in saunas or 
in leisure areas).
Description of the good practice
In 1994, the Catalan Health Department (currently, 
the Catalan Agency of Public Health; ASPCAT) 
funded a network of CBOs to offer free, voluntary and 
confidential HIV testing in the region. The purpose of 
this programme, the DEVO Project, was to complement 
existing facility-based HIV testing. The DEVO Project 
has since then expanded from six CBVCT services 
to the current 12, mainly operated by NGOs and 
serving various populations. While a few organizations 
specifically target MSM, SWs, young people or people 
who use drugs, most sites serve all vulnerable groups 
and people at risk. The counsellors have been trained 
on a peer-led basis to perform and interpret rapid 
HIV/syphilis diagnostic tests with finger-prick blood 
samples. The centres of the network are all CBVCT 
services, providing HIV testing through community 
and outreach services and by trained lay providers. In 
addition to providing HIV testing, most organizations 
affiliated with the DEVO Project conduct additional HIV 
prevention activities.
The DEVO Project has been collecting harmonized and 
systematic data on activity, process and results since 
1994. The CBVCT sites use a web-based data entry tool 
through which data can be analysed and disseminated 
in collaboration with the Centre for Epidemiological 
Studies on HIV/STI of Catalonia (CEEISCAT) as part of 
the Catalan Agency of Public Health. For monitoring 
and evaluation purposes, the network currently uses 
the standardized core indicators defined in HIV-
COBATEST (http://www.cobatest.org), aligned with 
UNAIDS, WHO and ECDC recommendations. The 
indicators allow evaluation of service activity and 
comparison with services in other countries which use 
the COBATEST tools.
Anonymized data is extracted and analysed by 
the Centre for Epidemiological Studies on HIV/STI 
of Catalonia and forms part of HIV surveillance in 
Catalonia. The data collected in the DEVO Project 
includes basic demographic data of the tester, location 
of the test, history of testing, results of HIV testing, 
syphilis testing and soon also HCV testing. Services in 
the DEVO Project use a unique identifier for each client, 
which makes it possible to determine the number of 
people tested.
Evidence of impact/efficacy
The DEVO Network makes it possible to collect 
standardized data on each person tested in the CBVCT 
services. The information collected can be analysed 
and disaggregated by sex, age, population group, risk 
behaviours and previous HIV test history. The data 
collected complement strategic information about 
some key populations and thus makes it possible to 
improve prevention HIV strategies addressed to these 
key populations. The continual monitoring performed 
by the DEVO Network enables improved public health 
decision-making in the Catalan Public Health Agency 
by detecting any changes in HIV testing uptake, in HIV 
tester’ profiles or in HIV test-seeking behaviours.
From 1995 to 2016, the number of HIV tests performed 
in Catalonia annually increased, from 716 to 12 371 
overall (Fig. 49). The replacement of traditional tests 
with rapid HIV tests in 2007 allowed for the expansion 
of testing in the community. The DEVO Network 
succeeded in scaling up HIV testing of key populations, 
with the number of tests performed in the following year 
increasing to 103% of the previous number of tests 
(140). The DEVO Network has also been shown to be 
successful in providing testing to at-risk populations: 
70.7% of people tested were MSM, 6.6% were SWs, 
0.5% were people who inject drugs and 38.2% were 
migrants.
The use of an anonymous unique identifier37 in the 
network made it possible to determine the number 
of persons tested (9815 in 2016) as well as number 
of tests. Of the people tested in 2016, 2.2% had a 
positive test (Fig. 51); of these, 91.7% were referred for 
a confirmatory HIV test (all of whom had a confirmed 
positive test), and 98.0% were linked to care.
Continual monitoring by the DEVO Network enables 
improved public health decision-making in the Catalan 
Agency of Public Health. Currently, the DEVO Project 
diagnoses around 20% of all HIV cases reported in 
Catalonia, suggesting that CBVCT services comprise a 
valuable element of the strategy to increase HIV testing 
in Spain.
The longstanding experience of the DEVO Network in 
Spain was presented as an example of a successful 
approach for monitoring community-based testing in 
the meeting report Monitoring of HIV testing services in 
37 From 2014, the anonymous unique identifier used is the one suggested by 
the COBATEST Network: one digit for the sex, eight digits for the birthdate, 
plus the number of older brothers, the number of older sisters and the initial 
of their mother’s name.
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the EU/EEA, which was organized by the ECDC (17). 
The DEVO Network was also presented as an example 
of a good practice in the WHO document Consolidated 
guidelines on the use of antiretroviral drugs for treating 
and preventing HIV infection: recommendations for a 
public health approach (5).
Owing to the good performance of the DEVO Network 
and the positive results described during the years the 
network has been active in Catalonia, the Regional 
Office for Europe implemented a project following the 
DEVO Network model, to integrate different CBVCT 
services across Europe, creating the COBATEST 
Network in 2009.
Sustainability
The DEVO Network is supported by the Catalan Public 
Health Agency, supporting partially the CBVCT services 
and purchasing the HIV tests. The sustainability of the 
DEVO Network is further linked to the sustainability of 
the CBVCT services.
Fig. 51. DAVO Network: number of HIV tests and percentage of positive tests, 1995–2016
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Background
In Sweden, more than 7000 people live with a diagnosed 
HIV infection. In 2016, 430 cases of HIV infection were 
reported. In the last five years, on average 447 new 
cases of HIV have been reported each year; of these, 
60% are men. The number of reported cases of HIV in 
which HIV infection has been transmitted in Sweden 
has decreased over the last five years, mainly among 
MSM. However, the majority of cases in Sweden are still 
reported among MSM. The number of HIV infections 
reported among injecting drug users has remained low 
over the last five years but increased slightly in 2016. The 
increase is mainly seen in the major cities, in both men 
and women. Of the total number of cases, approximately 
75% are foreign-born persons, most of whom have been 
HIV infected prior to their arrival in Sweden in countries 
with a higher prevalence of HIV. Where the HIV infection 
was transmitted outside Sweden, the transmission of 
HIV through heterosexual contact was reported in the 
majority of cases.
The preventive work in Sweden is based on the 
national strategy against HIV/AIDS and certain other 
communicable diseases (141). One of the main 
objectives in the strategy is to improve the awareness 
about HIV in the public sector, in workplaces and in the 
general population. HIV is covered in the Swedish law on 
infectious disease control, and testing and treatment is 
free of charge for everyone.
The Public Health Agency of Sweden is the national 
coordinator of the national HIV prevention, a task that 
also includes undertaking actions aiming to reduce the 
stigma and discrimination associated with the infection. 
National surveys show that the knowledge about HIV and 
the living conditions of people living with HIV in Sweden 
SWEDEN. Hiv idag [HIV today]: a national campaign to increase awareness, 
promote testing and reduce stigma
Submitted by: Mannheimer, Louise | Wallin, Malin
The Public Health Agency of Sweden
Fig. 52. Campaign image- HIV i dag, Swedish. ©Emilia B. Jimenez/Söderberg Agentur
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in the general public is relatively low (142). Another study 
showed that people living with HIV in Sweden are afraid 
to talk openly about the infection, because of the risk of 
negative reactions. The physical health among people 
living with HIV is good, but the mental health is worse 
than in the general public, due to the stigma related to 
HIV (143).
Description of the good practice
Within this framework, in 2015 the Public Health 
Agency in cooperation with local councils and CSOs 
developed a national information campaign about HIV 
in Sweden targeted towards the general public and 
health care staff. The Public Health Agency ran a media 
campaign with information targeted towards health 
care staff. As part of the information campaign, local 
activities in the regions and CSOs were also funded. 
Activities funded in regions and by CSOs were in many 
cases educational activities towards health care staff, 
such as, for example, web trainings.
The campaign message was:
Living with HIV in Sweden today is not like it 
was yesterday. The treatment of HIV is now 
so effective that it can reduce virus levels 
to practically zero and minimize the risk of 
transmission. Today, HIV is no longer a fatal 
disease but a chronic, treatable infection. With 
prompt intervention, you can expect to live for 
as long as you would have done without HIV.
Activities organized by the Public Health Agency to 
target the general public were:
• a media campaign via digital and print media at 
national, regional and local levels;
• an advertising campaign using social media 
(Facebook, YouTube, Grindr) and advertising in the 
local public transport system; and
• a website with in-depth information in 12 languages 
(http://www.hividag.se/).
Activities organized by the Public Health Agency to 
target health care staff were as follows.
 HIV TODAY IS NOT 
 LIKE YESTERDAY.
Did you know that the treatment of HIV in Sweden is  
now so effective that it reduces virus levels to practically  
zero and minimises the risk of infection. Living with HIV 
in Sweden today is not like it was yesterday.
Read more at www.hividag.se
Fig. 53. Campaign image- HIV i dag, English. ©Emilia B. Jimenez/Söderberg Agentur
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• All primary health care centres, child care centres, 
dentists, school nurses and youth clinics received 
information in advance about the campaign, 
including training material for the staff.
• A special website for health care staff was created 
with up-to-date information about HIV and the living 
conditions for people living with HIV in Sweden 
today (144).
Activities organized by CSOs and local councils, funded 
by the campaign, were as follows.
• Organizations were invited during the creational 
process of the campaign and also received funding 
to work with the key message of the campaign in 
their own target groups, such as MSM, migrants 
and people living with HIV.
• County councils also received funding earmarked 
for running local activities, such as holding trainings 
for health care staff, advertising in the local public 
transport and holding events in cinemas and train 
stations to target the general public.
Evidence of impact/efficacy
The media campaign ran from 1 November 2015 until 
31 December 2017. During this period, the website 
http://www.hividag.se had a total of 152 126 unique 
page views. The campaign films were seen 5.6 million 
times, and 5 million interactions (clicks, shares) were 
undertaken with the campaign units. Evaluations made 
by the opinion institute, Novus Group International AB, 
show that the media campaign worked well, despite it 
addressing a complex subject. This external evaluation 
showed that 44% of the general population had seen 
the campaign, and seven out of 10 respondents stated 
that it had made a positive impression. Seventy-nine 
per cent reported that it was credible, and 78% found 
that the purpose of the campaign was clear. Seventy 
per cent believed that the campaign was relevant, 
and 57% stated that they liked it. Approximately 52% 
reported that it improved their knowledge, and 33% 
replied that the campaign made them actively update 
their knowledge about HIV (Novus Group International 
AB, unpublished/internal report). The efficiency of the 
campaign targeting the health care was measured 
through focus groups in a few areas, and the 
knowledge was found to be low. Thus, this area needs 
to be developed further.
Sustainability
Additional funding was provided to CSOs and local 
governments during 2016 and 2017 to continue using 
the campaign messages. Websites are still functional 
but will be closed down during 2018, owing to copyright 
issues.
TAJIKISTAN. Implementation of HIV testing and counselling services via NGOs
Submitted by: van Dam, Anke | Ibragimov, Ikram | Dilshod, Pulatov | Davlyatova, Zarina
AIDS Foundation East–West (AFEW)
Background
Tajikistan is one of the countries where the prevalence 
of HIV has increased by more than 25% over the last 
10 years. Tajikistan is at the early stage of an HIV/
AIDS epidemic, with an estimated 16 000 people 
living with HIV at the end of 2016. In 2017, 346 new 
cases of HIV (29%) out of a total of 1207 new cases 
of HIV infections were officially registered in Khatlon 
Region; in this area, since 2010, new HIV infections 
have increased by 23%, and AIDS-related deaths have 
decreased by 5%. Key populations in Tajikistan include 
prisoners, SWs, MSM and people who inject drugs. 
Migrants, children and women of reproductive age are 
also considered vulnerable groups by the Tajik National 
AIDS Programme (145).
As part of its response to HIV, Tajikistan is planning to 
increase the coverage of harm reduction services, scale 
up HIV testing among its population and increase the 
number of people living with HIV who get treatment. 
Prevention, treatment, care and support are where 
NGOs can leverage strength in the HIV response. In 
2015, AFEW in Tajikistan (AFEW-Tajikistan) began the 
advocacy process of introducing community-based 
HIV testing and counselling services managed by 
medical specialists from NGOs.
According to Tajikistan’s MoH, 361 public organizations 
(i.e. NGOs) are registered in Khatlon Region; of  these, 
13 organizations regularly implement HIV prevention 
projects. Of these organizations, three are represented 
by the community of people who use drugs and people 
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living with HIV, and the remaining 10 organizations are 
represented by specialists committed to the fight against 
AIDS. The average number of years of experience held 
by the HIV service community organizations in Khatlon 
Region is 11, with the beginning of work taking place 
in 1996 and the recent registration of an NGO in 2013.
Despite the favourable legal environment and access to 
external financial support until 2015, NGOs providing HIV 
services faced technical and organizational difficulties 
in the practical implementation of pretest and rapid HIV 
testing and counselling (HTC) services, as they did not 
have full information on the procedure for obtaining a 
license, had no medical personnel trained in HTC and 
did not have the appropriate technical capabilities. 
According to the Republican AIDS Centre, as of 1 
January 2015, no public organization in Tajikistan had 
a permit to independently provide pretest counselling 
and rapid HIV testing services.
Description of the good practice
In preparation for community-based testing, AFEW-
Tajikistan conducted a series of consultations with 
representatives of HIV service organizations, the 
Republican AIDS Centre and UNAIDS. The introduction 
of community-based testing in Tajikistan demanded 
a process of consulting different stakeholders and 
developing an advocacy strategy.
Before applying to the MoH for a permit to provide 
pretest counselling and rapid HIV testing services, 
AFEW-Tajikistan received questions from the Regional 
and Republican AIDS Centres on the feasibility of 
introducing community-based HTC services. An 
appropriate motion was also received from UNAIDS 
country office in Tajikistan. AFEW-Tajikistan then 
prepared an analytical background paper on the 
importance of introduction of community-based HTC 
services. After lengthy negotiations, on 30 September 
2015, the MoH, by Order No. 832, allowed the 
introduction of community-based HTC services not just 
from AFEW-Tajikistan but from all HIV service NGOs in 
the country.
Two staff members from AFEW-Tajikistan passed post-
diploma courses for providing HTC services; an HTC 
point was then organized and equipped in Khatlon 
Region, and the first batch of rapid HIV tests was 
purchased. On 1 December 2016, in Qurghonteppa, 
the first HIV voluntary counselling and rapid testing 
point opened at the Representative Office of the AFEW-
Tajikistan in Khatlon Region, where key populations are 
already provided with direct services. The number of 
people who inject drugs is high in Khatlon Region, as 
it is intersected by one of the primary routes of Afghan 
drug trafficking. People who use drugs are the main 
key population that AFEW-Tajikistan works with.
In 2017, AFEW-Tajikistan decided to share its experience 
with its partners. AFEW-Tajikistan was able to replicate 
its practice in other regions of Tajikistan through the 
education of partners, and effective knowledge sharing. 
AFEW-Tajikistan conducted two regional working 
meetings in Sughd Region and Khatlon Region, 
respectively, to introduce methods to implement 
community-based HTC points for 60 representatives 
of state, public and international agencies from three 
regions of the country. In cooperation with the State 
Institute of Post-Diploma Education for Medical 
Workers, AFEW-Tajikistan organized two-week 
courses for 10 representatives of five NGOs which 
intended to organize community-based HTC points. 
AFEW-Tajikistan additionally supported NGOs in the 
construction of premises, provided technical equipment 
for HTC points and provided training and staffing for 
the NGOs.
As a result, on 1 December 2017, three new voluntary 
HTC points, run by three public organizations, were 
opened in different regions of Tajikistan: Vita, in 
Dushanbe; SVON Plus, in Kulob; and Amali Nek, in 
Khujand.
AFEW-Tajikistan widely shares its experience and 
supports the organizations that are willing to provide 
HTC services for key populations on the premises 
of their NGOs. On AFEW-Tajikistan’s website (146), 
visitors may learn about the addresses of HTC points 
and familiarize themselves with monthly updated results 
of HTC services provided by NGOs. NGOs may find the 
flow of documentation for HTC points and regulatory/
legislative information which will support the opening 
of community-based HTC sites. Using the experience 
and success of AFEW-Tajikistan on the implementation 
of community-based HTC services, the USAID Flagship 
program on HIV/AIDS also began to introduce salivary 
express testing, to be implemented by Tajik NGOs.
Evidence of impact/efficacy
By 1 April 2018, in four voluntary HIC points, 930 
persons in key populations and residents of six regions 
of Tajikistan used the community-based HTC services, 
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including 547 (58.8%) men and 383 (41.2%) women. 
The age of clients ranged from 18 to 56 years.
Out of 930 clients, 350 (37.6%) were people who inject 
drugs, 261 (28.06%) sexual partners of people who 
inject drugs, 96 were (10.32%) MSM, 51 (5.5%) were 
SWs and 46 (4.9%) had formerly been incarcerated. 
The rest, 126 (13.5%) people, included TB patients, 
medical specialists, law enforcement officers, and so 
on (Fig. 54).
Out of 930 people tested, 13 (1.4%) were determined 
to be HIV-positive; of these, eight were reconfirmed HIV 
cases, and five (four men and one woman) were newly 
detected HIV cases. All five of the new cases were 
representatives of key populations: MSM and people 
who inject drugs.
Sustainability
The main achievement and sustainable result of 
this practice is that NGOs in Tajikistan now have the 
legal framework to provide community-based HCT 
services which have been approved and certified by 
the government of Tajikistan. The community-based 
provision of HIV testing requires funding that is so 
far provided by project-based financial resources. 
The current activities allow continued advocacy for 
effective and sustainable mechanisms of funding for 
community-based HTC through state funding in the 
future. As such, both the National Health Strategy 
and the National AIDS Programme recognize the 
importance of the involvement and cooperation of 
the state health sector with civil society and NGOs. 
Although larger population sample sizes may improve 
the efficacy of the practice, it may be particularly 
efficient to help local governments establish procedural 
regulatory frameworks for the implementation of further 
HIV service NGOs and HTC sites in the country, which 
bears a large proportion of people who inject drugs, as 
well as other key populations.
Fig. 54. Number and characterization of persons tested in NGOs
Wives of PLHIV/sexial 
partners of PLHIV
Others
TB patients
Spesialists
General population
Labour migrants
Youth
Wives of  PWIDs
Former convicts/convicts
MSM
CSW
PWIDs
Total tested
1330
616
58
112
58
339
14
1
7
5857
46
PWID: people who inject drugs.
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Background
There were 240 000 (220 000–260 000) people 
living with HIV in Ukraine in 2016; of these, only 37% 
(34–40%) were reported to be accessing ART (147). 
Progress towards the second UNAIDS 90–90–90 
target and increasing the number of persons on ART 
has been slow, owing to pharmaceutical patents. 
Three of the most common ARV medicines in Ukraine, 
lopinavir/ritonavir, abacavir and tenofovir/emtricitabin/
efavirenz, as well as dolutegravir,38 were therefore 
procured without competition among pharmaceutical 
companies. This was the same for HCV treatment, 
which few persons in Ukraine had been able to access.
Description of the good practice
To increase access to HIV and HCV treatment, since 
January 2015 the All-Ukrainian Network of People 
Living with HIV/AIDS started actively addressing the 
limitations posed by patent medicine exclusivity. Within 
the last three years, a number of positive results in this 
sphere had been achieved.
Dolutegravir (HIV)
Since 2015, the Network initiated active negotiations 
about possibility of entry of dolutegravir generics 
to the Ukrainian market. The negotiations included 
letter correspondence and meetings with patent-
holder representatives. As a result, on 25 April 2016, 
the Medicines Patent Pool (MPP) and ViiV Healthcare 
announced the extension of the MPP dolutegravir 
license to Ukraine. 
Tenofovir/emtricitabine/efavirenz (HIV)
On 15 February 2016, the Network organized a 
meeting entitled Regarding Provision of Uninterrupted 
Access to ARV Treatment, with the participation of 
major originator (148) pharmaceutical companies, 
international and patient organizations. The Network 
outlined at the meeting that generic substitution is one 
38 In May 2018, WHO issued a statement concerning a potential risk of neural 
tube defects in infants born to women taking dolutegravir at the time of con-
ception (59). As more countries have scaled up ART optimization efforts and 
include or plan to include dolutegravir-containing regimens in their national 
protocols as the preferred first-line option, WHO issued a briefing note in April 
2018 on the clinical advantages of and programmatic information about the 
new fixed-dose combination tenofovir/lamivudine/dolutegravir (60). Additional 
and diverse analyses are planned for July 2018 to expand on the original 
data, which originated from a single country.
of the key ways to provide uninterrupted access to ART 
in 2016–2018 and continues working on all flexibilities 
provided by the TRIPS agreement (149) to achieve 
100% coverage of ARVs in Ukraine. In particular, after 
the meeting, the Network and the pharmaceutical 
company-initiated negotiations regarding the tenofovir/
emtricitabine/efavirenz patent. During negotiations with 
one pharmaceutical company, the Network repeatedly 
emphasized that patent monopoly on tenofovir/
emtricitabine/efavirenz is unjustified, as the tenofovir/
emtricitabine/efavirenz patent does not comply with 
patentability requirements and was opposed in other 
countries. As a result of negotiations, the Network 
received a non-enforcement letter, which was dated 
1 September 2016, from the pharma company; since 
then, tenofovir/emtricitabine/efavirenz generics have 
been procured in Ukraine.
Abacavir (HIV)
In 2015, the Network prepared a patent opposition 
warning to the existing abacavir patent. Later in 2015, 
the Network submitted a letter to the respective 
pharma company requesting generic access in 
Ukraine. On 4 January 2016, they received a negative 
response for the generic importation of abacavir and 
abacavir/lamivudine. In response, on 15 February 
2016, the Network raised a question during a meeting 
about the possibility of generic substitution of ARV 
medicines and, in particular, their compulsory licensing. 
At this meeting representatives of the respective 
pharmaceutical company’s Ukrainian representatives 
and ViiV Healthcare Regional Office were present, 
and they expressed concerns regarding potential 
compulsory licensing of ARVs in Ukraine. On 25 
April 2016, the global headquarter of the company 
announced increased programming and support for 
lower- and middle-income countries (LMICs), and the 
MPP and ViiV Healthcare subsequently announced the 
extension of a dolutegravir license to LMICs, including 
Ukraine. The Network submitted a new request to the 
company requesting extension of the MPP license on 
abacavir and abacavir/lamivudine in the country and, 
in time, received a non-enforcement letter from the 
pharma company regarding abacavir-related products.
UKRAINE. Patent interventions aimed at increasing access to HIV and HCV 
treatment
Submitted by: Sherembey, Dmytro | Kondratyuk, Serhiy | Trofymenko, Mykyta
All-Ukrainian Network of People Living with HIV/AIDS
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Sofosbuvir and sofosbuvir/ledipasvir (HCV)
Since the beginning of 2015, the Network submitted 
several claims to the patent office that invalidated/
delayed consideration of sofosbuvir- and sofosbuvir/
ledipasvir-related patent applications. It allowed 
a generic manufacturer to register sofosbuvir in 
Ukraine, and this resulted in a reduction of the price 
from US$ 1350 to US$ 750 per treatment course. 
Further pressure caused the pharmaceutical company 
to extend its license with generic manufacturers to 
Ukraine, which will lead to a further reduction in prices 
for sofosbuvir and sofosbuvir/ledipasvir in the country. 
Therefore, it is expected that the price of sofosbuvir will 
probably be reduced to below US$ 300 per treatment 
course. There are also plans to continue patent 
claim activities and attempt to invalidate all blocking 
sofosbuvir and sofosbuvir/ledipasvir patents and 
patent applications. Current pharmaceutical company 
licenses with generic manufacturers usually have a 
provision for a royalty fee of approximately 9–12%. 
Also, the respective pharma company usually agrees to 
license sofosbuvir and sofosbuvir/ledipasvir in Ukraine 
via manufacturers from China, India and South Africa. 
This manufactural outsourcing restricts competition in 
the Ukrainian market, as it prevents national Ukrainian 
companies and companies in other countries from 
manufacturing their own sofosbuvir and sofosbuvir/
ledipasvir or importing then into Ukraine. The price for 
sofosbuvir in Ukraine during the recent procurement 
was reduced to US$ 60 per treatment course, owing 
to the competition from generics.
Evidence of impact/efficacy
As a result of the Network’s interventions and the 
entry of the generic versions to the market, the price 
decreases (in US dollars) were as shown in Table 13.
These price reductions may lead to improved access 
to affordable treatment and increase coverage with 
antiretroviral treatment in Ukraine for an additional 
80 000 patients. As the Network expected, entry of 
generic versions reduced prices of ARV medicines on 
average by two to four times. 
Sustainability
The practice may be maintained for a long period by 
improving patent law, in particular, patent prosecution 
proceedings aimed at the prevention of unmerited 
patents granting. Aside from the lack of allocating the 
additional resources, this work is exemplary in showing 
what even smaller groups of people and NGOs may 
do when facing large pharmaceutical companies and 
regulatory issues such as patent laws, which may fall 
out of the purview of NGO service delivery for HIV.
Table 13. Prices for HIV and HCV drugs before and after the introduction of generic versions to the market, 
Ukraine, US dollars
Drug (disease treated) Pre-intervention 
(2016)
Post-intervention 
(2017)
Dolutegravir (HIV), per pack 228.00 5.00
Tenofovir/emtricitabine/efavirenz (HIV), per person per year 353.67 95.04
Abacavir (HIV), per pack 24.22 9.24
Sofosbuvir (HCV), per treatment course 1350.00 750.00
UNITED KINGDOM. Digital vending machine technology to distribute HIV  
self-tests to high-risk MSM populations in Brighton and Hove
Submitted by: Vera, Jaime H2,3 | Dean, Gillian2,3 | Pollard, Alex1 | Soni, Suneeta2| Llewellyn, Carrie1 | Peralta, Carlos3| Rodriguez, Liliana4
1Brighton and Sussex Medical School; 2Brighton and Sussex University Hospitals NHS Trust; 3University of Brighton; 4Loughborough 
University and The Martin Fisher Foundation
Background
Novel strategies are needed to increase HIV testing in 
high-risk groups, including MSM, and meet goals to 
reduce undiagnosed HIV infection. HIV self-testing is 
an attractive strategy enabling user autonomy in the 
timing, location and disclosure of testing as well as 
convenience. Self-testing also creates opportunities 
for providers to reach populations disengaged with 
conventional testing. We developed and evaluated a 
vending machine approach to target HIV self-testing 
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to high-risk MSM in a United Kingdom community 
setting. This project piloted the use of digital vending 
machine technology and HIV self-testing in a sex-on-
premises site (at the Brighton Sauna) for MSM in a 
known high-prevalence location (Brighton and Hove). 
The Martin Fisher Foundation, Brighton Sauna staff, 
digital vending machine manufacturers and HIV self-
test manufacturers, formed a unique team to launch 
the project, as well as establishing a sustainability plan 
for future initiatives. This innovative pilot of a new HIV 
self-test distribution method aimed to encourage self-
testers to access care during sauna operating hours 
in a convenient and confidential manner and when the 
client felt it was an appropriate time to test. The pilot 
location sees approximately 400 clients each week, 
with sauna staff previously noting high levels of sexual 
risk-taking but low levels of engagement with outreach 
workers to discuss HIV testing. There is evidence that 
MSM attending sexual venues are at a greater risk 
of HIV transmission and, therefore, interventions that 
could improve HIV testing in these settings could lead 
to a reduction in HIV transmission rates.
Description of the good practice
A cross-sectional survey in a sex-on-premises venue 
(sauna) assessed feasibility and informed development 
of the self-test vending machine interface. Codesign 
workshops involving designers and LGBT community 
volunteers explored attitudes towards self-testing and a 
vending machine interface delivering HIV self-test kits in 
community settings (bars/clubs, pharmacies, university 
campuses and train stations). A total of 281 sauna 
clients (out of 400 per week) completed the survey, 
and 10 volunteers participated in the vending machine 
development codesign workshops. The survey found 
that 32% (n = 89) sauna clients had never tested for 
HIV, with 44% (n = 123) stating that they did not feel 
at risk of HIV infection despite high HIV infection risks 
known to this population. When clients were asked 
about considering self-testing via a vending machine, 
acceptability was 93% (n = 260) for this intervention. 
The codesign workshops also demonstrated high 
levels of acceptability for HIV self-testing.
The prototype machine (see Fig. 55) was installed in 
the venue on 16 June 2017. It was sited in a prominent 
part of the entrance area of the sauna. The digital 
screen advertised that the test was quick and required 
only one drop of blood. When the client engaged with 
the machine, they were asked to answer three short 
questions (age, the date of their last HIV test and 
whether they were a resident of Brighton and Hove), 
as well as to input their mobile phone number so they 
could be sent a link to a post-test questionnaire (it was 
made clear that the mobile number was not stored 
permanently; rather, the machine was designed so it 
would not issue a further test to the same number for a 
28-day period to deter clients from obtaining tests and 
selling them for profit). The client then received an HIV 
self-test. The HIV test employed for this intervention 
was a third-generation HIV 1 and 2 antibody point-
of-care test that provided a result within 15 minutes 
after providing a small sample of blood obtained by a 
simple finger pinprick. The rapid test is CE (European 
Conformity) certified with a sensitivity of 97% and 
specificity of 99%.
This intervention aligns with the principles of HIV 
testing recommended by the WHO, including consent 
(self-testing), confidentiality (self-testing), counselling 
Fig. 55. The prototype vending machine
Source: Martin Fisher Foundation
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and connection which are represented in the clear 
information on support and linkage to care provided 
with each HIV self-test kit dispensed by the vending 
machine. A sticker with clear information on what to 
do in case of a positive result was used. This included 
a helpline and weblinks as well as information on the 
nearest sexual health clinic. The sticker (see Fig. 56) 
also provides information about the window period and 
when to retest. As with many self-testing interventions, 
a balance must be struck between obtaining accurate 
data about HIV-positive/negative results and creating 
barriers for HIV testing. With the intervention, as it 
stands, the project was unable to determine accurately 
how many negative and positive HIV tests have been 
obtained; however, two individuals tested positive. They 
used the linkage to care information provided with the 
kits to access services. The project team is currently 
working on innovative ways to overcome this challenge 
and hope to incorporate them in the next generation of 
vending machines.
Fig. 56. Referral pathway (sticker)
Evidence of impact/efficacy
Following the design and installation of the machine, 
a cross-sectional mixed methods evaluation was 
conducted among vending machine users. HIV 
testing rates by community outreach workers at the 
venue before and after the intervention were used as 
a comparison. Community workers offer HIV testing 
twice a week during opening hours of the venue. 
Demographics were collected via the machine’s user-
friendly touchpad screen (age, date of the last HIV 
test, residence in the city). An online questionnaire 
and structured interviews gathered information on 
user experience of the machine, and experience, 
acceptability and attitudes towards HIV self-tests 
accessed via the machine.
A total of 204 testing kits were accessed between 8 
July 2017 and 31 December 2017. The median age of 
users of the machine was 31 years (range 18–70 years); 
4% (n = 7) of users had never tested for HIV before, 
and only 11% (n = 22) had tested within the last one 
to five years. Uptake of HIV testing was higher via the 
vending machine compared with testing conducted by 
community outreach workers in the same venue and 
study period (35 versus 4.5 tests per month).
Twenty-three per cent (n = 48) of vending machine 
users completed an online survey evaluating their 
experience. The median age was 42 years (range 17–
70 years). Thirty-four per cent (n = 16) of respondents 
had last tested more than a year previously, or never. 
Fifty-four per cent (n = 25) had engaged in condomless 
anal sex with a new or casual partner in the previous six 
months, and 34% (n = 16) had engaged in condomless 
sex with more than partners in the last year. Twenty-
nine per cent (n = 14) had used the tests within two 
days of buying it, five had waited two to six weeks to 
use it and one had waited for 12 weeks before using 
it. Significantly, 93% (n = 44) said that they would 
recommend this intervention to others.
Twenty-three vending machine users completed semi-
structured interviews. Interviewed users expressed 
high levels of acceptability for the convenience and 
discretion of both the vending machine and HIV self-
testing. Fig. 57 shows extracts from comments from 
vending machine users.
Overall, the reaction to self-testing was positive. The 
idea of placing the vending machine in the sauna was 
widely regarded for its accessibility and simplicity. 
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The convenience and discretion provided were highly 
valued as key advantages of both the vending machine 
and self-testing in general. The intervention has had 
wide coverage in the media, and this not only helps 
to normalize HIV testing in the community but also 
demonstrates the innovative nature of the intervention 
(150,151).
Sustainability
This project offers an alternative and cost-effective way 
of accessing HIV tests. Prior to implementation, HIV 
testing was available in the sauna for only six hours per 
week (when community outreach workers were available 
on Wednesday and Saturday evenings) compared with 
the 123 hours per week the sauna operates. Peak 
visiting times to the sauna were often in the late evening 
and early morning, when staff would be difficult to 
secure and would require higher wages. Since the self-
test has clear user instructions, no additional staff or 
training costs are incurred, other than baseline training 
to ensure staff understand how the test works and the 
correct referral pathways. The price per unit cost for 
this type of HIV self-test is currently around £35. The 
cost of the HIV self-test for this intervention (bought in 
bulk) is only £11.76 with no onwards laboratory costs, 
compared with £53.11 if a patient attends a sexual 
health clinic for a single HIV test (national sexual health 
tariff). There are also major savings to the state’s health 
service through the reduction of onwards transmission 
and reduced costs resulting from late presentation of 
HIV infection. While the prototype vending machine 
was costly (over £5000), there have been significant 
economies of scale in ordering multiple additional 
machines, which now cost less than a fifth of the 
original price (under £2000). The additional machines 
use payless technology, which means that they will 
have an increased ability to accept payment. The 
survey revealed that clients are willing to pay a fair 
price for the kits (up to £10, equal to €9). This means 
that the intervention is cost-effective for health care 
services and clients alike, ensuring the sustainability 
of the approach. The intervention is still in place, 
and it is planned to roll out the next generation of 
digital vending machines distributing HIV self-tests in 
mainstream venues (gay bars, gay club, sex shops) in 
Brighton, thus improving access to HIV tests for the 
wider MSM community. In addition, plans are in place 
to roll out and evaluate the acceptability of using this 
technology in other key populations, including black 
MSM, heterosexual men and women from ethnic 
minorities and populations where English is not the 
first language, in other parts of the United Kingdom 
such as London and Manchester. Innovative ways 
to get accurate information on the exact number of 
positive and negative results without creating barriers 
for testing are being developed. In addition, a mobile 
phone application is under development, which 
will support the vending machines with information 
about the location of machines in the city and the 
potential for direct communication with health care 
professionals in case any questions regarding testing 
or results arise.
Fig. 57. Responses to the vending machine
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